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ABSTRACT 
 
Pulmonary arterial hypertension (PAH) is a rare and progressive disease 
characterised by increased pulmonary vascular resistance and elevated 
pulmonary artery pressure, leading to right ventricular failure and eventually 
death.  The monoamine 5-hydroxytryptamine (5HT) has been implicated in the 
processes of pulmonary vasoconstriction and pulmonary artery remodelling that 
contribute to the development of the PAH.  However, the signalling mechanisms 
utilised by 5HT that contribute to pulmonary vascular remodelling are still 
unclear and appear to be cell-type specific, with much of the work having been 
carried out in pulmonary artery smooth muscle cells (PASMCs).  Fibroblasts 
also contribute significantly to the pulmonary vascular remodelling that occurs 
during PAH, however little is known of the role 5HT plays in this cell type.  Using 
Chinese Hamster Lung Fibroblast (CCL-39) cells as a model system to 
investigate the mitogenic effects of 5HT, this study has characterised potential 
5HT-mediated signalling pathways in fibroblasts that may contribute to 
pulmonary vascular remodelling.  
5HT was found to induce a rapid and transient activation of extracellular 
regulated mitogen-activated protein kinase (ERK), a process central to the 
mitogenic effects of 5HT in CCL-39 cells.  Furthermore, the 5HT transporter 
(5HTT), 5HT1B and 5HT2A receptors were all required for optimal ERK-
dependent proliferation.  Pharmacological inhibition of the Rho/ROCK (Rho-
associated kinase) pathway significantly inhibited 5HT-stimulated ERK 
activation, cyclin D1 accumulation and proliferation.  Inhibition of ROCK had no 
effect on the translocation of active ERK to the nucleus, but did however 
selectively inhibit 5HT-induced activation of a cytoplasmic pool of ERK.  
Additionally, ROCK inhibition had no effect on the ability of 5HT to activate 
mitogen-activated protein kinase kinase (MEK), suggesting ROCK is required 
for maintaining functional interactions between MEK and ERK.  Sensitivity to 
ROCK inhibition is restricted to 5HT1B receptor activation of the ERK pathway.  
Moreover, the role of ROCK in maintaining cytoskeletal integrity is important in 
mediating 5HT-induced ERK activation, as disruption of the actin cytoskeleton 
markedly and specifically reduces 5HT- stimulated ERK activation. 
 III 
Using a model of PAH, arising from overexpression of 5HTT (5HTT+), the 
effects of ROCK inhibition in vivo were investigated.  ROCK 1 and ROCK 2 
transcripts were upregulated in response to chronic hypoxia, with the 
upregulation of ROCK 1 potentiated in 5HTT+ mice.  Administration of the 
ROCK inhibitor Y27632 had significantly greater effects in 5HTT+ mice 
compared to WT, highlighting the functional importance of the increase in 
ROCK 1 transcript.  Hypoxia-induced pulmonary vascular remodelling and 
elevated right ventricular pressure were attenuated more significantly by ROCK 
inhibition in 5HTT+ mice than in WT.   Furthermore, ROCK inhibition only 
reduced hypoxia-derived right ventricular hypertrophy significantly in 5HTT+ 
animals and not WT. 
In conclusion, this study highlights a role for ROCK in the pulmonary vascular 
changes that occur during PAH and proposes a new mechanism by which 
cross-talk between ROCK and 5HT signalling systems occurs. 
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Chapter 1 
INTRODUCTION 
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1.1  PULMONARY ARTERIAL HYPERTENSION 
 
Pulmonary arterial hypertension can be characterised by sustained elevation of 
pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP), 
leading to impaired right-heart function and eventually failure.  The condition is 
defined clinically by a mean pulmonary arterial pressure exceeding 25 mmHg at 
rest or 30 mmHg during exercise (Barst et al., 2004).  Common symptoms 
include fatigue, exertional dyspnea, edema and syncope (Rich et al., 1987).  As 
symptoms experienced by most patients are non-specific, diagnosis is 
frequently delayed.  
Pulmonary hypertension is classified into 5 main categories: pulmonary arterial 
hypertension (PAH), pulmonary hypertension with left heart disease, pulmonary 
hypertension associated with lung diseases and/or hypoxaemia, pulmonary 
hypertension due to chronic thrombotic and/or embolic disease, and 
miscellaneous (Simonneau et al., 2004) (Table 1.1).  Around 10% of patients 
that present with PAH without any identifiable cause have a family history of the 
disease, and are referred to as having familial PAH (Loyd et al., 1984), with 
remaining patients classified as having idiopathic PAH (IPAH).  Familal PAH is 
an autosomal dominant disorder with incomplete penetrance and genetic 
anticipation, that was initially mapped to a locus designated PPH1 on 
chromosome 2q31-32 (Morse et al., 1997, Nichols et al., 1997).  PPH1 was 
subsequently fine mapped to a 3cM region on chromosome 2q33 (Deng et al., 
2000a), that has been associated with mutations in the BMPR2 gene encoding 
bone morphogenetic protein (BMP) type 2 receptor (BMPR-2) (Lane et al., 
2000, Deng et al., 2000a).  Germline mutations in BMPR-2 have been identified 
in 60% of patients with familial PAH and also in around 10% to 30% of those 
with the idiopathic form of the condition (Lane et al., 2000, Deng et al., 2000b, 
Thomson et al., 2000).  Other genetic factors, such as polymorphisms in the 5-
hydroxytryptamine (5HT) transporter gene, have also been associated with the 
development of the condition (Eddahibi et al., 2001).  Moreover, PAH may occur 
secondary to other conditions, including collagen vascular disease, HIV 
infection or lung diseases such as chronic obstructive pulmonary disease 
(COPD) (Simonneau et al., 2004). 
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The idiopathic form of the disease occurs more frequently in women than men 
(>2:1) and is usually fatal within 3 years if untreated (Newman et al., 2004).  
Current therapies, such as prostacyclin and endothelin antagonists markedly 
improve physical function and survival, with the 5 year mortality rate around 
50% (Newman et al., 2004).  
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Revised World Health Organisation Clinical Classification of 
Pulmonary Hypertension (Venice 2003)  
 
Pulmonary arterial hypertension 
 
Primary pulmonary hypertension 
Idiopathic 
Familial 
Related to: 
Collagen vascular disease 
Congenital systemic to pulmonary shunts 
Portal hypertension 
HIV infection 
Drugs/Toxins 
Anorexigens 
Other 
Associated with significant venous or capillary involvement 
  Pulmonary veno-occlusive disease 
  Pulmonary capillary haemangiomatosis 
  Persistent pulmonary hypertension of the newborn 
 
Pulmonary venous hypertension 
 
Left-sided atrial or ventricular heart disease 
Left-sided valvular heart disease 
 
Pulmonary hypertension associated with lung diseases and/or 
hypoxaemia 
 
Chronic obstructive pulmonary disease 
Interstitial lung disease 
Sleep-disordered breathing 
Alveolar hypoventilation disorders 
Chronic exposure to high altitude 
Developmental abnormalities 
 
Pulmonary hypertension due to chronic thrombotic and/or embolic 
disease 
 
Thromboembolic obstruction of proximal pulmonary arteries 
Thromboembolic obstruction of distal pulmonary arteries 
  Nonthrombotic pulmonary embolism (tumour, parasites, foreign material) 
 
Miscellaneous 
 
Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels 
(adenopathy, tumour, fibrosing mediostinitis) 
 
 
 
 
 
 
Table 1.1  Revised Clinical Classification of Pulmonary Hypertension.  
The aim of classification was to identify different categories of pulmonary 
hypertension that shared similarities in pathophysiological mechanisms and 
clinical symptoms.  Clinical classification is important in standardising diagnosis 
and treatment. 
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1.2  THE PULMONARY CIRCULATION 
 
The pulmonary circulation is a closed circuit of vessels carrying blood between 
the heart and lungs.  In healthy adults the system is a low-pressure, low-
resistance circuit, with a mean PAP between 9 - 19 mmHg at sea level (Chemla 
et al., 2002).  In addition to this, the pulmonary vessels are thin-walled and 
highly distensible, able to accommodate large increases in blood flow, such as 
that occurring during exercise, with minimal increases in PAP (Chemla et al., 
2002, Vonk-Noordegraaf et al., 2005). 
Pulmonary blood vessels are arranged to facilitate efficient gas exchange, 
carrying blood into the pulmonary microvasculature of the alveoli, where uptake 
of oxygen and the unloading of excess carbon dioxide occurs.  The pulmonary 
arteries run alongside the airways, branching with them and producing a large 
surface area within the alveolar region by means of a capillary network sheet 
flow (Mandegar et al., 2004, Hislop and Pierce, 2000).  Blood flow in the 
pulmonary arteries must be sufficient and at a linear velocity with the counter 
current for gas exchange to occur (Hislop and Pierce, 2000).  Larger vessels in 
the proximal region of the pulmonary arterial network are elastic in structure 
with several layers of smooth muscle separated by collagen and elastic laminae 
(Hislop and Pierce, 2000).  As the arterial tree advances distally and the vessels 
decrease in diameter, there is a gradual decrease in the level of 
muscularisation, with arteries only partially muscular or completely non-
muscular (Hislop and Pierce, 2000, Meyrick and Reid, 1983, MacLean et al., 
2000). 
Unlike the systemic circulation, where hypoxic conditions result in vasodilation, 
in the pulmonary circulation vasoconstriction occurs (Aaronson et al., 2006).  
Hypoxic pulmonary vasoconstriction (HPV) is thought to be an adaptive 
mechanism, unique to the vessels of the lungs.  HPV is greatest in resistance 
pulmonary arteries (200-300 µm diameter).  In contrast, large pulmonary 
arteries behave like systemic arteries, relaxing in response to hypoxic 
conditions.  HPV appears to be an intrinsic property of pulmonary artery smooth 
muscle cells (PASMCs) (Murray et al., 1990, Yuan et al., 1990) and is important 
in redirecting blood flow from poorly ventilated areas of the lung to better 
ventilated areas, maximising oxygenation of pulmonary venous blood 
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(Mandegar et al., 2004, Moudgil et al., 2005).  The mechanisms of HPV are not 
fully understood but appear to involve the coordinated inhibition of voltage-
gated K+ (Kv) channels and activation of voltage-gated L-type calcium channels 
in resistance PASMCs (Weir et al., 2005).  Furthermore, mitochondrial 
generation of reactive oxygen species (ROS) have been implicated in the 
mechanism of HPV.  However, controversy exists as to whether an increase or 
decrease in ROS production occurs in response to hypoxia (Weissmann et al., 
2006). 
 
1.3 PATHOBIOLOGY OF PAH 
 
Pulmonary hypertension is a disease of the small pulmonary arteries, resulting 
from the combined effects of pulmonary vasoconstriction, vascular remodelling 
and thrombosis (Gurbanov and Shiliang, 2006, Mandegar et al., 2004).  These 
processes contribute to the increases in PVR and PAP witnessed in patients 
with PAH, putting excessive burden on the right ventricle due to the increased 
workload required to compensate for elevated downstream pressure, and 
eventually results in right-sided heart failure (Mandegar et al., 2004, Humbert et 
al., 2004).  The pathogenesis of PAH is complicated and multifactorial. 
 
1.3.1  PULMONARY VASOCONSTRICTION IN PAH 
 
Pulmonary vasoconstriction is a main contributing factor to PVR and thus 
elevated PAP.  Hypoxia plays a major role in vasoconstriction during PAH.  For 
instance, in patients with conditions such as COPD and high altitude pulmonary 
edema, sustained alveolar hypoxia results in vasoconstriction of pulmonary 
vessels and vascular remodelling leading to the development of PAH 
(Mandegar et al., 2004).  Excessive pulmonary vasoconstriction has also been 
related to abnormal K+ channel functions and/or expression as well as 
endothelial dysfunction and calcium sensitisation (Moudgil et al., 2005). 
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ROLE OF K+ CHANNELS IN PULMONARY VASOCONSTRICTION    
 
K+ channels play an important role in the regulation of pulmonary vascular tone 
(Nelson et al., 1990).  Inhibition of K+ channels depolarises PASMCs, resulting 
in the opening of voltage-gated Ca2+ channels, increasing cytoplasmic Ca2+ 
levels (Nelson et al., 1990, Yuan, 1995), which may trigger pulmonary artery 
vasoconstriction.  Indeed, blockade of Kv channels using 4-aminopyridine has 
been found to cause pulmonary vasoconstriction (Hasunuma et al., 1991).  
Hypoxia also inhibits K+ currents and depolarises PASMC membranes (Post et 
al., 1992, Yuan et al., 1993), suggesting a role for K+ channels in mediating 
HPV .  Certain K+ channels are sensitive to O2 levels as they possess cysteine 
and methionine groups which are subject to reduction or oxidation by redox 
mediators, such as reactive oxygen species (Moudgil et al., 2005).   Some Kv 
channels, such as the Kv1.5 channel, respond to redox mediators by altering 
their gating and open-state probability (Archer et al., 2004).  Oxidants, including 
H2O2, increase potassium currents in PASMCs, whereas reducing agents inhibit 
them (Reeve et al., 1995).  The redox theory of HPV suggests that under 
normoxic conditions, there is basal production of reactive oxygen species, such 
as H2O2 by the electron transport chain of PASMC mitochondria maintaining the 
Kv current (Archer et al., 1986, Reeve et al., 1995).  However, this mechanism 
is upset during hypoxic conditions, resulting in the decreased production of 
H2O2 inhibiting Kv channels and resulting in activation of voltage gated L-type 
Ca2+ channels, which subsequently increases intracellular Ca2+ levels and 
induces HPV (Moudgil et al., 2005, Moudgil et al., 2006) (Figure 1.1).  Several 
O2-sensitive Kv channels may be involved in mediating HPV, including Kv1.5 
(Archer et al., 1998, Archer et al., 2001), Kv2.1 (Archer et al., 1998, Patel et al., 
1997) and possibly Kv1.2 (Hulme et al., 1999) and Kv3.1b (Osipenko et al., 
2000).  For instance, in mice deficient in Kv1.5, HPV is markedly attenuated 
(Archer et al., 2001).  Indeed, Kv1.5 channels have been found to be 
downregulated in PASMCs from patients with PAH (Yuan et al., 1998), as have 
both Kv1.5 and Kv2.1 channels in rats with chronic hypoxia-induced PAH 
(Michelakis et al., 2002b).   
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ROLE OF INTRACELLULAR Ca2+ HOMEOSTASIS IN PULMONARY 
VASOCONSTRICTION  
 
Intracellular Ca2+ plays an essential role in pulmonary vasoconstriction, with 
both extracellular calcium influx and release of intracellular calcium from the 
sarcoplasmic reticulum involved in mediating HPV (Salvaterra and Goldman, 
1993, Gelband and Gelband, 1997).  Smooth muscle contraction is initiated by 
an elevation in intracellular free calcium concentration ([Ca2+]i).  Calmodulin 
(CaM), an intracellular Ca2+-binding protein, binds to Ca2+ as [Ca2+]i rises.  The 
resulting CaM/Ca2+ complex then binds to and activates myosin light chain 
kinase (MLCK) leading to phosphorylation of the myosin light chain (MLC) of the 
contractile apparatus.  This process stimulates the activation of the myosin 
ATPase, hydrolysing ATP to generate energy for the cycling of myosin cross-
bridges with actin filaments.  The formation of these cross bridges brings about 
smooth muscle contraction, resulting in vasoconstriction (Somlyo and Somlyo, 
1994) (Figure 1.2). 
[Ca2+]i is elevated in PASMCs exposed to hypoxia (Salvaterra and Goldman, 
1993, Wang et al., 2005, Bakhramov et al., 1998, Cornfield et al., 1993).  This 
hypoxia-induced increase in [Ca2+]i results in PASMC contraction (Murray et al., 
1990, Leach et al., 1994, Jin et al., 1992). Furthermore, hypoxia triggers 
increases in [Ca2+]i  and contraction in small intrapulmonary arteries that is 
sustained during the hypoxic period and reversed on return to normoxia 
(Robertson et al., 2000b).  Several studies have reported the predominant 
source of Ca2+ contributing to elevated [Ca2+]i during hypoxic conditions is 
extracellular and enters PASMCs via the voltage-gated L-type calcium channel 
(Bakhramov et al., 1998, Cornfield et al., 1993).  Inhibition of these channels 
has been shown to attenuate hypoxic responses in pulmonary arteries (Jin et 
al., 1992, Leach et al., 1994) and HPV in isolated lungs and intact animals 
(Redding et al., 1984, Stanbrook et al., 1984, Simonneau et al., 1981, McMurtry 
et al., 1976). 
In addition to this, the release of calcium from intracellular stores has also been 
proposed to mediate HPV.  Gelband and Gelband (1997) reported that in rat 
pulmonary arteries, the initial event in HPV is the release of Ca2+ from 
intracellular stores, resulting in elevated [Ca2+]i and increased pulmonary artery 
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tone.  Furthermore, in canine pulmonary arteries, release of Ca2+ from the 
sarcoplasmic reticulum was found to contribute significantly to HPV (Jabr et al., 
1997).  Depletion of Ca2+ stores have also been shown to abolish hypoxic 
responses in PASMCs (Dipp et al., 2001).  Similarly, release of intracellular 
calcium, from ryanodine-sensitive stores contributes significantly to HPV in 
perfused lungs (Morio and McMurtry, 2002). 
Entry of Ca2+ via store-operated Ca2+ channels (SOCCs) may also be important 
in mediating HPV.  As mentioned previously, in PASMC under acute hypoxic 
conditions, release of Ca2+ from intracellular stores has been observed resulting 
in increased [Ca2+]i .  In some instances this has been reported to enhance 
capacitative Ca2+ entry via SOCCs (Kang et al., 2003, Ng et al., 2005) and may 
therefore contribute to HPV.  Furthermore, in another study where intracellular 
Ca2+ stores were depleted and voltage-gated L-type Ca2+ channels blocked, 
hypoxia still resulted in an increase in [Ca2+]i.  This was attributed to the ability 
of acute hypoxia to enhance Ca2+ entry via SOCCs (Wang et al., 2005).  
Chronic hypoxia has also been found to upregulate members of the canonical 
transient receptor potential channel (TRPC) gene family (TPRC1 and TPRC6) 
in pulmonary arteries, resulting in increased expression of SOCCs and 
receptor-operated Ca2+ channels (ROCs) in PASMCs.  The enhanced activity of 
these channels under hypoxic conditions contributes to elevated [Ca2+]i and 
increased pulmonary vascular tone (Lin et al., 2004) (Figure 1.3).  Further 
highlighting the role of intracellular Ca2+ release in mediating HPV, cyclic ADP 
ribose, which acts on ryanodine receptors to stimulate intracellular Ca2+ release, 
is elevated by hypoxia in small pulmonary arteries.  Moreover, contraction to 
hypoxia in these arteries was completely suppressed by using a cyclic ADP 
ribose antagonist (Wilson et al., 2001). 
Smooth muscle cell contraction is dependent not only on [Ca2+]i but also on the 
Ca2+ sensitivity of the contractile apparatus (Morgan, 1987).  Under conditions 
of agonist-mediated contraction, Ca2+ sensitisation can occur.  For example, in 
permeabilised SMCs, agonists can enhance the force of contraction when 
intracellular Ca2+ remains constant (Kitazawa et al., 1989).  One mechanism of 
Ca2+ sensitisation suggests altered relations between myosin regulatory light 
chain phosphorylation and intracellular Ca2+, involving the MLCK or 
phosphatase cascades (de Lanerolle and Paul, 1991).  Another possible 
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mechanism of sensitisation involves alterations in Ca2+ affinity of regulatory 
proteins such as caldesmon and calponin.  These proteins are associated with 
thin filaments and inhibit actin-myosin interaction, a process attenuated by Ca2+ 
(Winder et al., 1998).  Ca2+ sensitisation also occurs in pulmonary arteries 
under hypoxic condition.  During sustained HPV, force development continues 
to increase while [Ca2+]i attains a constant level (Robertson et al., 1995, 
Robertson et al., 2003).  In addition to this, Rho-associated kinase (ROCK) 
inhibition has been shown to suppress sustained HPV in pulmonary arteries and 
perfused lung (Robertson et al., 2000a).  Furthermore, ROCK has been 
proposed to contribute to sustained HPV by mediating Ca2+ sensitisation in 
pulmonary arteries (Nagaoka et al., 2004).  
  
ROLE OF REACTIVE OXYGEN SPECIES IN PULMONARY 
VASOCONSTRICTION 
 
HPV is an important physiological response of the lung to alveolar hypoxia, 
required to redistribute pulmonary blood flow from areas of low oxygen to high 
oxygen availability.  However, the underlying oxygen sensing and signal 
transduction mechanisms of HPV remain unclear.  Several studies have 
reported that inhibition of the mitochondrial electron transport chain (ETC) 
specifically inhibits HPV (Michelakis et al., 2002a, Weissmann et al., 2003, 
Waypa et al., 2001).  These findings suggest a role for mitochondria as oxygen 
sensors for HPV.  Two conflicting hypotheses have developed concerning a role 
for mitochondria in HPV.  (1)  The redox hypothesis of HPV suggests that a 
decrease in mitochondrial ROS occurs during hypoxia, shifting the cellular 
redox balance towards a more reduced state.  As mentioned previously, this 
can result in the inhibition and closure of Kv channels, a process mediated by 
the redox pairs GSH/GSSG and NADH/NAD (Moudgil et al., 2005, Michelakis et 
al., 2002c).  (2)  In direct contrast to this, a hypoxia-induced increase in 
mitochondrial ROS production has also been reported.  This increase in ROS is 
thought to mediate HPV by triggering intracellular calcium release (Waypa et 
al., 2001, Waypa and Schumacker, 2005). 
In support of the former hypothesis, rotenone and antimycin A (inhibitors of the 
proximal region of the ETC), were shown to mimick the effects of HPV in 
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isolated pulmonary arteries and PASMCs, decreasing ROS production and 
subsequently resulting in the inhibition of potassium channels (Michelakis et al., 
2002a).  Furthermore, under normoxic conditions, pharmacological inhibition of 
the ETC proximal to complexes II and III (sites of mitochondrial ROS release) 
resulted in a reduction in ROS production and an increased pulmonary artery 
pressure (Michelakis et al., 2004).  Taken together these findings suggest a 
decrease in mitochondrial-produced ROS mediates HPV. 
On the other hand, others have provided evidence that increased ROS release 
from ETC complex III occurs under hypoxic conditions in isolated rat lung, and 
that this increase in ROS mediates HPV (Waypa et al., 2001).  Furthermore, 
inhibition of the proximal region of the ETC was found to attenuate hypoxia-
induced constriction in PASMCs by decreasing intracellular Ca2+ levels (Waypa 
et al., 2002).  Conversely, hypoxia has been reported to trigger increases in 
[Ca2+]i by augmenting ROS signalling from mitochondria (Waypa et al., 2006). 
Therefore, these findings suggest an increase in mitochondrial-produced ROS 
mediates HPV by facilitating increases in [Ca2+]i. 
NAD(P)H-oxidases, enzymes that function to generate superoxide, have also 
been proposed as possible oxygen sensors of HPV.  Again, two conflicting 
concepts exist as to the contribution of NAD(P)H-oxidase-derived superoxide in 
HPV, with one reporting an upregulation and another reporting a 
downregulation of superoxide.  Reports that NADPH-oxidase is activated in 
response to hypoxia in PASMCs (Marshall et al., 1996), and that the generation 
of superoxide and subsequent formation of H2O2 are required for HPV in 
perfused rabbit lung (Weissmann et al., 1998), suggest that NADPH-mediated 
increases in superoxide are required to mediate HPV.  Increased superoxide 
generation and an increased expression of NADPH-oxidase has also been 
observed in pulmonary arteries from pulmonary hypertensive fetal lambs 
(Brennan et al., 2003).  The hypothesis that NADPH-mediated superoxide 
production contributes to HPV is further confirmed by the ability of NADPH-
oxidase inhibitors to attenuate HPV in intact lungs (Weissmann et al., 2000).  
But, it has also been suggested an NADPH-oxidase-mediated decrease in 
superoxide occurs during HPV (Wolin et al., 1999).  Several studies have 
reported decreases in superoxide and H2O2 generation under hypoxic 
conditions. This has been suggested to attenuate the cellular levels of cyclic 
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guanosine 3’, 5’ monophosphate (cGMP) due to reduced stimulation of soluble 
guanylyl cyclase and thus results in vasoconstriction (Burke-Wolin and Wolin, 
1989, Burke-Wolin and Wolin, 1990, Cherry et al., 1990, Wolin et al., 1999).   
In summary, while ROS play a key role in mediating pulmonary vascular tone in 
hypoxia, there is no consensus as to whether ROS are increased or decreased 
under hypoxic conditions. 
 
ROLE OF ENDOTHELIAL DYSFUNCTION IN PULMONARY  
VASOCONSTRICTION 
 
Endothelial dysfunction results in an imbalance in the production of vasodilatory 
and vasoconstrictive agents.  In PAH an insufficient level of vasodilators such 
as nitric oxide (NO) and prostacyclin, in addition to an increase in the production 
of vasoconstrictors such as endothelin-1 (ET-1), favours the vasoconstriction of 
pulmonary arteries.  For instance, prostacyclin synthesis has been found to be 
decreased in endothelial cells from patients with PAH due to a reduction in the 
expression of prostacyclin synthase, the enzyme responsible for its synthesis 
(Christman et al., 1992, Tuder et al., 1999).  Endothelium-derived vasodilators 
are further decreased in PAH by the reduction of endothelial NO synthesis 
(eNOS) expression, reported in endothelial cells of patients (Giaid and Saleh, 
1995).  In addition to this, vasoactive interstitial peptide (VIP), a potent 
pulmonary vasodilator, has also been found to be reduced in serum from PAH 
patients (Petkov et al., 2003).  To further contribute to the vasoconstrictive 
environment, increased levels of ET-1, which induces vasoconstriction, have 
been reported in both animal models and patients with PAH (Giaid et al., 1993).  
It can therefore be seen that endothelial dysfunction results in an imbalance of 
endothelium-derived mediators, favouring vasoconstriction and contributing to 
the pathobiology of PAH.  
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Figure 1.1  The role of potassium channel activity in mediating hypoxic 
pulmonary vasoconstriction.   
Normoxia is associated with open, oxidised Kv channels.  Under hypoxic 
conditions, Kv channels become reduced, resulting in their closure and 
membrane depolarisation.  This facilitates the opening of voltage-gated L-type 
Ca2+ channels.  Ca2+ influx via these channels elevates intracellular Ca2+ 
concentrations, resulting in vasoconstriction.  Oxidising compounds mimic the 
effects of normoxia, while reducing agents mimic the effects of hypoxia. 
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Figure 1.2  Signal transduction mechanisms mediating contraction of vascular smooth muscle. 
The level of free intracellular calcium (Ca2+) is a major determinant of smooth muscle contraction.  As free intracellular calcium 
(Ca2+) rises, it binds and forms a complex with calmodulin (CaM).  The Ca2+/CaM complex then activates myosin light chain kinase 
(MLCK), which subsequently phosphorylates the myosin light chain (MLC).  This stimulates myosin ATPase activity and promotes 
crossbridge cycling with actin filaments.  The formation of these crossbridges underlies smooth muscle cell contraction and results 
in vasoconstriction. 
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Figure 1.3 Diagram of the proposed mechanisms contributing to increased intracellular Ca2+ concentrations and hypoxic 
pulmonary vasoconstriction (HPV). 
Hypoxia results in decreased activity of Kv channels and membrane depolarisation, thereby initiating the opening of L-type Ca2+ 
channels and allowing Ca2+ influx.  Intracellular Ca2+ is also elevated by the hypoxic activation of receptor-operated Ca2+ channels 
(ROC) and store-operated Ca2+ channels (SOCC).  In addition, hypoxia induces calcium release from intracellular stores in the 
sarcoplasmic reticulum, further elevating intracellular Ca2+.  The depletion of these stores is also thought to contribute to the 
activation of SOCC.  
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1.3.2  PULMONARY VASCULAR REMODELLING 
 
Vascular remodelling is a term often used to describe structural and functional 
alterations to blood vessels, allowing them to function more effectively.  It is an 
adaptive process which occurs in response to long-term changes in 
haemodynamic conditions that occur during development (Mulvany et al., 
1996).  However, the process can contribute to the pathobiology of various 
vascular diseases, including PAH. 
Under normal conditions the diameter of the pulmonary artery wall is maintained 
by a balance between proliferation and apoptosis of pulmonary artery 
fibroblasts (PAFs), PASMCs and pulmonary artery endothelial cells (PAECs) 
(Gurbanov and Shiliang, 2006, Mandegar et al., 2004).  In PAH this balance is 
disrupted in the favour of proliferation, resulting in an increase in the thickness 
of the artery wall and a narrowing of the vessel lumen which eventually results 
in its complete occlusion.  These structural changes result in the loss of 
vascular compliance and are responsible for the increase in PVR observed in 
PAH patients (Mandegar et al., 2004, Gurbanov and Shiliang, 2006).  
Pulmonary vascular remodelling can be initiated by a variety of stimuli, including 
anorectic drugs, collagen vascular disease and chronic hypoxia (Mandegar et 
al., 2004).  This process involves all layers of the vessel wall and is complicated 
by the cellular heterogeneity that exists within the pulmonary artery wall (Jeffery 
and Morrell, 2002) (Figure 1.4).   
 
CONTRIBUTION OF PULMONARY ARTERY SMOOTH MUSCLE CELLS 
(PASMCs) TO VASCULAR REMODELLING 
 
Common to the pathogenesis of all forms of human PAH is an increase in the 
thickness of the medial layer of muscular pulmonary arteries and the 
muscularisation of distal, previously non-muscular pulmonary arteries (Humbert 
et al., 2004, Stenmark and Mecham, 1997, MacLean et al., 2000).  The 
increased thickness of the medial compartment is due to hypertrophy and 
proliferation of SMCs and the increased synthesis and deposition of matrix 
proteins including elastin and collagen (Stenmark and Mecham, 1997).  The 
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muscularisation of previously non-muscular arteries may be due to the 
differentiation and hypertrophy of intermediate cells and pericytes present in the 
vessel wall, which acquire a smooth muscle like appearance (Meyrick and 
Perkett, 1989, Durmowicz and Stenmark, 1999) .  During PAH, changes in the 
phenotype of PASMCs occur, which contribute to the process of vascular 
remodelling.  For instance, PASMCs taken from patients with PAH have been 
shown to have increased proliferative capabilities (Eddahibi et al., 2001).  
Furthermore, it has also been suggested that smooth muscle cells (SMCs) may 
contribute to intimal thickening and neointima formation by migrating from the 
media to the subendothelial layer, where they change phenotype from contactile 
to synthetic and secrete excessive extracellular matrix proteins (Olschewski et 
al., 2001).  In addition to this, the pulmonary artery is composed of 
phenotypically diverse SMC populations (Frid et al., 1994).  These 
subpopulations exhibit different proliferative responses to hypoxia-induced PAH, 
a property that be may important in the process of medial remodelling (Wohrley 
et al., 1995)(Figure 1.4). 
 
CONTRIBUTION OF PULMONARY ARTERY FIBROBLASTS (PAFs) TO 
VASCULAR REMODELLING 
 
Fibroblasts also play an important role in vascular remodelling.  Located in the 
adventitial compartment, fibroblasts proliferate, hypertrophy and increase 
production of extracellular matrix proteins (Stenmark et al., 2002, Stenmark and 
Mecham, 1997).  The most dramatic structural changes occur in the adventitia 
of small pulmonary arteries as a result of these processes (Stenmark et al., 
1987, Murphy et al., 1981, Durmowicz et al., 1994).  The pulmonary vasculature 
appears to contain multiple, functionally distinct subpopulations of fibroblasts.  
These subpopulations have marked differences in morphology and proliferative 
capabilities and this may play a crucial role in regulating vascular remodelling 
(Das et al., 2002).  Unlike, SMCs, hypoxia induces proliferation in pulmonary 
artery fibroblasts in the absence of exogenous growth factors (Falanga and 
Kirsner, 1993, Storch and Talley, 1988).  Furthermore, fibroblasts have been 
observed to proliferate earlier and have a greater response to hypoxia than 
endothelial or SMCs (Belknap et al., 1997).  In addition to an increase in the 
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number of fibroblasts in the adventitial layer of hypoxic pulmonary arteries, a 
large increase in matrix protein deposition has been observed, with increases in 
collagen, elastin and tropoelastin reported (Durmowicz et al., 1994).  Fibroblasts 
have also been shown undergo changes in cytoskeletal and contractile protein 
expression, significantly altering their function.  This process results in the 
expression of α-smooth muscle actin within the cells, suggesting conversion to 
myofibroblasts, which may contribute to the development of PAH (Short et al., 
2004).  The hypoxic activation of fibroblasts may also have some bearing on the 
increase in SMC proliferation observed in PAH (Rose et al., 2002).  Moreover, 
fibroblasts have been proposed to migrate to the medial and intimal layers of 
pulmonary vessels during PAH contributing to neointimal formation (Humbert et 
al., 2004) (Figure 1.4). 
 
CONTRIBUTION OF PULMONARY ARTERY ENOTHELIAL CELLS (PAECs) 
TO VASCULAR REMODELLING 
 
In chronic hypoxic PAH, increases in intimal thickness occur due to hypertrophy 
and hyperplasia in both the endothelial and sub-endothelial layers (Stenmark 
and Mecham, 1997).  Plexiform lesions occur in a large percentage of patients 
with PAH (Tuder et al., 1994).  These lesions originate in small precapillary 
vessels usually at blood vessel bifurications (Stevens, 2005).  Increases in 
endothelial cell proliferation contribute to the formation of such lesions (Tuder et 
al., 1994, Voelkel and Tuder, 1995) and in some instances plexiform lesions 
occur as a result of monoclonal endothelial cell proliferation (Lee et al., 1998a).  
Plexiform lesions grow into the vessel resulting in lumen occlusion (Stevens, 
2005).  Enothelial cells within these lesions have a pro-proliferative, anti-
apoptotic phenotype and no longer grow in a monolayer, with the resulting 
intravascular growth resembling a tumour (Tuder et al., 2001).   Other 
abnormalities have been observed in the endothelial cells of these lesions 
compared to normal pulmonary endothelial cells (Loscalzo, 1992).  For 
example, a decreased production of vasodilators (Tuder et al., 1999, Giaid and 
Saleh, 1995)  and increased production of vasoconstrictors have been reported 
(Giaid et al., 1993).  Furthermore, these endothelial cells also express pro-
angiogenic molecules such as vascular endothelial derived growth factor 
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(VEGF) and VEGF receptor (VEGFR), which may contribute to cell proliferation 
and vascular remodelling (Tuder and Voelkel, 2001).  Changes in surface 
coagulant properties and proinflammatory cytokine production have also been 
observed in endothelial cells from PAH patients.  For instance, under hypoxic 
conditions, thrombomodulin production is suppressed and procoagulant activity 
increased (Ogawa et al., 1990).  Furthermore, hypoxia also increases 
interleukin-1α (IL-1α) production by endothelial cells and upregulates 
endothelial-leukocyte adhesion molecule-1 (ELAM-1) and intracellular adhesion 
molecule-1 (ICAM-1) on the cell surface (Shreeniwas et al., 1992).  This 
suggests hypoxia induces changes in the endothelial layer promoting 
coagulation and increasing the interaction of endothelial cell with circulating 
inflammatory cells.  In support of this hypothesis, increased adherence of 
leukocytes and platelets has been observed in in vivo models of PAH (Hung et 
al., 1986).  Increased inflammatory infiltrates have also been observed in a 
variety of plexiform lesions (Balabanian et al., 2002).  Recently, it has also been 
proposed that PAECs may contribute to vascular remodelling under chronic 
hypoxic conditions by transdifferentiating into smooth muscle-like cells (Zhu et 
al., 2006).  This may be an alternative explanation for the muscularisation of 
previously non-muscular vessels in the process of PAH (Figure 1.4). 
 
ROLE OF APOPTOSIS IN VASCULAR REMODELLING 
 
Apoptosis, or programmed cell death, is a fundamental biological function 
involved in many physiological and pathological processes.  It can be defined as 
a well ordered form of cell death comprised of a regulated sequence of events, 
resulting in removal of cell material without the release of harmful substances to 
surrounding tissue (Renehan et al., 2001).  In PAH the balance between 
proliferation and apoptosis is disturbed.  In PASMCs, increased proliferation 
and decreased apoptosis contribute to the thickening of the vessel wall and 
vascular remodelling (Stenmark and Mecham, 1997, Mandegar et al., 2004).  
Several lines of investigation implicate decreases in apoptosis in the 
development and maintenance of PAH.  For instance, PASMCs from patients 
with PAH have been shown to be resistant to apoptotic inducers such as BMP -
2, 5 and 7 (Zhang et al., 2003).  Furthermore, a reduction in Kv channel 
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expression and function in PASMCs attenuates programmed cell death by 
decelerating apoptotic volume decrease (AVD) and inhibiting cytoplasmic 
caspases (Zhang et al., 2003).  The anti-apoptotic protein Bcl-2 has also been 
reported to be increased in the lungs of PAH patients.  Further highlighting the 
role of apoptosis in pulmonary vascular remodelling, the induction of apoptosis 
in models of PAH has been found to result in the regression of hypertrophied 
PASMCs (Cowan et al., 1999, Rabinovitch, 1998)(Figure 1.4). 
 
1.3.3  VASCULAR THROMBOSIS 
 
Thrombosis often occurs in the pulmonary arterioles of many PAH patients and 
may result from injury to the endothelium, abnormal fibrinolysis, enhanced 
procoagulant activity and platelet abnormalities (Humbert et al., 2004, Veyssier-
Belot and Cacoub, 1999, Herve et al., 2001).  Indeed, decreased fibrinolytic 
activity has been observed in the plasma of patients with PAH  (Welsh et al., 
1996, Frank et al., 1997).  Furthermore, the endothelium plays an important role 
in regulating coagulation.  The decrease in production of prostacyclin and NO 
by endothelial cells of PAH patients is likely to contribute to thrombosis as both 
of these mediators inhibit platelet aggregation (Moncada and Vane, 1979, 
Moncada et al., 1991).  Moreover, the production of thrombomodulin, a co-
factor produced by endothelial cells that binds and inactivates thrombin to 
attenuate coagulation, is significantly decreased in individuals with PAH (Welsh 
et al., 1996).  The imbalance in the level of pro- and anti-coagulant factors in the 
favour of coagulation contributes to thrombus formation in PAH patients (Figure 
1.4). 
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Figure 1.4  Schematic diagram of how individual pathophysiological components contribute to increased pulmonary 
vascular resistance and pulmonary artery pressure during pulmonary hypertension. 
Changes in cellular function within the wall of pulmonary arteries contribute to pulmonary vascular remodelling, vasoconstriction 
and thrombosis, leading to increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP), characteristic of 
pulmonary hypertension.  Figure adapted from Mandegar et al., (2004). 
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1.3.4  MEDIATORS OF PAH 
 
Given the multifactorial pathobiology of PAH, various mediators have been 
implicated in the development and progression of the disease.  Several factors 
mentioned previously, which affect vascular tone, also promote vascular 
remodelling e.g. ET-1 and Kv channels (Mandegar et al., 2004).  Genetic 
factors, such as mutations in the BMPR-2 gene also contribute to the 
development of the condition, however in most cases PAH is not attributed to 
inherited genetic mutations (Thomson et al., 2000).   Therefore, other external 
stimuli play a major role in contributing to the development of PAH.  Some of 
the key mediators involved in the development and maintenance of PAH are 
described below. 
 
ROLE OF THE TRANSFORMING GROWTH FACTOR-β (TGF-β) 
SUPERFAMILY AND SIGNALLING PATHWAYS IN VASCULAR 
REMODELLING 
 
The TGF-β superfamily of structurally related cytokines includes TGF-β, BMPs 
and activins.  The TGF-β superfamily members induce a multitude of effects 
such as cell differentiation, proliferation, migration and apoptosis in a variety of 
cell types (Roberts and Sporn, 1993). As mentioned previously, mutations in the 
BMPR-2 gene have been associated with the pathogenesis of PAH, as have 
somatic mutations in the TGF-β type 1 receptor (TGF-βR1) and abnormalities in 
TGF-β signalling (Yeager et al., 2001, Richter et al., 2004).    Briefly, signal 
transduction of TGF-β superfamily receptor ligands requires the ligand-induced 
formation of heteromeric complexes of type 1 and type 2 transmembrane 
serine/threonine kinase receptors (Derynck and Zhang, 2003).  Different 
receptor combinations allow for differential ligand binding properties and diverse 
signalling responses to the same ligand (Derynck and Zhang, 2003). Ligand 
binding induces the phosphorylation of the GS segment in the type 1 receptor 
by the type 2 receptor kinases.  The active type 1 receptor then phosphorylates 
the receptor-activated mothers against decapentaplegic (R-Smad) proteins.  
Activated R-Smads can then dimerise with a common mediator-Smad (Co-
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Smad) to form a signalling complex capable of translocating to the nucleus, 
resulting in the transcription of Smad-responsive genes, some of which encode 
anti-proliferative and pro-apoptotic proteins (Derynck and Zhang, 2003) (Figure 
1.5).  The BMPR-2 receptor has been documented to interact with three 
different type 1 receptors (ALK-2, ALK-3 and ALK-6) and signals via the R-
Smads, Smad 1,5 and 8 (Derynck and Zhang, 2003, Moustakas et al., 2001) 
(Figure 1.5).  
The exact mechanisms as to how BMPR-2 and TGF-β mutations and 
alterations in signalling pathways contribute to vascular remodelling in PAH are 
not fully understood, but it is thought they have a negative effect on pro-
apoptotic Smad complexes.  In normal human PASMCs, treatment with BMPs 
results in increased apoptosis and a reduction in levels of the anti-apoptotic 
protein Bcl-2, thereby triggering the release of cytochrome C from mitochondria 
and activating caspases 3, 8 and 9 (Lagna et al., 2006, Zhang et al., 2003).  
However, in cells taken from patients with PAH, BMP-induced apoptosis is 
significantly attenuated (Zhang et al., 2003, Yang et al., 2005, Lagna et al., 
2006).  These cells displayed mutations in the kinase domain or carboxy-
teminus of BMPR-2 and were also found to be deficient in Smad signalling 
(Lagna et al., 2006, Yang et al., 2005, Zhang et al., 2003).  Loss of function 
mutants in BMPR-2 have also been reported to contribute to increased 
endothelial cell survival and decreased apoptosis (Teichert-Kuliszewska et al., 
2006).  In addition to this, in the monocrotaline-rat model of PAH, TGF-β 
receptor (TGF-βR) 1 and TGF-βR2, as well as Smad 3 and 4, were all found to 
be reduced in the lung and PASMCs, resulting in decreased TGF-β-induced 
signalling and apoptosis (Zakrzewicz et al., 2007). Furthermore, in mice 
developed to incorporate an inducible dominant-negative mutant of the TGF-
βR2 receptor, chronic hypoxia-induced pulmonary hypertension was 
significantly attenuated (Chen et al., 2006).   
TGF-β activity may also influence other factors implicated in vascular 
remodelling.  For instance, TGF-β induces ET-1 production in human pulmonary 
arteries (Markewitz et al., 2001), as well as stimulating connective tissue growth 
factor (CTGF) production in pulmonary fibroblasts (Kucich et al., 2001).  These 
findings suggest a role for the TGF-β superfamily of receptors and downstream 
signalling cascades in the development of pulmonary hypertension, and also 
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highlight the requirement for a balance between apoptosis and proliferation in 
the maintenance of a healthy vascular system. 
 
POTASSIUM CHANNELS AND VASCULAR REMODELLING 
 
As mentioned previously, Kv channels play an important role in mediating 
vasoconstriction during PAH.  The downregulation of Kv1.5 and Kv2.1 channels 
that occurs during PAH also play a significant role in pulmonary vascular 
remodelling.  Chronic decreases in K+ channel expression induces PASMC 
proliferation and hypertrophy (Mandegar et al., 2004). This is thought to occur 
as loss of Kv current depolarises the cell membrane resulting in the intracellular 
accumulation of calcium, with the Ca2+/Calmodulin complex subsequently 
formed responsible for activating several steps of the cell cycle and thus favours 
cellular proliferation (Hardingham et al., 1997).  In addition to the 
downregulation of Kv channels contributing to proliferation, it also appears to 
have an effect on apoptotic processes.  Previously, activation of Kv channels 
has been reported to play an important role in both early and late volume 
decrease associated with the induction of apoptosis (Platoshyn et al., 2002).  
Therefore, the downregulation of these channels in PAH has an inhibitory effect 
on apoptosis.  Furthermore, the resulting intracellular accumulation of K+ ions 
due to the loss of Kv channels has been shown to inhibit caspases and thus 
decrease apoptosis (Thornberry and Lazebnik, 1998, Bortner and Cidlowski, 
1999, Bortner et al., 1997).  In addition to this, survivin, a known inhibitor of 
apoptosis has been reported to be expressed in PAH, resulting in Kv channel 
downregulation in PASMCs (McMurtry et al., 2005).  Overexpression of survivin 
in normal PASMCs promotes proliferation and decreases Kv current.  
Conversly, treatment with a dominant negative survivin mutant was found to 
significantly increase Kv current  in PASMC from PAH patients and attenuate 
the effects of  experimental PAH in vivo (McMurtry et al., 2005). 
In summary, it can be seen that Kv channels play an important role in 
maintaining the balance between apoptosis and proliferation in pulmonary 
smooth muscle cells, and that the downregulation of these channels in PAH tips 
the balance in favour of proliferation and thus contributes to vascular 
remodelling.  
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ENDOTHELIUM-DERIVED FACTORS AND VASCULAR REMODELLING 
 
As mentioned previously, endothelial-derived factors play an important role in 
regulating vascular tone.  However, changes in the synthesis and expression of 
these mediators during PAH also contribute to vascular remodelling.  In addition 
to its potent vasodilatory effects NO also has anti-proliferative capabilities.  
Therefore its reduction in PAH may be a factor in the remodelling process.  
Indeed, decreases in endothelial NOS (eNOS) expression were reported in the 
vascular endothelium of patients with PAH, with expression levels correlating 
inversely to the severity of the histological changes observed (Giaid and Saleh, 
1995).  Furthermore, in a hypoxic model of PAH, prolonged inhaled NO therapy 
resulted in a marked attenuation in the level of muscularised arteries and right 
ventricular hypertrophy (RVH) (Horstman et al., 1998).  Inhaled NO has also 
been used in the treatment of patients, markedly reducing pulmonary artery 
pressure and PVR (Channick et al., 1996). 
NO mediates it effects by binding to and activating guanylyl cyclase, thus 
elevating intracellular levels of cGMP (Stasch et al., 2002).  Phosphodiesterase 
(PDE) enzymes are important in regulating the cellular levels of cGMP and 
cyclic 3’, 5’ adenosine monophosphate (cAMP), by controlling their rates of 
degradation (Bender and Beavo, 2006).  Several studies have reported the 
upregulation of PDEs during PAH, including elevated levels of PDE1, 3 and 5 
(Schermuly et al., 2007, Murray et al., 2002, Murray et al., 2007, Maclean et al., 
1997).  Selective inhibition of these PDEs has been found to have 
antiproliferative effects (Murray et al., 2007, Wharton et al., 2005) and reduce 
pulmonary vascular remodelling (Schermuly et al., 2004, Schermuly et al., 
2007, Sebkhi et al., 2003, Garg et al., 2006). 
In addition to its vasoconstrictive effects, ET-1 acts as a growth factor 
(Yanagisawa, 1994) and has been found to play a crucial role in vascular 
remodelling during PAH.  ET-1 predominantly binds to two receptors, 
endothelin-A (ETA) and endothelin-B (ETB) receptors. Responses to ET-1 
appear to be mainly via the ETA receptor subtype (Arai et al., 1990, Barnes and 
Liu, 1995).  ETA receptors are found on smooth muscle cells only and, when 
activated, induce vasoconstriction and cellular proliferation. ETB receptors on 
smooth muscle cells, when activated, cause vasoconstriction, whereas those on 
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endothelial cells produce vasodilation (via production of NO) and clearance of 
circulating ET-1 (Galie et al., 2004).  Hypoxia has been shown to attenuate ETB-
induced vasoconstriction in rat pulmonary arteries.  This study suggested that 
the hypoxia-induced production of ROS increases ET-1 release from endothelial 
cells and results in the downregulation of ETB receptors on SMCs (Wang et al., 
2006).  
The upregulation of ET-1 occurs in the lungs of patients with various etiologies 
of PAH (Giaid et al., 1993).  Confirming the role of ET-1 in the development of 
PAH, treatment with ET antagonists have been found to attenuate the 
development of pulmonary vascular remodelling in a variety of models of the 
condition (Kim et al., 2000, Oparil et al., 1995, Eddahibi et al., 1995, Okada et 
al., 1995).  Furthermore, bosentan, a competitive antagonist at both ETA and 
ETB receptors, is benefical in the treatment of human PAH (Rubin et al., 2002).  
Therefore, endothelial-derived mediators play an important role in regulating 
vascular tone and cell proliferation within the pulmonary vasculature, with 
dysregulation of these mediators significantly contributing to the development of 
PAH. 
 
THE POTENTIAL ROLE OF EICOSANOIDS IN PULMONARY VASCULAR 
REMODELLING 
 
Eicosanoids such as prostacyclin and thromboxane A2 (TXA2) have been 
implicated in the pathophysiology of PAH.  As mentioned previously, TXA2 
levels are elevated in endothelial cells from patients with PAH.  This contributes 
to vasoconstriction during PAH and also has mitogenic effects, in addition to 
contributing to platelet aggregation.  Patients with PAH have elevated levels of 
urinary 11-dehydro-TXB2, a major urinary metabolite of TXA2, suggesting a role 
for TXA2 in the pathogenesis of PAH (Christman et al., 1992).  In an in vivo 
model of the condition, inhibition of TXA2 significantly reduced arterial media 
thickness, as well as RVH, delaying the onset of PAH.  These beneficial effects 
were suggested to be mediated mainly by inhibiting platelet aggregation 
(Nagata et al., 1997). 
Prostacyclin synthesis is also altered in PAH.  In addition to its vasodlilatory 
properties, prostacyclin inhibits smooth muscle cell proliferation and platelet 
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aggregation (Fetalvero et al., 2007).  As mentioned earlier, endothelial cells 
from patients with PAH have reduced expression of prostacyclin synthase 
(Tuder et al., 1999) and decreased levels of prostacyclin metabolites have been 
observed in the urine of such patients (Christman et al., 1992).  Prostacylin 
therapy is a mainstay in the treatment of PAH, with many prostacylin analogues 
such as epoprostenol, treprostinil and beraprost improving the pulmonary 
function of patients (Lee and Rubin, 2005).  Another such analogue, iloprost, 
has been reported to have beneficial effects on pulmonary vascular remodelling 
in vivo; reducing RVH, medial wall thickness and the number of muscularised 
pulmonary arteries in monocrotaline-induced PAH (Schermuly et al., 2005b).  In 
summary, the balance between the actions of TXA2 and prostacyclin are 
important in maintaining a healthy pulmonary vasculature.  Alterations in levels 
of these mediators during PAH contribute to the progression of the disease. 
 
ANGIOGENIC AND GROWTH FACTORS AND VASCULAR REMODELLING 
 
Abnormalities in the expression of various angiogenic factors and growth factors 
have been suggested to play a role in PAH.  One such factor, namely VEGF, 
has been implicated in various etiologies of PAH.  VEGF is a vascular 
endothelial cell-specific mitogen with pro-angiogenic properties and is secreted 
by various cell types.  In systemic vessels, increases in VEGF bioavailability at 
sites of endothelial injury accelerate repair and attenuate neointimal formation 
(Asahara et al., 1995).  In addition to this, VEGF overexpression within the 
vascular wall restores endothelium dependent relaxation and protects against 
vasoconstriction and platelet aggregation (Thomas, 1996).  VEGF is abundant 
in the adult lung (Monacci et al., 1993) and can be regulated by hypoxia 
(Monacci et al., 1993, Liu et al., 1995).  Indeed, increase in VEGF, VEGFR1 
and VEGFR2 have been observed in the lungs of hypoxic rats (Tuder et al., 
1995, Christou et al., 1998).  Similary, the upregulation of VEGF has also been 
observed in platelets from patients with PAH (Eddahibi et al., 2000b), in addition 
to increased levels of VEGF and VEGFRs in the lungs of such patients (Hirose 
et al., 2000).  In particular VEGF and VEGFR expression appears to be 
upregulated in plexform lesions (Tuder and Voelkel, 2001), with VEGF levels 
elevated in SMCs inside and adjacent to these areas (Hirose et al., 2000).  
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Furthermore, VEGFRs were also observed to be expressed on endothelial cells 
in and around these lesions (Hirose et al., 2000).  In addition to its beneficial 
effects in the systemic circulation, overexpression of VEGF also appears to play 
a protective role in the pulmonary circulation, as highlighted by various in vivo 
studies.  For instance, VEGFR2 inhibition in chronically hypoxic rats results in 
severe PAH (Taraseviciene-Stewart et al., 2001).  Conversly, VEGFA 
overexpression markedly attenuates the development of hypoxic PAH in rats.  
Comparable effects were also observed in rats where gene transfer of VEGFA 
to the pulmonary microvasculature had been undertaken.  In these animals the 
effects of monocrotaline-induced PAH were significantly reduced even in PAH 
that was already established (Campbell et al., 2001).  VEGFA overexpression in 
chronically hypoxic rats also has a protective effect (Partovian et al., 2000).  
Similarly, overexpression of VEGFB has also been reported to have beneficial 
effects (Louzier et al., 2003).  It has been suggested the advantageous effects 
of VEGF overexpression may be due to its ability to protect endothelial function 
and upregulate mediators such as eNOS (Kroll and Waltenberger, 1998, Hood 
et al., 1998, Partovian et al., 2000).  Furthermore, it has also been proposed 
that endogenous levels of VEGF do not counteract PAH, but that it is the 
upregulation of VEGF that assists in combating the condition.  This is supported 
by data showing that in mice, where VEGFB has been knocked out, 
haemodynamic changes in response to hypoxia remain unaffected (Louzier et 
al., 2003).  Moreover, in patients with PAH receiving prostacyclin therapy, levels 
of VEGF are elevated compared to control (Eddahibi et al., 2000b). 
Angiopoetin-1 (Ang-1), a smooth muscle-secreted ligand that plays a pivitol role 
in vasculogenesis and is an important mediator of both physiological and 
pathological angiogenesis (Hayes et al., 1999), has also been implicated in the 
development of PAH.  Ang-1 signal transduction occurs via the endothelial-
specific receptor Tie2 (Davis et al., 1996).  Ang-1 is absent in normal adult lung 
tissue, but appears to be constitutively expressed in lungs from PAH patients 
(Du et al., 2003).  A potential role for Ang-1 in PAH is also highlighted by 
development of the condition in rodents genetically engineered to constitutively 
express Ang-1 in the lung (Sullivan et al., 2003).  Furthermore, Ang-1 has also 
been reported to attenuate the expression of BMPR1a, which is required for 
BMPR2 signalling in PAECs (Du et al., 2003).  Given the role of BMPR2 in 
 29 
PAH, inhibition of its signalling by Ang-1 may contribute to vascular remodelling.  
It has also been suggested that Ang-1 may contribute to pulmonary artery 
remodelling by stimulating the proliferation of PASMCs.   Human PAECs treated 
with Ang-1 have been shown to produce 5HT, which then acts on SMCs 
resulting in their proliferation (Sullivan et al., 2003).  However, in contrast to a 
notion that Ang-1 contributes to the development of PAH, a protective role has 
also been reported.  In this study, Ang-1 gene therapy reduced mortality, 
systolic right ventricular pressure (sRVP) and RVH in monocrotaline-induced 
PAH (Zhao et al., 2003).  Although contradictory, these studies imply a role for 
Ang-1 in the pulmonary hypertensive process.  More recently, other studies 
have confirmed the pathogenic effects of Ang-1 in PAH.  For instance in some 
rodent models of PAH, gene transfer of a Tie2 receptor antagonist markedly 
reduced the development of PAH (Kido et al., 2005).  Furthermore, another 
study showed increased levels of Tie2 receptor expression and phosphorylation 
in PAECs from PAH patients (Dewachter et al., 2006).  This also suggests the 
Ang-1/Tie 2 pathway is potentiated in PAH patients, resulting in the increased 
production of endothelial cell-derived growth factors such as ET-1 and 5HT 
which may then contribute to SMC proliferation. 
Platelet-derived growth factor (PDGF) may also contribute to PAH.  In an animal 
model of the condition, increased levels of PDGF receptors (PDGFR) have 
been observed (Balasubramaniam et al., 2003).  Furthermore, it has also been 
reported that PDGF antagonists have beneficial effects in rats with 
monocrotaline-induced PAH, in addition to the chronic hypoxic mouse model of 
the condition, reversing vascular remodelling in both instances (Schermuly et 
al., 2005a).   
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Figure 1.5  TGF-β receptor signal transduction pathway induced by BMP ligands. 
 
BMP ligands (BMP-2,-4,-7) bind the receptor complex at the cell surface inducing phosphorylation of the type 1 receptor by the type 
2 receptor.  The active type 1 receptor then phosphorylates and activates Smad1/5/8, which subsequently dimerise and interact 
with the common mediator Smad, Smad 4.  This complex then translocates to the nucleus resulting in the transcription of Smad-
responsive genes such as Id (inhibitor of differentiation) and Msx-1 (Miyazono et al., 2005, Alvarez Martinez et al., 2002).  Figure 
adapted from Derynck and Zhang (2003). 
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1.4  5-HYDROXYTRYPTAMINE (5HT) 
 
In addition to the mediators of PAH mentioned previously, 5HT has been shown 
to play a pivitol role in the disease process, as will be described in the following 
section. 
 
1.4.1  5HT STRUCTURE, SYNTHESIS AND METABOLISM  
 
5HT, or “serotonin”, was chemically identified by Rapport et al (1948) as one of 
the major vasoconstricting substances in defibrinated blood, originating from 
platelets.  It was subsequently found to also act as a major neurotransmitter, 
being involved in a variety of  processes carried out by the central nervous 
system (CNS), as well as regulating several functions in the periphery (Hoyer et 
al., 2002).  5HT is a monoamine, its structure comprising an amino group 
connected to an “indole” group by an ethyl chain (Figure 1.6).   
Production of 5HT occurs in a variety of cells including neurons, 
enterochromafin cells and endothelial cells.  The biosynthesis pathway converts 
dietary tryptophan to 5-hyroxytryptophan by the action of the enzyme 
tryptophan hydroxylase (TPH).  This process is the rate-limiting step in the 
generation of 5HT.  Two isoforms of TPH exist; TPH2 which is expressed 
abundantly in the brain, and TPH1, which is responsible for the synthesis of 
5HT in the periphery (Nakamura and Hasegawa, 2007).  5-hydroxytryptophan is 
then decarboxylated by a ubiquitous animo-acid decarboxylase, resulting in the 
formation of 5HT (Figure 1.7).  Upon synthesis, 5HT is taken up and stored by 
platelets as they pass through the intestinal circulation, as well as being stored 
in neurons and chromaffin cells. 
Degradation and inactivation of 5HT occurs through the action of monoamine 
oxidases (MAO), which catalyse its oxidative deamination.  Monoamine 
oxidases are found in most tissues and exist in 2 forms encoded by different 
genes, MAO-A and MAO-B.  It is MAO-A that preferentially catalyses the 
degradation of 5HT (Youdim and Bakhle, 2006).  Deamination by MAO-A is 
then followed by oxidation to 5-hydroxyindoleacetic acid, which is excreted in 
the urine (Figure 1.7).  
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1.4.2 PHYSIOLOGICAL FUNCTIONS OF 5HT 
 
The actions of 5HT are numerous and complex, varying between species and 
this is reflected by the large array of 5HT receptors that have been identified.  
The physiological effects of 5HT are mediated by 14 different receptor 
subtypes.  These receptors are divided into 7 distinct classes (5HT1 – 5HT7), 
mainly on the basis of their structural and functional characteristics (Hoyer et 
al., 2002).  5HT is also a substrate for the 5HT transporter (5HTT), which 
actively uptakes 5HT into cells (Torres et al., 2003).   
The gastrointestinal tract is one of the main sites of action of 5HT, where the 
monoamine stimulates gastrointestinal motility, fluid secretion and is involved in 
eliciting nausea and vomiting (Gershon and Tack, 2007).  In addition to this, 
5HT is also involved in the process of platelet aggregation, the dysregulation of 
which can contribute to thrombus formation and vascular disease (McNicol and 
Israels, 2003, Torr et al., 1990, Noble and Drake-Holland, 1990).  5HT also 
plays a role in nociception, stimulating nociceptive sensory nerve endings in a 
variety of tissues (Goadsby, 2000, Graven-Nielsen and Mense, 2001, Jeong et 
al., 2004).  Drugs targeting 5HT receptors are widely used in the treatment of 
migrane (Villalon et al., 2003).  Furthermore, a variety of processes in the CNS 
are regulated by 5HT; these include hallucinations and behavioural changes, 
sleep wakefulness, mood, feeding behaviour and control of sensory 
transmission (Barnes and Sharp, 1999). Clinical conditions associated with 
disturbed 5HT function include depression, anxiety, schizophrenia, carcinoid 
syndrome, and, as mentioned previously, migraine. (Bleich et al., 1988),  
 
1.4.3  GPCR REGULATION 
 
With the exception of the 5HT3 receptor, which is a ligand-gated ion channel, 
the 5HT receptors are members of the G-protein-coupled receptor (GPCR) 
suprefamily (Hoyer et al., 2002).  GPCRs regulate many physiological 
processes and include receptors for a range of chemically diverse hormones, 
neurotransmitters and chemokines (Pierce et al., 2002).  Comprised of an 
extracellular N-terminus, 7 transmembrane spanning helices and an intracellular 
C-terminus, most GPCRs signal by activating heterotrimeric G-proteins (Pierce 
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et al., 2002) (Figure 1.8).  G-proteins consist of α, β and γ subunits, and are 
generally referred to by their α-subunit.  To date 16 Gα subunits have been 
identified and grouped into 4 families, Gs, Gq, Gi and G12/13 (Milligan and 
Kostenis, 2006).  In addition to this, 5 β and 12 γ subunits have been reported 
(Milligan and Kostenis, 2006).  The pathways stimulated by GPCRs are 
dependent on the type of G-protein they associate with and receptors typically 
couple with one or more type of G-protein (Hamm, 1998).  The association of G-
protein with receptor is generally via the second or third intracellular loop of the 
GPCR (Hawes et al., 1994, Lameh et al., 1992).  The binding of agonist to its 
receptor results in a conformational change, facilitating the activation of the G-
protein by promoting the exchange of GDP for GTP at the guanine nucleotide 
binding site of Gα-subunit (Hamm, 1998, Pierce et al., 2002).  This process 
results in the dissociation of the Gα subunit from the Gβγ subunits, which 
remain bound together.  The activated Gα subunit and βγ dimer are then free to 
act as mediators of receptor-stimulated signalling pathways (Hamm, 1998) 
(Figure 1.9).  Giα subunits mediate intracellular signalling by inhibiting adenylyl 
cyclase, where as Gsα subunits stimulate adenylyl cyclase (Pierce et al., 2002).  
In addition to this, Gqα, activates phospholipase Cβ, while G12/13 have been 
shown to be involved in small G protein activation and cytoskeletal remodelling 
(Pierce et al., 2002, Ulloa-Aguirre et al., 1999).  Furthermore, Gβγ subunits can 
activate a variety of proteins, including PLCβ, (Clapham and Neer, 1997). 
   
1.4.4 5HT RECEPTOR CLASSES 
 
5HT mediates its physiological effects via activation of its multiple receptor 
subytpes.  The 5HT1 receptor class consists of 5 receptor subtypes:  5HT1A, 
5HT1B, 5HT1D, 5ht1E and 5ht1F receptors.  In humans these receptors share 40-
63% sequence identity and mediate their effects by coupling preferentially to 
Giα, thus inhibiting adenylyl cyclase and  cAMP production (Hoyer et al., 2002).  
5ht1E and 5ht1F receptors are designated with lower case to indicate that a 
physiological role for these endogenous receptor has not yet been 
demonstrated (Hoyer et al., 2002).  However, physiological functions for 5HT1A, 
5HT1B and 5HT1D receptors have been well characterised.  5HT1A receptors are 
largely distributed throughout the CNS and in the raphe nuclei act as 
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autoreceptors to attenuate serotonergic neuron firing (Hoyer et al., 2002).  This 
receptor subtype is also  involved in modulating many behavioural effects such 
as anxiety and depression (Hoyer et al., 2002).  Currently, the 5HT1A receptor 
agonist buspirone is used clinically in the treatment of these conditions (Den 
Boer et al., 2000).   
5HT1B receptors are expressed in the CNS where they act as terminal 
autoreceptors (Hoyer et al., 2002) and may also be involved in controlling the 
release of other neurotransmitters such as acetylcholine and noradrenaline 
(Pauwels, 1997).  Also located on cerebral arteries and other vascular tissues, 
they play a role in mediating contraction (Hoyer et al., 2002).  The 5HT1D 
receptor possesses 63% structural homology with the 5HT1B receptor, although 
its expression is low compared with the 5HT1B (Hoyer et al., 2002).  5HT1D 
receptors have been found in the human heart where they modulate 5HT 
release (Hoyer et al., 2002).  In addition to this, the receptor may also play a 
role in neurogenic inflammation and nociception.  Indeed, 5HT1D receptor 
antagonists have been shown to suppress these processes in guinea pig 
models, suggesting it may be a therapeutic target in the treatment of migraine 
(Cutrer et al., 1999). Many currently available drugs used in the treatment of 
migraine act as antagonists at both 5HT1B and 5HT1D receptors (Hoyer et al., 
2002). 
The 5HT2 class of receptor includes the 5HT2A, 5HT2B and 5HT2C receptors 
which exhibit 46-50% overall sequence homology.  These receptors couple 
preferentially to Gq, activating phospholipase C (PLC) to increase the formation 
of inositol 1,4,5 trisphosphate and elevate cytosolic Ca2+ (Hoyer et al., 2002).  
5HT2A receptors are widely expressed in both the CNS and periphery, where 
they are involved in mediating vascular SMC contraction in bronchial, uterine 
and urinary tissues (Hoyer et al., 2002).  5HT2A receptors are also involved in 
mediating platelet aggregation, thrombosis and increased capillary permeability 
following exposure to 5HT (Nagatomo et al., 2004).  In the CNS, stimulation of 
this receptor mediates secretion of hormones such as renin and prolactin (Van 
de Kar et al., 2001).  Furthermore, activation of this receptor class also 
mediates many behavioural functions and has been implicated in conditions 
such as schizophrenia (de Angelis, 2002).  The 5HT2B receptor has been 
located in the gastric fundus where it mediates fundic SMC contraction (Hoyer 
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et al., 2002).  They are also expressed in the heart, brain and lung (Hoyer et al., 
2002).  The 5HT2B receptor has been associated with promoting cell cycle 
progression in fibroblasts (Nebigil et al., 2000b) and cell survival in 
cardiomyocytes (Nebigil et al., 2003).  It may also contribute to cardiac 
hypertophy (Nebigil and Maroteaux, 2003).  Furthermore, the 5HT2B receptor is 
required for normal heart formation during embryogenesis (Nebigil et al., 
2000a). Expression of the 5HT2C receptor is widespread throughout the CNS 
and also found in the choroid plexus (Hoyer et al., 2002).  5HT2C receptors have 
been found to mediate various behavioural effects and are involved in 
conditions such as anxiety, depression and panic disorders (Lacivita and 
Leopoldo, 2006).  This receptor subtype also plays a role in regulating 
dopaminergic function and inhibits dopaminergic transmission (Di Matteo et al., 
2002).  Additionally, 5HT2C receptors have been found to be involved in 
mediating seizures and convulsion and as such are being considered in the 
treatment of epilepsy (Isaac, 2005).  Furthermore, appetite and glucose 
homeostasis as also controlled, in part by the 5HT2C receptor (Lacivita and 
Leopoldo, 2006).  Notably, many antipsychotic drugs mediate their effects via 
antagonism of 5HT2A and 5HT2C receptors (Leysen, 2004).  
Located on both central and peripheral neurones, the 5HT3 receptors are 
ligand-gated ion channels which trigger rapid depolarisation due to Na+ and 
Ca2+ influx and K+ efflux (Hoyer et al., 2002).
 
 5HT3 receptors play a particularly 
important role in the gut, regulating gastric motility and intestinal secretion 
(Hoyer et al., 2002). These receptors are also involved in mediating 
chemotherapy- and radiotherapy-induced nausea and emesis (Gandara et al., 
1998, Hoyer et al., 2002). 
5HT4, 5ht6 and 5HT7 receptors all couple preferentially to Gs, promoting cAMP 
formation (Hoyer et al., 2002).  Located in the GI tract, heart and CNS, 5HT4 
receptors mediate a variety of functions (Hoyer et al., 2002).  In the gut, 5HT4 
receptors are involved in regulating gastric motility (Degen et al., 2001) and as a 
result, 5HT4-selective agonists such as prucalopride are used in the treatment 
of some forms of irritable bowel syndrome (IBS) (De Schryver and Samsom, 
2000, Spiller, 2004). In addition to this, 5HT4 receptors have been found in atria 
and ventricles of the heart, where they regulate heart rate, atrial contractile 
force and relaxation (Bach et al., 2001, Hegde and Eglen, 1996).  Furthermore, 
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CNS effects of the 5HT4 receptor include modulation of neurotransmitter 
release, enhanced synaptic transmission and a potential role in memory (Hoyer 
et al., 2002). 5ht6 receptors are almost exclusively expressed in the CNS, where 
they have been shown to regulate glutamatergic and cholinergic neuronal 
activity (Woolley et al., 2004).  This receptor may also be involved in the 
regulation of cognition and feeding (Woolley et al., 2004).  5HT7 receptors are 
expressed extensively in the vasculature and also in nonvascular smooth 
muscle, where it mediates relaxation (Thomas and Hagan, 2004).  In the CNS, 
this receptor may also be involved in anxiety and cognitive disturbances 
(Thomas and Hagan, 2004).  Possible roles in circadian rhythms, sleep, 
thermoregulation and learning and memory have also been reported (Hedlund 
and Sutcliffe, 2004, Jovanovska and Prosser, 2002, Thomas and Hagan, 2004).  
Little is known about the 5ht5 receptor class.  Two subtypes (5ht5A and 5ht5b) 
have been identified in rodents, however only the 5ht5A gene has been found to 
encode a functional protein in humans (Nelson, 2004).  5ht5 receptors are 
thought to couple to Gi/o, decreasing levels of cAMP (Carson et al., 1996, 
Francken et al., 1998).   With widespread expression in the CNS, the 5ht5A 
receptor has been proposed to act as an autoreceptor and may also be involved 
in the control of circadian rhythms (Thomas, 2006) (Figue 1.10).   
 
1.4.5 5HT TRANSPORTER (5HTT) 
 
The 5HT tansporter is a member of the NaCl-dependent transporter family that 
cotransport their substrate together with Na+ and Cl- ions (Torres et al., 2003).  
5HTT is responsible for the clearance of 5HT from the synaptic cleft following 
release of the neurotransmitter, thereby terminating its action (Torres et al., 
2003).  Other cell types also express 5HTT, including platelets (Talvenheimo 
and Rudnick, 1980), which acquire extracellular 5HT for subsequent release in 
the process of platelet activation (Cirillo et al., 1999). Expression has also been 
observed in the intestinal tract (Wade et al., 1996), adrenal gland (Schroeter et 
al., 1997), blood vessels, heart (Ni and Watts, 2006) and lungs (Marcos et al., 
2004).  Furthermore, 5HTT is one of the primary targets for drugs used in the 
treatment of depression, including tricyclic antidepressants and selective 
serotonin reuptake inhibitors (SSRIs) (Zohar and Westenberg, 2000), as well as 
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being a target for drugs of abuse such as amphetamines, NMDA and cocaine 
(Ricaurte et al., 2000, Koob, 2000). 
Structurally, 5HTT consists of 12 transmembrane domains (TMDs), connected 
by 6 extracellular and 5 cytoplasmic loops, with both the amino and carboxyl 
termini residing in the cytoplasm (Torres et al., 2003, Nelson, 1998) (Figure 
1.11).  In TMD1, an aspartic acid residue (D98) is key for substrate recognition, 
possibly through interactions between the carboxyl group and the positive 
change of the amine group of 5HT (Barker et al., 1999).  In addition to this 
TMD3 and the third intracellular loop are also important in the function of 5HT 
binding and translocation. The TMD3 binds 5HT at a site located in the 
translocation path, while the third intracellular loop contains a reactive cysteine 
residue (Cys357), sensitive to conformational changes that result from ion and 
ligand binding (Androutsellis-Theotokis et al., 2001). 
The driving force for 5HT uptake is the ion concentration gradient generated by 
the plasma membrane Na+/K+ ATPase.  5HTT cotransports 5HT with one Na+ 
and one Cl- ion, while the counter-transport of K+ outwards is required in the 
translocation mechanism (Torres et al., 2003, Nelson, 1998).  Binding of 5HT, 
Na+ and Cl- induces a conformational change in the transporter allowing 
exposure of the 5HT binding site to the opposite side of the membrane and thus 
transport of substrate and ions (Nelson, 1998, Torres et al., 2003).  The 
reorientation of 5HTT then requires the binding and outward transport of 
intracellular K+ ions (Nelson, 1998, Torres et al., 2003).  In certain 
circumstances 5HTT may act in reverse, transporting 5HT out of the cell.  This 
mechanism is especially important in the action of amphetamines, which induce 
massive release of monoamines (Seiden et al., 1993).    
The activity of 5HTT can be regulated by both pre- and post-transcriptional 
modifications.  5HTT is encoded by a single gene on chromosome 17q11.2 
(Ramamoorthy et al., 1993).  Polymorphisms in this gene have been identified 
and found to alter the activity of 5HTT.  These polymorphisms occur in the 5’- 
flanking promoter region and consist of multi-allelic 17-bp tandem repeat and an 
insertion/deletion of a 44-bp sequence (Lesch et al., 1996).  This results in long 
(L) and short (S) alleles, with the S form shown to have reduced transcriptional 
efficiency, decreased 5HTT expression and 5HT uptake (Lesch et al., 1996). 
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Posttranscriptionally, protein kinase C (PKC), protein phosphatase 2A (PP2A) 
and p38 are all involved in the regulation of 5HTT activity.  Multiple serine and 
threonine phosphorylation sites have been located on the cytoplasmic domains 
of 5HTT and phosphorylation appears to play a major role in regulating 5HTT 
trafficking and thus its ability to take up 5HT.  Activation of PKC has been 
shown to phosphorylate 5HTT in a calcium-dependent manner, resulting in its 
internalisation and a decreased activity (Jayanthi et al., 2005, Ramamoorthy et 
al., 1998, Samuvel et al., 2005).  Conversly, inhibition of protein phosphatase 
2A (PP2A) also increases 5HTT phosphorylation and subsequent internalisation 
(Ramamoorthy et al., 1998), highlighting the important role phosphorylation 
plays in regulating 5HTT.  Interestingly 5HT has been found to decrease 5HTT 
phosphorylation, thus inhibiting its internalisation (Ramamoorthy et al., 1998).  
This may be a negative feedback mechanism to prevent 5HTT downregulation 
when high levels of extracellular 5HT are present.   The mitogen-activated 
protein kinase (MAPK) p38 also regulates the activity of 5HTT in manner 
distinct from that of PKC, by regulating the delivery of 5HTT to the plasma 
membrane (Samuvel et al., 2005).  In this study inhibition of p38 decreased 5HT 
uptake by attenuating the levels of the transporter present at the membrane.  
Furthermore, receptor mediated activation of p38 has been shown to result in 
enhanced 5HTT activity, by a process that was independent of 5HTT trafficking 
(Zhu et al., 2005).  This effect was dependent on activity of PP2A.  Taken 
together, these finding suggest the importance of phosphorylation in the 
regulation of 5HTT activity, in addition to its regulation at a genetic level (Figure 
1.12). 
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Figure 1.6  Diagram of the chemical structure of 5-hydroxytryptamine 
(5HT). 
 
5HT is a biogenic amine. It structure comprises of an amino group, which is 
attached to an indole group by an ethyl chain. 
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Figure 1.7  5HT biosynthesis and metabolism pathway. 
 
5HT is synthesised from dietary tryptophan, which is converted to 5-hydroxytryptophan by the enzyme tryprophan hydroxylase, 
then to 5HT by a non-specific decarboxylase.  Degradation occurs by the enzyme monoamine oxidase-A, resulting in the formation 
of 5-hydroxyindoleacetic acid, which is excreted in urine. 
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Figure 1.8  General Structure of a GPCR. 
 
Diagram represents a typical GPCR, consisting of seven transmembrane-
spanning α-helices, with an extracellular N-terminus and intracellular C-
terminus.  The central core comprises transmembrane domain II, III, V and VI, 
and is essential in ligand binding.  Glycosylation sites towards the N-terminus 
as thought to be involved in receptor trafficking.  Figure adapted from Ulloa-
Aguirre et al (1999). 
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Figure 1.9  The function of the G-protein in mediating agonist induced signal transduction. 
 
The binding of agonist to a GPCR results in coupling of the α-subunit of its associated G-protein to the receptor and subsequent 
exchange of GDP for GTP.  Exchange of GDP for GTP results in the dissociation of α and βγ subunits, allowing them to interact 
with effector proteins and initiate cellular responses.  The intrinsic GTPase activity of the α-subunit hydrolyses GTP to GDP, 
resulting in the reassociation of α and βγ subunits and terminates receptor signalling. 
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Figure 1.10  Diagram summarising mechanisms by which 5HT receptors mediate their response. 
 
All 5HT receptors except the 5HT3 are G-protein-coupled receptors, with different receptors coupled to different G-proteins to elicit 
a reponse.  The 5HT3 receptor is a ligand-gated non-selective cation channel.
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Figure 1.11  Diagram of proposed topology of the 5HT transporter (5HTT). 
 
5HTT is comprised of 12 transmembrane domains connected by intracellular and extracellular loops with both the C- and N-
terminus located in the cytoplasm.  Figure adapted from Torres et al (2003). 
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Figure 1.12  Post-translational regulation of the activity of the 5HT 
transporter (5HTT). 
 
Activation of protein kinase C (PKC) results in the phosphorylation and 
subsequent inactivation and internalisation of 5HTT.  The presence of 5HT 
inhibits 5HTT phosphorylation retaining active 5HTT at the plasma membrane.  
p38 MAP kinase is required for the trafficking of active 5HTT back to the plasma 
membrane.  Furthermore the activation of p38 by cell surface receptors such as 
the adenosine receptor is important in maintaining 5HTT in its active state, a 
process that is dependent on protein phosphatase 2A (PP2A). 
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1.5  ROLE OF 5HT AND 5HTT IN PULMONARY HYPERTENSION 
 
In the lungs, 5HT is locally released from pulmonary neuroendocrine cells and 
neuroepithelial cell bodies distributed throughout the airways.  The lungs play 
an important role in the removal of 5HT from the circulation, with as much as 
95% being taken up or inactivated (Gaddum et al., 1953, Thomas and Vane, 
1967, Wiersma and Roth, 1980).  Under normal circumstances, pulmonary 
tissue is exposed to low levels of 5HT as it is taken up and stored in platelets, 
thus removing it from the circulation.  However, under hypoxic conditions 
(Johnson and Georgieff, 1989) and during situations involving mechanical strain 
(Pan et al., 2006) large amounts of 5HT are secreted.  In the pulmonary 
circulation 5HT is thought to play a role in promoting SMC proliferation, 
vasoconstriction and thrombosis, processes involved in the development of 
PAH. 
A large body of evidence now exists implicating 5HT in the development of the 
condition.  For instance, several patients with PAH have elevated plasma levels 
of 5HT, in addition to a decrease in the levels of 5HT stored in platelets (Herve 
et al., 1995).  Moreover, 5HT was also implicated in the development of PAH in 
patients following treatment with anorexigens such as aminorex and 
fenfluramine derivatives.  Aminorex increases plasma levels of 5HT by inducing 
its release from platelets and attenuating its breakdown by inhibiting MAO 
(Zheng et al., 1997, Fishman, 1999).  Fenfluramine derivatives also increase 
levels of circulating 5HT.  These anorexigens interact with 5HTT, stimulating the 
release of 5HT from platelets and inhibit its reuptake (Buczko et al., 1975, 
Fristrom et al., 1977). Furthermore, in PAECs from PAH patients, increased 
TPH1 expression and 5HT synthesis has been observed and this was thought 
to contribute to increased SMC proliferation (Eddahibi et al., 2006).  Another 
study found that the effects of chronic hypoxia were markedly attenuated in 
mice deficient in TPH, with reductions in right ventricular pressure (RVP) and 
vascular remodelling reported (Morecroft et al., 2007).  Together, these 
observations confirm an important role for 5HT in vascular remodelling during 
PAH. 
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Both 5HT receptors and 5HTT contribute to the actions of 5HT in the pulmonary 
hypertensive process.  5HT is a potent vasoconstrictor and in the human 
pulmonary arteries mediates its effects via the 5HT1B receptor (Morecroft et al., 
1999), whilst the 5HT2A receptor is important in the contractile response in other 
species, including rats (Chand and Altura, 1980, MacLean et al., 1996).  
However, in rats maintained under chronic hypoxic conditions, contractile 
responses to 5HT are enhanced and this process is mediated by both 5HT2A 
and 5HT1B receptors (MacLean et al., 1996, Keegan et al., 2001).  5HT1B 
receptors have also been found to be upregulated in experimental PAH 
(Rondelet et al., 2003).  In addition to the role of 5HT receptors in 
vasoconstriction, they also play a role in mediating vascular remodelling.  In 
chronically hypoxic rats, administration of a 5HT1B antagonist significantly 
reduced hypoxia-induced right ventricular hypertrophy (RVH) and vascular 
remodelling (Keegan et al., 2001).  Furthermore, in 5HT1B knock-out mice, 
chronic hypoxia-induced PAH was also markedly attenuated (Keegan et al., 
2001).  The 5HT2B receptor has also been reported to facilitate the development 
of PAH.  In one study, chronically hypoxic mice with inactive 5HT2B receptors 
failed to develop PAH (Launay et al., 2002).  This study also observed an 
increase in 5HT2B receptor transcript in patients with idiopathic PAH.  
Additionally, treatment with 5HT2A receptor-selective antagonists have been 
found to have beneficial effects, improving survival and reducing vascular 
remodelling in monocrotaline-induced PAH (Hironaka et al., 2003).  
Furthermore, several cellular studies have highlighted the mitogenic effects of 
5HT in the pulmonary cells and therefore its potential contribution to vascular 
remodelling.  In some cell types the mitogenic effects are mediated via 5HT 
receptors. In rat pulmonary artery fibroblasts for example, inhibition of the 5HT2A 
receptor markedly reduced 5HT-induced proliferation (Welsh et al., 2004).  
Similar effects have also been observed in other fibroblast cell lines (Lee et al., 
1999).  However, it is the 5HTT that has attracted most attention in recent times 
and several lines of evidence suggest a major role for 5HTT in vascular 
remodelling. 
5HTT expression has been found to be elevated in the lungs of many patients 
with PAH.  This increased expression has been associated with polymorphisms 
in the 5HTT gene (Eddahibi et al., 2003).  In a study carried out by Eddahibi et 
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al (2001), 65% of patients with idiopathic PAH were found to be homozygeous 
for the L-allelic variant, conferring increased expression of 5HTT, compared to 
only 27% of controls.  Subsequently, in patients with the LL-genotype, PAH was 
found to be more severe than those with LS or SS-genotypes who expressed 
lower levels of 5HTT (Eddahibi et al., 2003).  Various animal models also 
support the role of 5HTT in the development of PAH and its contribution to 
vascular remodelling.  Such studies have shown that administration of 5HTT-
selective inhibitors protect against both hypoxia- and monocrotaline-induced 
PAH (Guignabert et al., 2005, Marcos et al., 2003).  Furthermore, mice deficient 
in 5HTT display a marked reduction in RVH and vascular remodelling in 
response to hypoxia compared with control (Eddahibi et al., 2000a).  Conversly, 
mice over-expressing 5HTT display increased RVP under normoxic conditions, 
and have notably exaggerated responses to hypoxia compared to control 
animals, with elevated vascular remodelling and RVH (MacLean et al., 2004). 
The levels of 5HTT, as well as 5HT1B, 5HT2A and 5HT2B receptors have all been 
found to be elevated in pulmonary arteries of patients with PAH (Marcos et al., 
2004).  However, only 5HTT is upregulated in PASMCs (Marcos et al., 2004), 
suggesting it may contribute specifically to SMC hyperplasia and play a role in 
mediating vascular remodelling.    In fact, in mice engineered to over-express 
5HTT in SMCs only, increases in RVP, RVH and vascular remodelling were 
observed to occur spontaneously by 8 weeks of age, with these effects 
worsening with time (Guignabert et al., 2006).  Furthermore, augmented 
proliferative capabilities of PASMCs from patients with PAH have been 
associated with increased expression levels of 5HTT (Marcos et al., 2004, 
Eddahibi et al., 2001).  The enhanced proliferation of these cells to 5HT or 
serum can be abolished by 5HTT inhibitors such as citalopram and fluoxetine 
(Marcos et al., 2004).  In further support of its role in vascular remodelling, the 
increase in 5HTT expression observed in PAH patients was located mainly in 
the medial layer of remodelled vessels (Eddahibi et al., 2001).  Hypoxia has 
also been found to result in increased 5HTT expression and transport activity, 
augmenting mitogenic responses in PASMCs (Eddahibi et al., 1999). Therefore, 
through the actions of 5HTT and its receptors, 5HT appears to play a major role 
in the development of pulmonary hypertension, contributing to both 
vasoconstriction and vascular remodelling. 
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1.6  ERK MAP KINASE PATHWAY 
 
The extracellular-signal regulated kinase (ERK) MAP kinase pathway is crucial 
in mediating the mitogenic effects of 5HT (Lee et al., 1999, Lee et al., 2001, 
Suzuki et al., 2003, Liu et al., 2004).  MAP kinases (MAPKs) are a family of 
well-conserved proteins expressed in all eukaryotic cells.  Three major classes 
of MAPKs have been identified: ERK, p38 and c-jun N-terminal kinase (JNK).  
MAPKs are serine/threonine kinases and are activated by phosphorylation on a 
Thr-X-Tyr motif.  ERK has the dual phosphorylation motif Thr-Glu-Tyr, JNK has 
Thr-Pro-Tyr and the Thr-Gly-Tyr motif is present on p38 (Davis, 1995).  The 
overall sequence identity among ERK, p38 and JNK is 40-45%.  p38 and JNK 
are activated by various stress stimuli, including cytokines, osmotic shock and 
hypoxia (Welsh et al., 2001b, Davis, 2000, Zarubin and Han, 2005) (Figure 
1.13).   
Currently eight ERK MAPKs have been identified, termed as ERK1-8 
(Bogoyevitch and Court, 2004).  ERK1 and ERK2 were the first identified 
members and are the most extensively studied.  They are expressed 
ubiquitously and have 90% sequence identity (Boulton et al., 1991).  The 
Ras/Raf/MEK/ERK cascade is a well conserved pathway that is involved in the 
control of many fundamental cellular processes such as proliferation, 
differentiation and apoptosis (Lewis et al., 1998, Pearson et al., 2001).  A wide 
range of extracellular stimuli have been found to activate ERK, via the 
stimulation of tyrosine receptor kinases and GPCRs, through Ras-dependent 
and Ras-independent pathways (Lewis et al., 1998).  The Ras/Raf/MEK/ERK 
pathway conveys signals in the form of a cascade of phosphorylation events.  
Receptor-mediated activation of Ras, a small GTPase, at the plasma 
membrane promotes its binding to the N-terminus of Raf kinases (Raf-1, A-Raf, 
B-Raf), recruiting Raf to the membrane and subsequently activating them.  Raf 
activation is also dependent on phosphorylation at multiple sites.  In the case of 
Raf-1, phosphorylation sites important for its activation at Ser338, Tyr341, 
Thr491 and Ser 949 have been identified (Chong et al., 2001). Once active Raf, 
then phosphorylates MEK (mitogen activated protein kinase kinase) within its 
activation loop at two serine residues (Ser 217 and Ser 221) (Alessi et al., 
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1994).  MEK may then subsequently activate ERK by phosphorylating tyrosine 
and threonine residues located within its kinase activation loop.  In the case of 
human ERK1, phoshorylation occurs at Tyr202 and Thr 204, while human 
ERK2 is phosphorylated on Tyr185 and Thr197.  Unlike MEK, significant ERK 
activation requires phosphorylation at both sites, with Tyr phosphorylation 
preceeding that of Thr (Ferrell and Bhatt, 1997).  Active ERK is then able to 
mediate many cellular processes by acting on substrates in the nucleus and 
cytoplasm (Kolch, 2005) (Table 1.2).   
In quiescent cells ERK is localised in the cytoplasm (Torii et al., 2004).  Under 
these circumstances, ERK forms a complex with MEK, which retains it in the 
cytoplasm due to the presence of a nuclear export sequence in the amino-
terminal domain of MEK (Fukuda et al., 1996).  Activation of ERK leads to the 
dissociation of the MEK/ERK complex allowing ERK to translocate to the 
nucleus where it can phosphorylate multiple transcription factors (refer to Table 
1.2), modulating gene transcription and mediating many physiological 
responses (Torii et al., 2004, Brunet et al., 1999, Lewis et al., 1998, Pearson et 
al., 2001) (Figure 1.14).  ERK activity is terminated by dephosphorylation of the 
tyrosine and threonine groups within its activation loop.  Dual specificity 
phosphatases (DUSPs), which display differing levels of specificity for MAPKs, 
play an important regulatory role by dephosphorylating and inactivating ERKs.  
At least nine DUSPs have been isolated in mammalian cells and it is thought 
that these phosphatases participate in the negative feedback control of MAPK 
activation (Keyse, 2000).  Nuclear accumulation of ERK is transient and 
inactivated ERK must relocalise to the cytoplasm, a process which is critical for 
further stimulation to occur.  It has been suggested that the relocalisation of 
inactive ERK occurs by a MEK-dependent transport system, whereby MEK 
transiently enters the nucleus and binds inactive ERK, exporting it back to the 
cytoplasm (Adachi et al., 2000). 
The ERK MAPK cascade is regulated at many levels.  A number of scaffolding 
proteins regulate signalling through this pathway (Kolch, 2005).  Kinase 
suppressor of Ras-1 (KSR1) acts as a scaffold and has been found to bind all 
kinase members of the ERK cascade (Morrison, 2001, Kolch, 2005).  For 
example, KSR promotes MEK activation by presenting MEK to activated Raf 
(Muller et al., 2001).  Exogenous inhibitors of the ERK/MAPK pathway also 
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exist.  One such inhibitor RKIP (Raf kinase inhibitor protein) bind both Raf and 
MEK preventing their interaction and thus MEK phosphorylation and activation 
(Yeung et al., 1999).   
β-arrestins, which are known to play a role in desensitizing and internalising 
GPCRs, also act as scaffolding proteins for the ERK cascade.  β-arrestins 
consist of two 46kDa proteins, β-arrestin-1 and β-arrestin-2 (Luttrell and 
Lefkowitz, 2002).  Following agonist binding and subsequent GPCR 
phosphorylation by GPCR kinases (GRKs), β-arrestins directly interact with the 
phosphorylated GPCR at the cell surface.  β-arrestin binding uncouples the 
receptor from heterotrimeric G proteins and targets it to clathrin-coated pits for 
removal from the plasma membrane by endocytosis (Ceresa and Schmid, 
2000).  β-arrestin can simultaneously bind various other signalling proteins, 
including components of the ERK cascade.  All three ERK pathway components 
have been observed in GPCR/β-arrestin complexes.  In rat kidney epithelial 
cells, protease-activated receptor 2 (PAR2) stimulation results in the formation 
of complexes containing internalised receptor, β-arrestin-1, Raf-1 and activated 
ERK (DeFea et al., 2000).  Similarly, in COS-7 and HEK293 cells, activation of 
the angiotensin type 1a receptor (AT1aR) leads to the formation a receptor, β-
arrestin-2, Raf-1, MEK1 and ERK2 complex (Tohgo et al., 2002). 
β-arrestins not only bind ERK cascade components but also contribute to 
GPCR-mediated ERK activation.  For instance, overexpression of β-arrestin has 
been found to significantly increase angiotensin-mediated ERK activation in 
COS-7 cells (Tohgo et al., 2002).  Furthermore, levels of active ERK bound to 
β-arrestin complexes are increased when Raf-1 is overexpressed and markedly 
reduced when a kinase-inactive MEK protein is expressed, indicating that the β-
arrestin scaffold acts as a platform for signal transmission from Raf to MEK and 
ERK (Luttrell et al., 2001).  In addition to this, β-arrestins appear to target ERK 
activity to a pool of cytoplasmic substrates.  In the case of the AT1aR, β-arrestin 
facilitates GPCR-mediated ERK activation but inhibits ERK-dependent 
transcription by binding to active ERK and retaining it in the cytoplasm (Tohgo 
et al., 2002).  Furthermore, the stability of the GPCR/ β-arrestin interaction 
determines the level of β-arrestin-bound ERK, thus influencing the subcellular 
localization of activated ERK and the physiological consequences of ERK 
activation (Tohgo et al., 2003). 
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Figure 1.13  p38 and JNK signalling cascades. 
 
The activation of p38 and c-Jun N-terminal kinase (JNK) requires a 3-tiered 
cascade.  A MAP kinase (MAPK) is activated by a MAP kinase kinase 
(MAP2K), which it turn is also activated by phosphorylation by a MAP kinase 
kinase kinase (MAP3K).  MAPKs can be activated by a least 2 MAP2Ks and 
several MAP3Ks.  MAP2Ks display substrate specificity, while MAP3Ks can 
activate multiple MAPK cascades.  p38 has 4 isoforms, α,β,γ and δ, while JNK 
has 3 isoforms, JNK 1,2 and 3 (Raman and Cobb, 2003). 
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Transcription 
factors 
Kinases and 
phospatases 
Cytoskeletal 
proteins 
Signaling 
proteins 
Apoptotic 
proteins/ 
proteinases 
Other 
proteins 
      
ALM1 DAPK Annexin XI EGFR Bad Amphiphysin 1 
Androgen receptor ERK1/2 Caldesmon ENaCβ/γ Bim-EL CPSII/CAD 
ATF2 FAK1 CENP-E Fe65 Calpain CR16 
BCL6 GRK2 Connexin FRS2 Caspase 9 GRASP55 
BMAL1 Inhibitor-2 Cortactin Gab1 EDD GRASP65 
CBP Lck Crystallin Gab2 IEX1 HABP1 
CEBPβ MAPKAP3 DOC1R GAIP MCL-1 Histone H 
CRY1/2 MAPKAP5 Dystrophin Grb10 TIS2 HnRNP-K 
E47 MEK1/2 Lamin B2 IRS1 TNFR CD120a KIP 
Elk1 MKP1/2 MAP1 LAT  MBP 
ER81 MKP3 MAP2 LIFR  PHAS-I 
ERF MKP7 MAP4 MARCKS  CPLA2 
Estogen receptor MLCK MISS Naf1α  Rb 
c-Fos MNK1/2 NF-H PDE4  SAP90/PDS95 
Fra1 MSK1/2 NF-M PLCγ  Spinophilin 
GATA1/2 PAK1 Paxillin PLCβ  Topoisomerase II 
HIF1α PTP2C Stathmin KV4.2  Tpr 
HSF1 Raf1 SWI/SNF KSR1  TTP(Nup47) 
ICER B-Raf Synapsin 1 Rab4  Tyrosine  
c-Jun RSK1-4 Tau SH2-B  hydroxylase 
Microphthalmia S6K Vinexin β ShcA  Vif 
c-Myc Syk Calnexin Sos1  Vpx 
N-Myc   Spin90   
Net (Sap2)   TSC2   
NFATc4      
NF-IL6      
NGF1-
B/TR3/Nur77 
     
Pax6      
PPARγ      
p53      
Progesteron 
receptor 
     
RNA Pol II      
PUNX2      
Sap1      
Smad1      
Smad2/3      
SP1      
SRC1      
SREBP1/2      
STAT1/3      
STAT5a      
TAL1/SCL      
TFII-I      
TFIIIB      
TGIF      
TIF1A      
Tob      
UBF      
 
Table 1.2  ERK Substrates. 
 
Once activated ERK is able to phosphorylate its substrates, with different 
activating stimuli resulting in the phosphorylation of different substrates.  More 
than 150 cytoplasmic and nuclear ERK substrates have been identified, including 
protein kinases, protein phosphatases, transcription factors, scaffolding proteins, 
signalling molecules, cytoskeletal proteins, receptor and apoptosis-related 
proteins.  Table adapted from Lu and Xu (2006). 
 54 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14  ERK1/2 MAP kinase signalling pathway. 
 
Generally, ERK1/2 is activated by a cascade initiated by activation of the small G protein Ras, followed by activation of a Raf family 
member and subsequent activation of MEK1/2.  Raf can also be activated independently of Ras resulting in ERK activation (Lu and 
Xu, 2006).  Once active, ERK can then activate substrates in the nucleus, resulting in the transcription of target genes or act on 
substrates in the cytoplasm (refer to Table 1.2 for examples of substrate). 
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1.7  Rho AND Rho EFFECTORS 
 
Rho and its effectors have been implicated in the signalling pathways that 
contribute to vasoconstriction and vascular remodelling during the development 
of PAH and may also be involved in signal transduction downstream of 5HT.   
 
1.7.1  SMALL G-PROTEINS 
 
Rho belongs to the small GTP-binding protein superfamily of monomeric G 
proteins with molecular masses in the region of 20-40kDa.  Currently, more than 
one hundred small G proteins have been identified in eukaryotic cells, which 
can be characterised into five major families: Ras, Rho, Rab, Sar/Arf and Ran 
(Takai et al., 2001).  Small GTP-binding proteins play an important role in signal 
transduction, with the Ras family involved in gene expression, playing an 
important role in the activation of the ERK MAPK cascade. Cytoskeletal 
regulation is mediated via the Rho family, whereas the Rab and Sar1/Arf family 
are involved in regulating vesicular trafficking.  Finally, the Ran family regulate 
nucleocytoplasmic transport and microtubule dynamics involved in cell cycle 
progression (Takai et al., 2001). The Rho family has around 20 distinct 
members including, Rho, Rac, Cdc42, RhoD, RhoG, TC10, Rnd and TTF, which 
share 50-55% identity (Hall and Nobes, 2000).  In particular, Rho has 3 
isoforms A, B and C, with Rho A the most extensively studied.  All Rho isoforms 
can be selectively inhibited by the C3 transferase (C3) enzyme from Clostridium 
Botulinum by ADP-ribosylation  (Aktories et al., 1989).     
 
1.7.2 REGULATION OF Rho-GTPases 
 
Rho-GTPases, like other small G proteins, act as molecular switches by cycling 
between inactive GDP-bound and active GTP-bound states (Schmidt and Hall, 
2002, Jaffe and Hall, 2005).  These interactions take place at the plasma 
membrane and Rho-GTPases interact with the membrane via a twenty-carbon 
chain geranylgeranyl lipid residue attached to their C-terminus (Seabra, 1998).  
Guanine nucleotide exchange factors (GEFs) facilitate the exchange of GDP for 
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GTP, resulting in activation of the Rho-GTPase and subsequent downstream 
effector pathways.  GTPase activating proteins (GAPs) accelerate the intrinsic 
GTPase of Rho family members, resulting in their inactivation.  Guanine 
nucleotide dissociation inhibitors (GDIs) also play a role in regulating the activity 
of these small G proteins.  GDIs interact with GDP bound Rho-GTPases, 
sequestering them in the cytosol, inhibiting GDP dissociation and controlling 
cycling between the membrane and cytosol (Schmidt and Hall, 2002, Jaffe and 
Hall, 2005) (Figure 1.15).  Lysophosphatidic acid (LPA) was the first agonist 
identified to activate Rho (Ridley et al., 1992). Since then several other ligands 
acting on both GPCRs and receptor tyrosine kinases (RTKs) have been found 
to activate the small GTPase.  GEFs are critical mediators of Rho-GTPase 
activity and extracellular stimuli acting on membrane receptors are thought to 
activate GEFs, subsequently resulting in the activation of Rho-GTPase and 
downstream signalling pathways (Schmidt and Hall, 2002).  Some GEFs are 
highly specific towards a single GTPase, for example, p115RhoGEF is selective 
for Rho (Hart et al., 1996), whilst others such as Vav1 regulate the activity of 
Cdc42, Rac and Rho (Olson et al., 1996). 
 
1.7.3 PHYSIOLOGICAL FUNCTIONS OF Rho 
 
The Rho-GTPase family mediates a variety of biological responses.  In addition 
to the major role regulating assembly of the actin cytoskeleton (Hall, 1998), 
Rho-GTPases also participate in a variety of other functions mediated by a wide 
variety of effector proteins.  These process include cell polarity, gene 
transcription, vesicular transport, cell cycle progression, enzyme regulation and 
microtubule dynamics (Etienne-Manneville and Hall, 2002, Jaffe and Hall, 
2005).   
Rho itself mediates many diverse biological functions.  Implicated in the 
regulation of neuronal development, activation of Rho has been found to inhibit 
neurite extension and the formation of dendritic spines (Luo, 2000, Li et al., 
2000, Wong et al., 2000).  Rho also plays an important role in cell contraction.  
In the cardiovascular system for instance, vasoconstriction and vasodilation, 
process that control blood flow and are also important to normal physiological 
function can be regulated by Rho.  In aortic smooth muscle, numerous agonists 
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have been shown to activate Rho, which via its effector protein ROCK induces 
myosin light chain phosphorylation thereby promoting contraction (Fukata et al., 
2001, Sakurada et al., 2001).  Futhermore, Rho is also involved in the control of 
barrier function in vascular endothelial cells, which controls functions such as 
the extravasation of circulating lymphocytes into underlying tissues (van Nieuw 
Amerongen et al., 2000).  The contractile forces generated by Rho activation 
are thought to destabilise endothelial cell-cell junctions (Wojciak-Stothard et al., 
2001).  Moreover, during migration, the small GTPase regulates contractile 
forces required at the rear of the cell and is also associated with focal adhesion 
assembly (Raftopoulou and Hall, 2004).  In addition, Rho plays a role in 
phagocytosis, mediating type II phagocytosis by macrophages via the 
complement receptor (Caron and Hall, 1998).  A role in cell proliferation and cell 
cycle progression has also been described.  In fibroblasts Rho plays two 
important roles in this process, inhibiting expression of cyclin/cyclin dependent 
kinase (Cdk) inhibitor p21Waf/Cip1 and also inducing cyclin D1 expression in mid-
G1 phase  (Olson et al., 1998, Welsh et al., 2001a).  Rho also participates in the 
secretion of mediators such as histamine from immune cells (Norman et al., 
1996, Pinxteren et al., 2000).  Furthermore, Rho modulates gene expression by 
regulating transcription factors such as serum response factor (SRF) and NFкB  
(Hill et al., 1995, Perona et al., 1997).  The large and diverse array of responses 
elicited by Rho activation are regulated by its many effector proteins.  
 
1.7.4.  Rho EFFECTOR PROTEINS 
 
Several cellular targets of Rho have been identified.  These effectors interact 
specifically with the GTP-bound form of the GTPase at specific sites (Bishop 
and Hall, 2000).  The Rho effectors protein kinase N1 (PKN1) and PKN2 are 
involved in endosomal trafficking.  Other Rho effectors, mammalian diaphanous 
protein 1 (mDia1), mDia 2 and mDia 3 mediate both microtubule stabilisation 
and actin polymerisation.   Citron, another mediator is a kinase that is critical for 
cytokenesis and has also been implicated in other elements of cell cycle 
progression.  One of the most widely studied Rho effector proteins is ROCK, 
which plays an important role in mediating cell contractility. 
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1.7.5.  RHO ASSOCIATED KINASE (ROCK) 
 
ROCK, a 160kDa serine/threonine kinase, was the first identified substrate of 
Rho and was initially characterised for its role in mediating stress fibre formation 
and focal adhesions (Leung et al., 1996, Somlyo and Somlyo, 2000).  Two 
isoforms have been identified, ROCK1 and ROCK2, which have 65% overall 
sequence identity.  The kinase domain of these proteins is highly conserved, 
exhibiting 92% identity (Nakagawa et al., 1996).  ROCK1 is widely expressed in 
a variety of tissues including, the heart, lung, kidney, pancreas and skeletal 
muscle, with little expression detected in the brain.  ROCK2 however, is highly 
expressed in the brain, with low levels also detected in the lung (Amano et al., 
2000).  Structurally, ROCK is composed of an N-terminal kinase domain, a 
coiled-coil domain and an auto-inhibitory C-terminus.  The auto-inhibitory region 
contains the Rho-binding (RB) and pleckstrin homology (PH) domains.  In its 
resting state, both RB and PH domains can bind independently to the amino 
terminal kinase domain, inhibiting kinase activity.  Binding of Rho-GTP with the 
RB domain alters the conformation of ROCK, disrupting the interaction between 
auto-inhibitory and kinase regions, freeing the kinase domain and thus 
activating ROCK (Amano et al., 2000, Riento and Ridley, 2003) (Figure 1.16).  
ROCK can also be activated independently of Rho by some lipids, especially 
arachadonic acid (AA) (Feng et al., 1999).  Furthermore, other small GTPases, 
including Gem and RhoE, have been shown to bind to ROCK and have an 
inhibitory effect.  RhoE inhibits ROCK1 by binding to its amino-terminal region, 
encompassing the kinase domain, and attenuates the ability of ROCK to 
phosphorylate its downstream targets (Riento et al., 2003).  Gem on the other 
hand, binds the coiled-coil domain of ROCK adjacent to the RB domain.  This 
has been suggested to modify the substrate specificity of ROCK, as it inhibits 
ROCK-mediated phosphorylation of myosin light chain but not LIM kinase 
(Ward et al., 2002).  
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1.7.6.  ROCK EFFECTOR PROTEINS 
 
ROCK activates a variety of proteins to mediate its effects.  Most notably, 
ROCK interacts with and phosphorylates both myosin light chain (MLC) and the 
myosin-binding subunit of MLC phosphatase (Amano et al., 1996, Kawano et 
al., 1999).  MLC phosphatase is inhibited by phosphorylation, resulting in 
increased MLC phosphorylation. This, in addition to the direct phosphorylation 
of MLC by ROCK, stimulates the actin-activated ATP-ase activity of myosin and 
promotes the assembly of actin-myosin filaments and mediates stress fibre 
formation (Amano et al., 1996, Kawano et al., 1999, Bresnick, 1999).  Activation 
of these substrates also increases tension generation and induces contraction 
in muscular cells (Fukata et al., 2001, Sakurada et al., 2001).  Another ROCK 
target is LIM kinase (LIMK) which, when phosphorylated by ROCK, 
subsequently phosphorylates and inactivates cofilin, resulting in stabilisation of 
actin filaments (Bamburg et al., 1999, Maekawa et al., 1999).  ROCK also 
activates a ubiquitous Na+/H+ exchange protein (NHE1), which also contributes 
to stress fibre formation as well as focal adhesion formation (Tominaga and 
Barber, 1998, Tominaga et al., 1998).  Other ROCK substrates that contribute 
to actin assembly are adducin and the ERM (ezrin/radaxin/moesin) family 
proteins.  Phosphorylation of adducin by ROCK may be necessary for 
membrane ruffling, while activation of ERM is thought to be involved in microvilli 
formation (Amano et al., 2000).  Furthermore, the ROCK-mediated activation of 
collapsin response mediator protein-2 (CRMP2) participates in the process of 
neuronal growth cone collapse (Arimura et al., 2000).  ROCK also 
phosphorylates the intermediate filament proteins, vimentin, neurofilament and 
glial fibrillary acidic protein (GFAP) to induce depolymerisation, a function 
important in cytokinesis (Kosako et al., 1997, Goto et al., 1998, Hashimoto et 
al., 1998, Yasui et al., 1998).  In summary, it can be seen that ROCK activates 
a wide range of effector proteins necessary to tranduce signals initiated by Rho 
activation (Figure 1.17).  Activation of the Rho/ROCK pathway has been 
implicated in variety of pathological condition such as hypertension, vascular 
inflammation, atherosclerosis and cerebral ischemia (Rikitake and Liao, 2005).  
ROCK may also play a role in the development of PAH, which is discussed 
extensively in the introduction to Chapter 4. 
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Figure 1.15  Regulation of Rho-GTPase activation. 
 
Small GTPases such as Rho cycle between an inactive GDP-bound form and 
an active GTP-bound form.  Activation is controlled by guanine nucleotide 
exchange factors (GEFs), which facilitate exchange of GDP for GTP.  GTPase 
activating proteins (GAPs) increase intrinsic GTPase activity of Rho family 
members thereby deactivating them.  Guanine nucleotide dissociation inhibitors 
(GDIs) also regulate activity by sequestering Rho-GTPases in the cytosol. 
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Figure 1.16  Regulation of Rho-kinase (ROCK) activity. 
 
Binding of Rho-GTP to the Rho-binding domain (RB) of ROCK disrupts an 
autoinhibitory intramolecular interaction, freeing the catalytic kinase domain and 
allowing it to interact with ROCK substrates.  ROCK remains active until GTP 
hydrolysis of Rho occurs.  (PH, pleckstrin homology domain).  Figure adapted 
from Amano et al (2000). 
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Figure 1.17.  Summary of ROCK effectors and functions. 
The activation of ROCK by the small G protein Rho results in the phosphorylation of downstream substrates that have multiple 
physiological effects.  ROCK substrates include collapsin response mediator protein 2 (CRMP2), adducin, intermediate filament 
proteins (IFs), LIM kinase (LIMK), ERM family proteins (ezrin/radixin/moesin), myosin light chain (MLC) and the myosin binding 
subunit of myosin phosphatase (MBS).  Figure adapted from Amano et al (2000). 
 63 
1.8  5HT-INDUCED SIGNALLING PATHWAYS INVOLVED IN 
VASCULAR REMODELLING 
 
Although 5HTT appears to be the major player in mediating the mitogenic 
effects of 5HT in human PASMCs (Marcos et al., 2004, Eddahibi et al., 1999), 
5HT receptors have also been found to contribute to the signalling process 
required for cellular proliferation even if they do not directly induce proliferation 
in their own right.  Much of the work on 5HT-induced mitogenic signalling has 
been carried out in bovine PASMCs.  Briefly, these studies suggest that 
formation of reactive oxygen species (ROS) by the activation of NADPH 
oxidase, following 5HT entry via 5HTT, results in the activation of ERK, a 
process that is pivotal in mediating the proliferative effects of 5HT (Lee et al., 
1999, Lee et al., 2001, Lee et al., 1998b).  Once in the nucleus, activated ERK 
can phosphorylate transcription factors including GATA-4 (Suzuki et al., 2003), 
Elk-1 and Erg-1, as well as inducing cyclin D1 expression (Liu et al., 2004) and 
thus promoting proliferation.  In this cell type, 5HT receptors have also been 
found to contribute to the proliferative effects of 5HT independently of ERK 
activation.  Stimulation of the 5HT1B/1D receptor has been shown to result in the 
activation of the small G-protein Rho and the resulting activation of ROCK, its 
downstream mediator, facilitates the translocation of ERK to the nucleus where 
it can mediate its mitogenic effects (Liu et al., 2004).  Futhermore, the 5HT2A 
receptor is also involved in the mitogenic response.  This receptor appears to 
activate the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB) 
pathway, resulting in the downstream activation of the mammalian target of 
rapamycin (mTOR) and subsequent p70 ribosomal S6 kinase (S6K1) activation 
(Liu and Fanburg, 2006).  Reactive oxygen species were also found to be a 
requirement for PKB activation in this instance.  Furthermore, inhibition of MEK 
by various means blocked 5HT-induced S6K phosphorylation but not that of 
PKB suggesting another pathway may be involved (Liu and Fanburg, 2006). 
Therefore, in this cell type, diverse, independent signalling pathways are 
activated by 5HT, via 5HT receptors and 5HTT, resulting in PASMCs 
proliferation (Figure 1.18). 
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The signalling pathways utilised by 5HT appear to be cell type-specific.  In a 
study using commercially available human PASMCs, 5HT was found to induce 
proliferation by a different mechanism for that seen in bovine PASMCs, 
however this model also highlighted the requirement for both 5HTT and 5HT 
receptors in the mitogenic process.  In this case, the 5HT2A receptor mediated 
ERK activation in response to 5HT, while 5HT transported into the cell via 5HTT 
was subsequently broken down by MAO-A to produce reactive oxygen species 
required to facilitate the translocation of ERK to the nucleus (Lawrie et al., 2005) 
(Figure 1.19).  A role for MAO has also been suggested in 5HT signal 
transduction in cardiac myocytes.  In these cells, the 5HT2B receptor was found 
to contribute to the proliferative effects of 5HT, as inhibition of this receptor 
resulted in the reduction of 5HT-mediated ERK activation.  However, inhibition 
of 5HTT had a more marked effect, inhibiting ERK activation by more than 80%.  
As suggested in human PASMCs, entry of 5HT into the cell via 5HTT, resulted 
in the generation of reactive oxygen species by the action of MAO-A.  In this 
instance, the generation of ROS were required to induce ERK activation 
(Bianchi et al., 2005).  Various 5HT receptors has been demonstrated to 
coupled positively to ERK activation, including 5HT1A (Cloez-Tayarani et al., 
2004, Adayev et al., 2003), 5HT2A (Gooz et al., 2006), 5HT2B (Nebigil et al., 
2003, Nebigil et al., 2000b), 5HT4 (Norum et al., 2003), and 5HT7 (Lin et al., 
2003, Norum et al., 2003). In the case of the 5HT2B receptor, activation of ERK 
promotes cell survival in addition to progression through the cell cycle (Nebigil 
et al., 2003, Nebigil et al., 2000b).  Taken together, these studies suggest that 
ERK activation is required in order to mediate the mitogenic effects of 5HT and 
also highlight the importance of 5HTT and 5HT receptors in this process.  
In addition to its role in mitogenesis, 5HT has also been found to promote cell 
migration.  In human aortic endothelial cells, 5HT has been shown to potently 
enhance cell migration through a RhoA- and ERK-dependent pathway mediated 
by 5HT1 receptors and 5HTT (Matsusaka and Wakabayashi, 2005a).  Similar 
effects were also observed in human aortic SMC, although in this cell type 
migration was mediated via the 5HT2A receptor (Matsusaka and Wakabayashi, 
2005b).  Likewise, 5HT induces PASMC migration, a process that may be 
important in vascular remodelling given the extension of PASMCs into non-
muscular pulmonary artery during PAH.  Day et al (2006) reported that in bovine 
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PASMC, 5HT stimulated migration and cytoskeletal reorganisation through 
activation of the 5HT4 receptor, a process that required the elevation of cAMP 
and activation of a chloride channel (Day et al., 2006).  In this cell type, ERK 
activation is also required for migration to occur, although this was not mediated 
by either the 5HT4 receptor subtype or elevation of cAMP.  Regulation of motility 
by ERK may therefore occur in parallel to 5HT-induced cytoskeletal 
rearrangments and be mediated by another receptor (Day et al., 2006).   
5HT also plays a role in PAH by influencing other pathways important in the 
development and maintanence of the condition.  For example recently, 5HT was 
found to transactivate PDGFRβ in PASMCs and this process was dependent on 
5HTT.  The transactivation process described was important in mediating SMC 
proliferation and migration (Liu et al., 2007).  Furthermore, 5HT has also been 
observed to interact with the BMP signalling pathway and promote the 
development of PAH.  In a study using BMPR2-deficient mice, treatment with 
5HT exaggerated the pulmonary hypertensive effects of chronic hypoxia 
compared to wild-type littermates.  It was proposed this effect occurred due to 
the ability of 5HT to inhibit BMPR2 signalling, attenuating Smad 1/5 
phosphorylation and the transcription of BMP/Smad target genes (Long et al., 
2006).  It can therefore be seen that 5HT stimulates diverse signalling 
pathways, mediated via 5HTT and various 5HT receptors, and also modulates 
other signalling pathways resulting in the promotion of vascular remodelling and 
thus contributing to the development of PAH.  
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Figure 1.18  5HT-induced mitogenic signalling transduction pathways in bovine pulmonary artery smooth muscle cells 
(PASMCs). 
 
In bovine PASMCs 5HT-induced proliferation requires co-operation between ERK, ROCK and PI3K pathways.  The action of 5HT 
on the 5HT transporter (5HTT) results in the activation of the ERK pathway, a process that is dependent on the production of 
reactive oxygen species (ROS) by NADPH oxidase.  The 5HT1B receptor is involved in mediating the activation of ROCK, which is 
required to facilitate the translocation of active ERK to the nucleus.  Additionally, activation of the PI3K/Akt pathway by the 5HT2A 
receptor is also important in the proliferative response.  Figure adapted from Liu and Fanburg (2006). 
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Figure 1.19  5HT-induced mitogenic signal transduction pathways in human PASMCs. 
 
In human PASMCs the 5HT2A receptor and the 5HT transporter (5HTT) co-operate to mediate the proliferative effects of 5HT.  The 
5HT2A receptor is involved in the process of ERK activation, while transport of 5HT into the cell via 5HTT results in the formation of 
reactive oxygen species (ROS) due to 5HT breakdown by the enzyme monoamine oxidase-A (MAO-A).  ROS produced are 
required for the translocation of ERK to the nucleus, where it activates the transcription factor GATA-4 and transcription of 
mediators that result in cellular proliferation.  Figure adapted from Lawrie et al (2005). 
 68 
1.9  AIM 
 
The monoamine and mitogen, 5HT has been implicated in the development of 
PAH.  However, the signal transduction pathways utilised by 5HT to induce cell 
proliferation and thus contribute to pulmonary vascular remodelling are not fully 
understood.  Therefore, the aim of this thesis is to characterise cellular 
signalling pathways that contribute to the mitogenic effects of 5HT and 
determine a role for these pathways in vivo. 
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Chapter 2 
MATERIALS AND METHODS 
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2.1  Materials 
 
Abcam Ltd, Cambridge, UK: 
Anti-SP1 antibody (ab13370), anti-GAPDH antibody (ab8245). 
 
Amersham Biosciences UK Ltd, Buckinghamshire, UK: 
[methyl-3H]Thymidine (specific activity 2.0Ci/mmol), Rainbow Markers (14.4-220 
kDa). 
 
Biorad Laboratories Ltd, Hemel Hempstead, UK: 
Bradford’s reagent. 
 
Calbiochem, Merck Biosciences Ltd, Nottingham UK: 
Anti-cyclinD1(Ab-3) mouse mAb (CC12), conconavalin A from 
Conconavalin ensiformis (conA), phorbol-12-myristate-13-acetate (PMA), 
U0126, SB203580.  
 
Cambrex Bio Science, Berkshire, UK: 
Dulbecco’s Modified Eagle Medium with 4.5g/l glucose (DMEM), Dulbecco’s 
Phosphate Buffered Saline without Ca2+ and Mg2+ (PBS). 
 
Cell Signaling Technology Inc, Beverly, MA, USA: 
Phospho-MEK1/2 (Ser217/221) antibody (9121), p44/42 MAP Kinase antibody 
(9102), phospho-p44/42 MAP Kinase (Thr202/Tyr204)(E10) mouse mAb 
(9106), phospho-p38 MAP Kinase (Thr180/Tyr182) antibody, p38 MAP Kinase 
antibody (9212). 
 
Cytoskeleton Inc, Denver, CO, USA: 
Cell permeable C3 transferase from Clostridium botulinum. 
 
Fisher Scientific, Loughborough, Leicestershire, UK: 
4-2-hydroxyethyl-1-piperazineethanesulphonic acid (HEPES), glycine, 
hydroxymethyl-aminomathane (Tris) base, sucrose, sodium hydroxide, 
ammonium persulphate, concentrated hydrochloric acid, sodium 
carbonate, sodium hydrogen carbonate, sodium dihydrogen ortho-
phosphate, disodium hydrogen ortho-phosphate. 
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Inverclyde Biologicals, Bellshill, Lanarkshire, UK 
Protan nitrocellulose membrane (Scleicher and Schuell; pore size 0.2µm). 
 
Invitrogen Ltd, Paisley, UK: 
AlexaFluor594 -conjugated phalloidin, Trizol reagent. 
 
McQuilkin Laboratory Supplies: 
Skimmed Milk 
 
Melford Laboratories Ltd, Ipswich, Suffolk, UK: 
Dithiothreitol (DTT). 
 
Meniel-Glaser, Braunschweig, Germany: 
Microscope slides, coverslips. 
 
Perkin Elmer, Boston, MA, USA: 
Western Lightning Chemiluminescence Reagent Plus, glass fibre filter 
mat A, sample bags, Betaplate Scint for Betaplate. 
 
Pierce, Rockford, IL, USA: 
Western blot stripping solution. 
 
Riedel-de Haen, Germany: 
Ethylenediaminetetra-acetic acid (EDTA), ethyleneglycol-bis(2-aminoethyl)-
N,N,N’,N-tetra acetic acid (EGTA), glycerol, methanol. 
 
Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA: 
Phospho-cofilin (Ser3) antibody (sc12912). 
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Sigma-Aldrich Ltd, Poole, Dorset, UK: 
Cytochalasin D from Zygosporium mansonii (Cyto D), latrunculin B (Lat 
B), monoclonal anti-α tubulin antibody (T9026), goat anti-mouse IgG 
(whole molecule) peroxidase conjugate (A4416), methiothepin (mesylate 
salt), iproniazid (phosphate salt), anisomycin (AN), 5-hydroxytryptamine 
(serotonin)(creatine sulphate salt) (5HT), foetal bovine serum (FBS), L-
glutamine (200mM), penicillin streptomycin solution (10,000 units 
penicillin and 10mg streptomycin per ml in 0.9% NaCl), N-acetyl-L-
cysteine (NAC), goat anti-rabbit IgG peroxidase conjugate (A8275), anti-
sheep IgG peroxidase conjugate (A3415), monodansylcadaverin (MDC), 
30% (w/v) acrylamide/0.8% (w/v) bis-acrylamide, trypsin-EDTA, 
Bromophenol Blue, phenylmethylsulphonyl fluoride (PMSF), benzamidine, 
soybean trypsin inhibitor, Tween-20, Triton X-100, bovine serum albumin 
(BSA), 4,4 dicarboxy-2, 2 biquinoline disodium salt, sodium deoxycholate, 
sodium potassium tartrate, copper (II) sulphate, N,N,N’,N’-
tetramethylethylenediamine (TEMED), paraformaldehyde, nonident P-40 
(NP-40). 
 
Tocris Bioscience, Bristol, UK: 
Y27632 dihydrochloride, citalopram hydrobromide, GR55562 dihydrochloride, 
ketanserin tartrate, fluoxetine hydrochloride, α-methyl-5-hydroxytryptamine, 
CP94253. 
 
Upstate Biotechnology, Lake Placid, NY, USA: 
Anti-phospho-MYPT1 (Thr 696)(rabbit polyclonal IgG)(07-251), anti-MYPT1 
(sheep immunoaffinity purified IgG)(07-159). 
 
VWR International Ltd, Poole, UK: 
Sodium chloride, sodium dodecyl sulphate (SDS), potassium hydroxide, 
potassium chloride. 
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2.2  METHODS 
 
2.2.1  Cell Culture. 
 
CCL-39 Chinese hamster lung fibroblast cells were cultured in T-75 flasks in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 2mM L-
glutamine, 100U/ml penicillin, 100µg/ml streptomycin and 10% (v/v) foetal 
bovine serum (FBS).  Cells were maintained at 37oC in a humidified 5% (v/v) 
CO2 atmosphere (5% CO2/95% air) until confluent.  Once confluent the cell 
monolayer was washed with Ca2+- and Mg2+ - free phosphate buffered saline 
(PBS).  The cells were then detached by addition of 2 ml trypsin, followed by 
incubation at 37oC.  6ml of media were then added to the flask and cells 
resuspended by gentle pipetting.  Thereafter, cells were either passaged into T-
75 flasks to maintain the cell line or seeded into dishes for experimental 
analysis. 
 
2.2.2  Preparation of Cell Extracts for Immunoblotting. 
 
Cells for immunoblotting were grown to confluence in 6-well tissue culture 
plates.  Following treatment with the appropriate stimuli, reactions were ceased 
by transferring to ice.  Media was then removed and the cell monolayer washed 
three times with 2 ml ice-cold PBS.  Cells were then lysed by scraping into 
200µl of RIPA buffer (50mM HEPES pH 7.5, 150mM NaCl, 1% (v/v) Triton X-
100, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS, 0.01M sodium 
phosphate, 5mM EDTA, 0.1mM PMSF, 1µg/ml soybean trypsin inhibitor, 1µg/ml 
benzamidine) and transferred to ice-cold micro-centrifuge tubes, then allowed to 
solublise for 30 minutes with occasional vortexing.  The insoluble cellular debris 
was then removed by centrifugation (20,000 g for 15 min, 4oC).  150µl of 
supernatant were then taken for assay to determine protein concentration and 
analysis by SDS-PAGE and immunoblotting. 
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2.2.3  Determination of protein concentration by bicinchoninic acid (BCA) 
protein assay. 
 
BCA assays were carried out in a 96-well plate format with duplicate bovine 
serum albumin (BSA) standards ranging in concentration from 0-2 mg/ml in a 
volume of 10µl.  The same volume of each sample of unknown protein 
concentration was also added in duplicate. Each well was then supplemented 
with 200µl of BCA solution (1% (w/v) 4,4 dicarboxy-2, 2 biquinoline disodium 
salt, 2% (w/v) sodium carbonate, 0.16% (w/v) sodium potassium tartrate, 0.4% 
(w/v) sodium hydroxide, 0.95% (w/v) sodium dicarbonate (pH 11.25), 0.08% 
(w/v) copper (II) sulphate) and incubated at room temperature for 10-15 
minutes.  Protein concentration was then determined by measuring absorbance 
of samples at 492nm (A492) using a MRX-TCII plate reader (Dynex 
Technologies).  The absorbance of the known standards was used to generate 
a best-fit straight-line plot of A492 versus protein concentration, from which the 
protein concentration of the unknown samples could be deduced. 
 
2.2.4.  Determination of protein concentration by Bradford’s protein assay. 
 
Bradford protein assays were carried out in a 96 well plate with duplicate BSA 
standards ranging in concentration from 0-2 mg/ml in a volume of 10µl.  The 
same volume of each sample with unknown protein concentration was also 
added in duplicate. Each well was then supplemented with 50µl of Bradford’s 
reagent which had been diluted 1:4 in distilled deionised water.  Samples were 
then incubated for 10 minutes at room temperature and protein concentrations 
determine by measuring absorbance at 630nm (A630).  A best-fit straight-line 
plot of A630 versus protein concentration was then constructed using data 
obtained from the standards.  This plot was then used to deduce the unknown 
protein concentration of the experimental test samples. 
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2.2.5  SDS-PAGE and Immunoblotting Analysis. 
 
The protein concentrations of samples prepared for SDS-PAGE were 
determined by bicinchoninic acid (BCA) protein assay, unless otherwise stated.  
Samples were then equalised for protein concentration and volume, and 2x 
SDS-PAGE sample buffer (50mM Tris, pH 6.8 at room temperature, 10% (v/v) 
glycerol, 12% (w/v) SDS, 10mM dithiothreitol, 0.0001% (w/v) bromophenol blue) 
added.  Samples then underwent fractionation by SDS-PAGE using a 10% 
acrylamide resolving gel (10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4M 
Tris (pH 8.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium persulphate and 0.001% 
(v/v) TEMED) and 3% acrylamide stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, 0.1M Tris (pH 6.8), 0.1% SDS, 0.01% ammonium persulphate 
and 0.001% (v/v) TEMED) unless otherwise stated.  Electrophoresis of samples 
was carried out in the presence of pre-stained protein markers (Rainbow 
Markers 14.3 - 220 kDa, Amersham Biosciences) in order to estimate the 
molecular mass of immunoreactive proteins.  Using Biorad Mini-Protean III gel 
electrophoresis systems, electrophoresis was carried out at 150V in running 
buffer (27.4mM Tris, 0.19M glycine, 0.1% (w/v) SDS) until the bromophenol 
blue dye front reached the bottom edge of the gel.  Fractionated proteins were 
then transferred to nitrocellulose membrane at 400mA for 45 minutes in transfer 
buffer (24.7mM Tris, 0.19M glycine and 20% (v/v) methanol).  Following 
transfer, the nitrocellulose membrane was washed briefly in Tris Buffered 
Saline-Tween (TBST) (20mM Tris pH 7.5 at room temperature, 150mM NaCl, 
0.1% Tween 20), before blocking for one hour at room temperature in Blotto 
(5% (w/v) skimmed milk in TBST). Membranes were then incubated overnight 
with 1:1000 dilution of primary antibody in 5% BSA (w/v) in TBST at 4oC.  
Subsequently, membranes were washed three times in TBST for 10 minutes 
each wash.  The appropriate HRP-conjugated secondary antibody diluted 
1:1000 in Blotto was then incubated with membranes for 1 hour at room 
temperature before three further 10-minute washes in TBST.  Each membrane 
was then treated with ECL reagents (Perkin Elmer) as per the manufacturer’s 
instructions and immunoreactive proteins were then visualised by exposure to 
X-ray film. 
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Densitometry was performed on each resulting film exposure to determine 
normalized levels of the protein of interest using Total Lab version 2.0 imaging 
software. 
 
2.2.6  [3H]-Thymidine incorporation assay of  DNA synthesis  
 
Cells were plated out at a density of 2x104 cell/ml into 96-well plates and grown 
in full media for 24 hours before serum starving for a further 24 hours.  The 
media was then replaced with fresh media containing no serum and the 
appropriate stimuli in a final volume of 200µl.  Each experimental condition was 
carried out in triplicate.  After an incubation period of 18 hours, 0.5µCi/well [3H]-
thymidine was added.  Proliferation was stopped after a further 6 hours by 
harvesting cells onto glass fibre filter mats using a Betaplate 96-well harvester 
(Wallac).  The glass fibre filter mats used are printed on both sides with a grid to 
aid alignment with the wells of 96-well plates. During the harvesting process the 
96-well plate harvester washes each well with distilled water three times, 
dislodging the cell monolayer.  The contents of the aspirate are then transferred 
directly to the corresponding grid square of the glass fibre filter mat by vacuum 
filtration.  Filter mats are then left to dry before being sealed in clear plastic 
sample bags with 10 ml of scintillation fluid (Betaplate Scint for Betaplate).  
Filters were then placed in a 96-format filtermat cassette and incorporated [3H]-
thymidine  assessed by liquid scintillation counting, using a 1205 Betaplate 
Liquid Scintilation Counter (Wallac) and results expressed as counts per minute 
(cpm). 
 
2.2.7  Preparation of cytosolic and nuclear cell fractions for nuclear 
translocation experiments.  
 
Cells were seeded into 10cm tissue culture dishes and grown to confluence.  
Media was then replaced with serum free media and incubated overnight.  
Following this, cells were treated with the appropriate stimuli in the presence or 
absence of inhibitors and the reaction stopped by transferring onto ice.  
Subsequent steps were also performed on ice.  Media was aspirated and the 
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cell monolayers washed twice with ice cold PBS.  Cells were then gently 
scraped from each tissue culture dish in a volume of 1ml PBS and transferred to 
ice cold micro-centrifuge tubes.  Samples were centrifuged at a temperature of 
4oC for 4 minutes at ~2000g.  The resulting pellet was then resuspended in 
400µl of nuclear extraction buffer A (10mM HEPES (pH 7.9 with KOH), 10mM 
KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM DTT) and left to incubate on ice for 15 
minutes, after which, 25µl of 10% (v/v) NP-40 were added and samples 
vortexed.  Subsequently, samples were briefly centrifuged and the resulting 
supernatant containing the cytosolic cellular fraction removed and transferred to 
another micro-centrifuge tube. 
The remaining pellet was then washed 4 times with 500µl buffer A, with brief 
centrifugation (20,000g for 15 seconds) between each wash and the 
supernatant discarded. After the final wash the pellet was resuspended in 
nuclear extraction buffer B (20mM HEPES (pH 7.9 with NaOH), 450mM NaCl, 
1mM EDTA, 1mM EGTA 1mM DTT), vortexed and incubated on ice with 
occasional agitation for 15 minutes.  Finally, samples were centrifuged at 
20,000g for 15 minutes and the resulting supernatant, containing the nuclear 
fraction removed and transferred to a fresh micro-centrifuge tube.  Protein 
concentrations were measured using Bradfords assay and samples analysed by 
SDS-PAGE and immunoblotting. 
 
2.2.8  Staining of Actin Cytoskeleton 
 
Cells were seeded in 6-well plates (approx 2 x 105 cells/ml) onto sterile glass 
coverslips and grown for 16-24 hours, prior to serum starvation for a further 16 
hours. Cells were then treated with agonist in the presence or absence of other 
agents as described for each individual experiment.   
The following steps were carried out at room temperature.  Firstly, the media 
was removed and discarded and coverslips washed three times in 2 ml PBS.  In 
order to fix the cell monolayer, coverslips were then incubated for 15 minutes in 
2 ml of 4% (w/v) paraformaldyde in a 5% (v/v) sucrose/PBS solution.  
Subsequently coverslips were washed a further twice with 2 ml PBS and the cell 
monolayer permeabilised by the addition of 2 ml 0.1% (v/v) Triton X-100 in PBS 
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for 2 minutes.  Coverslips were then washed twice in 2 ml PBS and blocked for 
30 minutes in 5% (w/v) BSA in PBS.  100µl of Alexa Fluor 594-conjucated 
phalloidin diluted 1:20 in a 5% (w/v) BSA/PBS were then added to each 
coverslip and incubated fro 20-30 minutes.  Finally, cells were washed twice in 
PBS and mounted on glass slides in 40% (v/v) glycerol/PBS.  Fluorescent 
proteins were visualised on a Zeiss fluorescent microscope using x 40 objective 
and pictures obtained using Axiovision AC version 4.4 software. 
 
 
2.3  In Vivo METHODS 
 
2.3.1  In Vivo Experimental Design 
 
Experiments were conducted in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986.  5HTT+ mice that overexpress 5HTT, 
previously generated as described by Jennings et al 2006, were used in this 
study.  These mice were generated from the C567BL/6 X CBA wildtype (WT) 
strain, which were also used as controls. 
Briefly, the transgene used to develop the 5HTT+ was 500 kb yeast artificial 
chromosome (YAC35D8) containing the human 5HTT (h5HTT) gene flanked by 
a 150 kb sequence towards the 5’ end and a 300kb towards the 3’ end, with the 
short allele of the 5HTTLPR in the promoter region and a 10-repeat allele of the 
VNTR in intron 2.  The yeast artificial chromosome was modified to include a 
hemagglutinin epitope tag at the C-terminus of the 5HT protein and a LacZ 
reporter gene downstream of an internal ribosomal entry site as described 
previously (Shen et al., 2000).  Analysis by in situ hybridisation showed that 
h5HTT mRNA was expressed in a pattern that closely resembled the 
endogenous mouse 5HTT gene (Jennings et al., 2006). 
For the purposes of this study both WT and 5HTT+ female mice aged 5-6 
months were maintained in either normoxic (~ 21% (v/v) oxygen) or 
hypoxic/hypobaric conditions for a period of 14 days.  To achieve hypoxic 
conditions, animal were housed in a hypobaric chamber that was initially 
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depressurised slowly by 50 mbar every 15 minutes until the pressure reached 
550 mbar (~10% O2).  Animals were then maintained at 550 mbar for 14 days. 
During this period mice were dosed daily with either vehicle (water) or 30mgkg-1 
Y27632 (a ROCK inhibitor) by oral gavage. 
 
2.3.2  In Vivo Haemodynamic Measurements 
 
After 14 days of drug dosage, anaesthesia was induced by 3% (v/v) halothane 
and body weight of mice determined.  Anaesthesia was then maintained with 
halothane (1% (v/v) to 1.5% (v/v)) and a mixture of nitrous oxide and oxygen 
(1:6) using a face mask.   Systemic arterial blood pressure (SAP) was 
measured by cannulation of the carotid artery.  In order to do so, the right 
carotid artery was first isolated and tied off distally using surgical thread.  
Following this a small artery clip was placed around the proximal end of the 
artery to prevent blood flow.  A small incision was made in the artery and the 
cannula (0.75mm OD, Portex) advanced in the proximal direction.  The cannula 
was then tied in place and the artery clip removed to allow measurement of 
SAP and heart rate (HR). 
Right ventricular pressure was measured using a 25 gauge needle mounted on 
a micromanipulator.  The tip of the needle was aligned with the mid point of the 
sternum and advanced through the diaphragm into the right ventricle.   Entry of 
needle into the right ventricle was confirmed by the morphology of the pressure 
trace obtained.  Both cannula and needle were attached to pressure 
transducers (Elcomatic E751A) connected to a MP100 data acquisition system 
(BIOPAC Systems Inc, Santa Barbra, CA). 
Results were analysed using an AcquiKnowledge 3.5 software package. 
Following the measurement of haemodynamics, heart and lungs were removed 
from each animal for analysis. 
 
2.3.3  Meaurment of Right Ventricular Hypertrophy 
 
Hearts removed following haemodynamic measurements were carefully 
dissected.  The atria were first removed, the right ventricular free fall was then 
dissected from the left ventricle plus septum.  The right ventricle free wall and 
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LV plus septum were weighed separately and the ratio of right ventricle to left 
ventricle calculated.   
 
2.3.4  TaqMan Reverse Transcription-Polymerase Chain Reaction 
 
RNA was extracted from mouse whole lung tissue using Trizol reagent.  Real-
time fluorogenic reverse transcription-polymerase chain reaction (PCR) was 
then performed by TaqMan® Gene Expression Assay (Applied Biosystems, CA, 
USA) using gene expression probes for mouse ROCK 1 and ROCK 2 
(Mn00485745_m1 and Mm00485761_m1 respectively) according to the 
manufacturers instructions.  Relative abundance of ROCK 1 and ROCK 2 
mRNA was determined by using the comparative delta CT method with 18s 
ribosomal RNA as an internal control. 
This work was carried out by Dr J Sheward, University of Edinburgh. 
 
2.3.5  Lung Histology 
 
Three sagittal sections were obtained from left lungs.  Sections were stained 
with Elastica-Van Gieson stain and pulmonary arteries (<80 µm) microscopically 
assessed in a blinded fashion for muscularization.  Arteries were considered 
muscularized if they processed a distinct double-elastic lamina visible for at 
least half the diameter in the vessel cross section.  At least 100 arteries were 
counted per lung section.  The percentage of vessels containing double-elastic 
lamina was calculated as the number of muscularized vessels/total number of 
vessels counted x 100. 
This work was carried out by Dr I Morecroft, University of Glasgow. 
 
2.3.6  Statistical Analysis. 
 
Statistical analyses were carried out using either Students two-tailed unpaired t-
test as described in Graphpad Prism 4 software. Where appropriate, one-way 
analysis of variance (ANOVA) with Newman-Keuls multiple comparison post 
test was applied, unless otherwise stated. 
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Chapter 3 
Characterisation of 5HT-stimulated  
Mitogenic Signalling Pathways 
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3.1  INTRODUCTION 
 
5HT plays an important role in the etiology of PAH, contributing to remodelling 
and vasoconstriction of the pulmonary circulation.  As described previously, 
5HT and the expression and activity of 5HTT have been reported to play a 
critical role in the disease process.  For instance, 5HT and 5HTT have been 
implicated in pulmonary vascular smooth muscle cell hyperplasia and vascular 
proliferation in both experimental hypoxic PAH and the human condition 
(Eddahibi et al., 2001; Eddahibi et al., 2000b).  Furthermore, polymorphisms in 
the promoter region of the 5HTT gene resulting in increased 5HTT expression 
have been reported in around 65% of patients with familial PAH (Eddahibi et al., 
2003). 
At a cellular level several studies have highlighted the ability of 5HT to induce 
proliferation in a variety of cell types including, cardiac myocytes, endothelial 
cells and PASMCs (Bianchi et al., 2005; Pakala et al., 1999; Liu and Fanburg, 
2006).  The ability of 5HT to mediate cellular proliferation may be an important 
contributing factor to pulmonary artery remodelling during pulmonary 
hypertension.  An array of intracellular pathways has been proposed to describe 
the signalling mechanisms utilised by 5HT to result in cellular proliferation.  A 
common theme of these hypotheses is the ability of 5HT to induce ERK1/2 
activation, a process which appears to be key to the proliferative response (Lee 
et al., 1999; Lee et al., 2001). 
5HT can mediate cell signalling by interacting with several 5HT receptor 
subtypes or through 5HTT, which transports 5HT across the plasma membrane 
using a Na+/Cl- gradient.  A large body of evidence exists suggesting the 
mitogenic effects of 5HT are largely mediated via 5HTT.  Much of this work has 
been carried out in bovine PASMCs.  In this cell type, signal transduction 
initiated by 5HT involves 5HTT-dependent generation of reactive oxygen 
species (ROS) and activation of the MEK/ERK pathway (Lee et al., 1998b; Lee 
et al., 1999; Lee et al., 2001).  In short, the 5HT-induced signalling response 
includes the sequential activation of Ras/Rac-1, NADPH oxidase activation, 
generation of ROS and finally the phosphorylation and activation of ERK
 
MAP 
kinase (Lee et al., 1999; Suzuki et al., 2003).  Downstream transcriptional 
components of this pathway have also been characterised.  For instance, in 
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PASMCs, stimulation with 5HT has been found to induce the ERK-dependent 
DNA binding of transcription factors, Erg-1, GATA-4, as well as phosphorylation 
of Elk-1 (Liu et al., 2004; Suzuki et al., 2003). 
5HT receptors also appear to be important in the proliferative response, with a 
number of studies reporting the combined action of receptors and transporter 
are required to mediate the effects of 5HT.  For example, in  rat pulmonary 
artery fibroblasts, the 5HT2A receptor and 5HTT are both involved in 5HT-
induced proliferation (Welsh et al., 2004).  In another fibroblast cell line, 5HTT, 
5HT1B/1D and 5HT2A  are all thought to be involved in 5HT-induced ERK 
activation and proliferation (Lee et al., 1999).  Interactions between 5HTT and 
receptors have also been highlighted in PASMCs, where stimulation of 5HT1B/1D 
and 5HT2 receptors result in the activation of distinct signalling pathways 
required to facilitate the activation of ERK via 5HTT (Liu et al., 2004; Liu and 
Fanburg, 2006). 
The role of the p38 MAP kinase cascade in 5HT-mediated signalling is unclear.  
In certain cell types 5HT has been shown to activate p38 (Lieb et al., 2005, 
Welsh et al., 2004) and also play a role in 5HT-mediated contraction (Tasaki et 
al., 2003).  On the other hand, several studies have also shown that 5HT has no 
effect on p38 and is unable to induce its activation (Cloez-Tayarani et al., 2004; 
Lee et al., 2001).  In addition to this, p38 is thought to play an important role in 
the regulation of 5HTT (Prasad et al., 2005; Zhu et al., 2005). 
Another possible mechanism for 5HT induced proliferation has been suggested.  
In this model 5HT entry into the cell may result in proliferation via receptor-
independent reactive oxygen species generation.  It has been reported recently 
that 5HT is able to induce hypertrophy in cultured rat cardiac myocytes (Bianchi 
et al., 2005; Vindis et al., 2000).  This process appears to require the production 
of hydrogen peroxide, generated by the breakdown of 5HT by the enzyme MAO 
A.  Furthermore, the reactive oxygen species formed are required for ERK 
activation, which in turn contributes to the myocardial remodelling.  MAO B has 
also been shown to generate hydrogen peroxide and that this leads to ERK1/2 
dependent mitogenesis (Vindis et al., 2000).   
Other factors may also be pivotal in regulating 5HT-induced ERK activation.  
For instance, components of the endocytotic pathway may be involved.  The 
scaffolding proteins β-arrestins have been shown to bind ERK1/2 and thus 
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regulate its activity (Tohgo et al., 2003; Tohgo et al., 2002).  In addition to this, it 
has been shown that the 5HT1A receptor must undergo calcium/calmodulin-
dependent receptor endocytosis in order to activate ERK (Della Rocca et al., 
1999).  Furthermore, several other scaffolding proteins have been shown to 
regulate the ERK pathway including MEKK1 and MP1 (Morrison and Davis, 
2003).  These proteins could potentially be involved in mediating 5HT-induced 
ERK activation. 
In summary, several potential signalling pathways required for 5HT-induced 
mitogenesis have been suggested.  However, much of this work has been 
carried out in PASMCs.  As mentioned previously, each cell type within the 
pulmonary artery contributes to the remodelling process that occurs during 
PAH.  It would therefore be beneficial to investigate the role of 5HT and the 
signalling mechanisms utilised in other cell types.  In this chapter, 5HT induced 
mitogenesis was investigated in a fibroblast cell line (Chinese hamster lung 
fibroblasts (CCL-39s)) in order to elucidate any novel signalling mechanisms 
that may be involved in the remodelling process. 
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3.2  RESULTS 
 
Prior to identifying components involved in 5HT mitogenic signalling, the 
timecourse of 5HT-induced ERK1/2 activation was first characterised.  
Quiescent CCL-39 cells were stimulated with 5HT (1µM) over a 24 hour period.  
Subsequent immunoblotting using a phospho-specific ERK1/2 antibody 
revealed that addition of 5HT rapidly and transiently induced ERK1/2 activation, 
with maximal activation occurring around 2 minutes (p<0.01 versus vehicle, 
n=3) (Figure 3.1).  Levels returned to that of basal after 30 minutes with no 
further activation noted during the 24 hour period.  5HT was also found to have 
a mitogenic effect in CCL-39 cells, inducing a dose dependent increase in 
proliferation as determined by [3H]-thymidine incorporation (Figure 3.2).  
Inhibition of the ERK1/2 MAP kinase signalling cascade using U0126 (1µM), a 
MEK inhibitor, markedly attenuated the effects of 5HT, reducing the maximal 
proliferation by 80±5% (Figure 3.2).  Furthermore, inhibition of MEK significantly 
reduced 5HT-induced ERK1/2 activation by around 73±3% (p<0.001 versus 
5HT alone, n=3) (Figure 3.3).  Under these circumstances responses to PMA 
were also significantly decreased (p<0.05, n=3), indicating U0126 was effective 
at the concentration used. 
Under certain conditions the p38 MAP kinase cascade has been implicated in 
signal transduction via 5HT receptors (Welsh et al., 2004) and in the regulation 
of 5HTT (Zhu et al., 2005).  To investigate the involvement of p38 in 5HT-
induced signalling in CCL-39 cells, cells were stimulated over a period of time 
with 5HT (1µM).  Treatment with 5HT was found to have no effect on the levels 
of phosphorylated p38 (p-p38) during the timecourse studied, suggesting 5HT is 
unable to activate p38 (Figure 3.4).  In addition to this, the role of p38 in 5HT-
induced proliferation was assessed (Figure 3.5).  Treatment with p38 inhibitor 
SB203580 at a concentration of 5µM had no effect on the ability of 5HT to 
induce proliferation.  In contrast, SB203580 at a concentration of 10µM 
markedly reduced 5HT-induced proliferation, resulting in levels of [3H]-thymidine 
incorporation similar to those witnessed under vehicle conditions.  SB203580 
(5µM) was effective in inhibiting p38 as pre-treatment with the inhibitor resulted 
in a significant attenuation in the response to anisomycin, a known p38 activator 
(63.7±3% reduction, p<0.001, n=3) (Figure 3.6).   
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Figure 3.1  Timecourse of 5HT-induced ERK activation.   
 
CCL-39 cells were serum starved for 16 hours and then stimulated with 5HT 
(1µM) for 0-24 hours.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).   * p<0.05, ** 
p<0.01 versus vehicle using Newman-Keuls multiple comparison test. 
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Figure 3.2  Effect of MEK inhibition by UO126 on 5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  UO126 (1µM) (MEK inhibitor) for a further 
24 hours, with 0.5µCi/well [3H]-thymidine added for the final 6 hours of this 
incubation.  Cell were then harvested onto a glass fibre filter mat and [3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are representative of n=3.  Results expressed as mean ± SEM of triplicate 
samples.   ** p<0.01 versus vehicle using an unpaired, two tailed t-test. 
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Figure 3.3  Effects of MEK inhibition with UO126 on ERK activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or UO126 (1µM) for 30 minutes prior to stimulation with 5HT (1µM) or 
PMA (2µM) for 5 minutes.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05 
versus PMA, *** p<0.001 versus 5HT using Newman-Keuls multiple comparison 
test. 
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Figure 3.4  Timecourse of the effects of 5HT on p38 activation.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes or with anisomycin (1µg/ml) for 5 minutes. Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and total p38 antibodies.  Blots shown are representative.   Results are 
expressed as mean ± SEM (n=3).  Statistical analysis using Newman-Keuls 
multiple comparison test revealed no significant differences.  Stimulation with 
anisomysin (1µg/ml) for 5 minutes resulted in a 1.8±0.3 fold increase from 
basal. 
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Figure 3.5  Effects of p38 inhibition by SB203580 on 5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  SB203580 (5µM or 10µM) (p38 inhibitor) for 
a further 24 hours, with 0.5µCi/well [3H]-thymidine added for the final 6 hours of 
this incubation.  Cell were then harvested onto a glass fibre filter mat and [3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are representative of n=3 assays.  Results expressed as mean ± SEM of 
triplicate samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two 
tailed t-test. 
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Figure 3.6  Effects of p38 inhibitor SB203580 on p38 activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or SB203580 (10µM) for 30 minutes prior to stimulation with 5HT (1µM) 
or anisomysin (1µg/ml) for 5 minutes.  Cell lysates were prepared and equalised 
for protein concentration by BCA assay.  Samples were then analysed by SDS-
PAGE and immunoblotting phospho-specific and total p38 antibodies.  Blots 
shown are representative.  Results are expressed as mean ± SEM (n=3). ** 
p<0.01 versus anisomycin using Newman-Keuls multiple comparison test. 
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However, the ability of SB203580 (10µM) to reduce 5HT-induced proliferation 
maybe owing to the fact, that at this concentration the p38 inhibitor also 
significantly reduced responses to PMA by 27±4% (p<0.01, n=3) (Figure 3.7), 
suggesting the ERK1/2 MAP kinase pathway may also be effected.  A large 
body of evidence exists implicating 5HTT in the development of pulmonary 
hypertension.  Therefore, the role of 5HTT in the pathways utilised by 5HT to 
induce its mitogenic effects were assessed.  Using CCL-39 cells 5HTT was 
blocked using citalopram, a commonly used selective serotonin reuptake 
inhibitor (SSRI) and the effects on 5HT-induced ERK1/2 activation monitored.  
Pre-treatment with citalopram (1µM) was found to significantly attenuated the 
dose-dependent increase in ERK1/2 activation induced by 5HT, reducing the 
maximal 5HT response by 35±9% (p<0.05, n=3) (Figure 3.8).  Moreover, 
treatment with citalopram also markedly decreased 5HT-induced proliferation by 
82±2% of the maximal response (Figure 3.9). 
5HT receptors, namely 5HT1B/1D and 5HT2A may also be involved in the 5HT-
induced mitogenic response (Lee et al., 1999; Liu and Fanburg, 2006).  Initially, 
the 5HT1/2 receptor antagonist methiothepin was used in order to determine if 
these 5HT receptors played any role in 5HT-induced ERK1/2 activation and 
proliferation in CCL-39 cells.  Pre-treatment with methiothepin (1µM) was able 
to significantly attenuate the dose-dependent increase in ERK1/2 activation 
elicited by 5HT (Figure 3.10), with the maximal 5HT response reduced by 
50±7% (p<0.01, n=3).  Inhibition of 5HT1/2 receptors using methiothepin also 
almost completely abolished 5HT induced proliferation reducing the maximal 
response by 91±1 % (Figure 3.11). 
The individual contribution of 5HT2A and 5HT1B/1D receptors was then assessed 
pharmacologically.  Pre-treatment of cells with ketanserin (1µM), a 5HT2A 
receptor antagonist, significantly reduced maximal 5HT-induced ERK1/2 
activation by 47±9% (p<0.05, n=3) (Figure 3.12).  Similarly, blockade of 5HT2A 
receptors using ketanserin almost completely abolished 5HT-induced 
proliferation, resulting in levels of [3H]-thymidine incorporation similar to those 
witnessed under vehicle conditions (Figure 3.13).  The role of 5HT1B/1D was also 
examined using GR55562, a selective 5HT1B/1D receptor antagonist.  Treatment 
with this compound also significantly reduced 5HT-induced ERK1/2 activation to 
57±7% of the maximal response (p<0.001, n=3) (Figure 3.14).  In addition to 
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this, 5HT1B/1D receptor antagonism abolished the dose-dependent increase in 
proliferation induced by 5HT (Figure 3.15).  Moreover, simultaneous inhibition of 
5HTT and 5HT receptors using a combination of citalopram (1µM) and 
methiothepin (1µM) did not completely abolish 5HT induced ERK1/2 activation.  
At the maximal response, inhibition of 5HTT and 5HT1/2 receptors reduced 5HT-
induced ERK1/2 activation by 57±5% (p<0.001, n=3) (Figure 3.16).  It should 
also be noted that the SSRI and 5HT antagonists used in this study had no 
effect on the ability of PMA to activate ERK, indicating the reductions in ERK 
activation observed are specific to the 5HT signalling pathway.  Taken together, 
these results suggest 5HTT, 5HT1B/1D and 5HT2A receptors all play a role in 
5HT-induced ERK1/2 activation and proliferation, with inhibition of any one of 
these components resulting in the attenuation of the mitogenic effects of 5HT. 
The role of receptor internalisation in 5HT-mediated ERK1/2 activation was also 
studied.  Endocytosis is known to play an important role in the regulation of 5HT 
receptors and GPCRs in general (Bhatnagar et al., 2001; Le Roy and Wrana, 
2005) as well as in regulating 5HTT signalling (Jayanthi et al., 2005).  Using 
structurally unrelated compounds, the role of endocytosis in 5HT-induced 
ERK1/2 activation was investigated.  Conconavalin A (Con A), a lectin and 
commonly used inhibitor of endocytotic processes (Pippig et al., 1995; Tang et 
al., 2000) was initially employed.  Con A binds to α-D-mannosyl and α-D-
glucosyl residues on cell surface proteins and lipid with high affinity, inhibiting 
their mobility and thus ability to be internalised (Zhao et al., 2002; Tang et al., 
2000).  Pre-treatment with this compound was found to significantly elevate 
basal levels of ERK1/2 activity within CCL-39 cells by 31±4% (p<0.01, n=3) 
(Figure 3.17).  In addition to this, the maximal 5HT response was similarly 
increased in the presence of Con A (40±10% increase, p>0.05, n=3).  
Monodansylcadaverin (MDC), a compound previously shown to inhibit 
internalisation from the plasma membrane (Schutze et al., 1999; Davies et al., 
1980, Chow et al., 1998) was also used (Figure 3.18).  MDC is an inhibitor of 
transglutaminase, a membrane-bound enzyme that participates in the 
internalisation of receptors (Schutze et al., 1999; Davies et al., 1980; Chow et 
al., 1998).  MDC was found to have no effect on either the basal levels of 
pERK1/2 or 5HT-induced ERK1/2 activation. 
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Figure 3.7  Effects of p38 inhibition by SB203580 on ERK activation.   
 
After serum starvation for 16 hours, CCL-39 cells were pre-treated with either 
vehicle or SB203580 (10µM) for 30 minutes prior to stimulation with PMA (2µM) 
for 5 minutes.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3). ** p<0.01 
versus PMA using a two-tailed unpaired t-test. 
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Figure 3.8  Effects of 5HTT inhibitor citalopram on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with citalopram (1µM) (5HTT inhibitor).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and total ERK antibodies.  Blots shown are representative.  Results are 
expressed as mean ± SEM (n=3).  * p<0.05 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test. 
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Figure 3.9  Effects of 5HTT inhibition by citalopram on 5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of  citalopram (1µM) (5HTT inhibitor) for a 
further 24 hours, with 0.5µCi/well [3H]-thymidine added for the final 6 hours of 
this incubation.  Cells were then harvested onto a glass fibre filter mat and [3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data show are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two tailed t-test. 
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Figure 3.10  Effects of 5HT1/2 receptor antagonist methiothepin on 5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with methiothepin (1µM) (5HT1/2 receptor antagonist).  Cells were then 
stimulated for 5 minutes with increasing concentrations of 5HT (0-10µM) or 
PMA (2µM).  Cell lysates were prepared and equalised for protein concentration 
by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05, ** 
p<0.01 versus vehicle pre-treated cells using an unpaired, two tailed t-test. 
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Figure 3.11  Effects of 5HT1/2 receptor antagonist methiothepin on 5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of methiothepin (1µM) for a further 24 hours, 
with 0.5µCi/well [3H]-thymidine added for the final 6 hours of this incubation.  
Cell were then harvested onto a glass fibre filter mat and [3H]-thymidine 
incorporation assessed by liquid scintillation counting.  Data shown are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples.  *** p<0.001 versus vehicle using an unpaired, two tailed t-test. 
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Figure 3.12  Effects of 5HT2A receptor antagonist ketanserin on 5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with ketanserin (1µM) (5HT2A receptor antagonist).  Cells were then stimulated 
for 5 min with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell 
lysates were prepared and equalised for protein concentration by BCA assay.  
Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific and total ERK antibodies.  Blots shown are representative.  
Results are expressed as mean ± SEM (n=3).  * p<0.05, ** p<0.01 versus 
vehicle pre-treated cells using an unpaired, two tailed t-test. 
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Figure 3.13  Effects of 5HT2A receptor antagonist ketanserin on 5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of ketanserin (1µM) for a further 24 hours, with 
0.5µCi/well [3H]-thymidine added for the final 6 hours of this incubation.  Cell 
were then harvested onto a glass fibre filter mat and [3H]-thymidine 
incorporation assessed by liquid scintillation counting.  Data shown are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples. ** p<0.01, *** p<0.001 versus vehicle using an unpaired, two tailed t-
test. 
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Figure 3.14  Effects of 5HT1B/1D antagonist GR55562 on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with GR55562 (1µM) (5HT1B/1D receptor antagonist).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  
Cell lysates were prepared and equalised for protein concentration by BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific and total ERK antibodies.  Blots shown are representative.  
Results are expressed as mean ± SEM (n=3).  ** p<0.01, *** p<0.001 versus 
vehicle pre-treated cells using an unpaired, two tailed t-test. 
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Figure 3.15  Effects of 5HT1B/1D receptor antagonist GR55562 on 5HT-
induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of GR55562 (1µM) for a further 24 hours, with 
0.5µCi/well [3H]-thymidine added for the final 6 hours of this incubation.  Cell 
were then harvested onto a glass fibre filter mat and [3H]-thymidine 
incorporation assessed by liquid scintillation counting.  Data shown are 
respresentative of n=3 assays.  Results expressed as mean ± SEM (n=3) of 
triplicate samples. * p<0.05, ** p<0.01, *** p<0.001 versus vehicle using an 
unpaired, two tailed t-test. 
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Figure 3.16  Effects of simultaneous 5HT1/2 receptor and 5HTT inhibition 
by methiothepin and citalopram on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated 
simultaneously for 1 hour with methiothepin (1µM) and citalopram (1µM).  Cells 
were then stimulated for 5 minutes with increasing concentrations of 5HT (0-
10µM) or PMA (2µM).  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  ** p<0.01, 
*** p<0.001 versus vehicle pre-treated cells using an unpaired, two tailed t-test. 
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Figure 3.17  Effects of conconavalin A (conA) on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with conconavalin A (conA) (0.25mg/ml).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  
Cell lysates were prepared and equalised for protein concentration by BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific and total ERK antibodies.  Blots shown are representative.  
Results are expressed as mean ± SEM (n=3).  * p < 0.05 , ** p < 0.01 versus 
vehicle pre-treated cells using an unpaired, two tailed t-test. 
 105 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18  Effects of monodansylcadaverin (MDC) on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with monodansylcadaverin (MDC) (100µM).  Cells were then stimulated 
for 5 minutes with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  
Cell lysates were prepared and equalised for protein concentration by BCA 
assay.  Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific and total ERK antibodies.  Blots shown are representative.  
Results are expressed as mean ± SEM (n=3).  Statistical analysis using an 
unpaired, two tailed t-test revealed no statistical differences between vehicle 
and MDC pre-treated cells. 
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In an attempt to distinguish between ERK1/2 activation elicited by 5HT 
receptors and 5HTT, selective inhibitors of each of these components were 
used to determine if endocytosis is important in either 5HT receptor or 5HTT-
mediated responses.  To investigate the role of the endocytotic pathway in 5HT 
receptor-mediated ERK1/2 activation, 5HTT was blocked using fluoxetine (1µM) 
so that 5HT applied to the cells would act only via 5HT receptors.  In this 
instance, inhibition of 5HTT with fluoxetine resulted in a significant reduction in 
5HT-induced ERK1/2 activation (p<0.05, n=3) (Figure 3.19).  However, pre-
treatment with both fluoxetine and MDC resulted in levels of ERK1/2 activation 
similar to that witnessed in vehicle pre-treated cells.  Conversely, to determine 
the role played by the endocytotic pathway in 5HTT-mediated ERK1/2, 5HT2A 
and 5HT1B/1D receptors were blocked using ketanserin (1µM) and GR55562 
(1µM) respectively.  Inhibition of 5HT receptors was found to significantly 
reduce 5HT-mediated ERK1/2 activation (p<0.01, n=3) (Figure 3.20).  Pre-
treatment with both MDC and 5HT receptor antagonists resulted in levels of 
ERK1/2 activation similar to that induced by 5HT under vehicle pre-treated 
conditions.  These findings suggest endocytosis is not a requirement for 5HT-
induced ERK1/2 activation via either 5HTT or 5HT receptors in CCL-39 cells. 
Possible downstream mediators of 5HTT and 5HT receptors were then 
investigated.  Several studies have reported that the production of reactive 
oxygen species (ROS) may be pivotal in the ability of 5HT to produce its 
mitogenic response (Bianchi et al., 2005; Lawrie et al., 2005).  In order to 
determine if ROS are involved in the 5HT-mediated response in CCL-39 cells, 
the antioxidant N-acetyl-cysteine (NAC) was employed.  At 10mM, NAC was 
found to significantly attenuate 5HT-induced ERK1/2 activation, with maximal 
5HT responses reduced by around 60±18% (p<0.05, n=3) (Figure 3.21).  
Reduction of ROS production using NAC also markedly reduced the 
proliferative effects of 5HT, with the maximal 5HT-induced response attenuated 
by 83±19% (Figure 3.22). 
It has previously been suggested that on entry into cells the breakdown of 5HT 
by monoamine oxidases results in the production of ROS (Liu et al., 2004).  
Thus, to test this hypothesis, iproniazid, a monoamine oxidase (MAO) inhibitor 
was used and its effects on 5HT-induced ERK1/2 activation and proliferation 
studied.  Pre-treatment with iproniazid (0.1mM) was found to have no effect on 
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the concentration dependent increase in ERK1/2 activation produced by 5HT 
(Figure 3.23).  Likewise, selective inhibition of MAO did not effect the ability of 
5HT to induce proliferation in this cell type (Figure 3.24).   
ROCK has also been implicated in the development of PAH and may be a 
downstream mediator of the 5HT mitogenic response (Lee et al., 1999).  In 
CCL-39 cells inhibition of ROCK using the selective inhibitor Y27632 (5µM) 
almost completely abolished 5HT-induced proliferation, attenuating the 
maximum response by 93±2% (n=3) (Figure 3.25).  In addition to this, Y27632 
also significantly attenuated the concentration-dependent increase in ERK1/2 
activation mediated by 5HT.  In this instance 5HT-induced ERK1/2 activation 
was reduced by 52±9% (p<0.05, n=3) (Figure 3.26).  The effects of a cell 
permeable C3 transferase, which inhibits the function of ROCK by inactivating 
Rho GTPase, an upstream effector in the ROCK pathway, was also utilised.  
Inhibition of the ROCK pathway by this means produced a similar effect as that 
seen with Y27632.  C3 transferase significantly attenuated the increase in 
ERK1/2 activation produced by 5HT by 43±15% (p<0.05, n=4) (Figure 3.27).    
In order to further determine the role of ROCK in the 5HT-mediated response, 
cyclin D1, a downstream mediator in the ERK1/2 cascade was also monitored.  
5HT (1µM) was found to increase levels of cyclin D1 present in CCL-39 cells in 
a biphasic manner over a 24 hour period (Figure 3.28).  Stimulation with 5HT 
significantly increased cyclin D1 levels after 6 hours (62.5±5% increase from 
basal, p<0.05, n=5), subsequently levels of cyclin D1 decreased before peaking 
at 16 hours (107±15% increase from basal, p<0.01, n=5) and remained 
elevated at 24 hours (85±8% increase from basal, p<0.01, n=3).  Inhibition of 
ROCK was able to abolish the elevation in levels of cyclin D1 induced by 6 hour 
stimulation with 5HT (p<0.05, n=3) (Figure 3.29).  Taken together these results 
highlight the involvement for ROCK in the signalling pathway required for 5HT-
induced ERK activation and proliferation. 
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Figure 3.19  Effects of MDC on receptor mediated 5HT-induced ERK 
activation.   
 
CCL-39 cells were serum starved for 16 hours.  Following this, cells were 
treated with either fluoxetine (1µM) or MDC (100µM) alone or in combination for 
30 minutes.  Cells were then stimulated for 5 minutes with increasing 
concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates were prepared and 
equalised for protein concentration by BCA assay.  Samples were then 
analysed by SDS-PAGE and immunoblotting using phospho-specific and total 
ERK antibodies.  Blots shown are representative.  Results are expressed as 
mean ± SEM (n=3).  * p < 0.05 versus vehicle pre-treated cells using an 
unpaired, two tailed t-test. 
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Figure 3.20  Effects of MDC on 5HTT mediated ERK activation.   
 
CCL-39 cells were serum starved for 16 hours.  Following this, cells were 
treated with either, ketanserin and GR55562 (1µM) or MDC (100µM) or a 
combination of both for 30 minutes.  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and total ERK antibodies.  Blots shown are representative.  Results are 
expressed as mean ± SEM (n=3).  ** p < 0.01 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test. 
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Figure 3.21  Effects of N-acetylcysteine (NAC) treatment on 5HT-induced 
ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with N-acetylcysteine (10mM).  Cells were then stimulated for 5 
minutes with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell 
lysates were prepared and equalised for protein concentration by BCA assay.  
Samples were then analysed by SDS-PAGE and immunoblotting using 
phospho-specific and total ERK antibodies.  Blots shown are representative.  
Results are expressed as mean ± SEM (n=3).  * p<0.05 versus vehicle pre-
treated cells using an unpaired, two tailed t-test. 
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Figure 3.22  Effects of NAC treatment on 5HT-induced proliferation.  
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of N-acetylcysteine (NAC) (10mM) for a further 
24 hours, with 0.5µCi/well [3H]-thymidine added for the final 6 hours of this 
incubation.  Cell were then harvested onto a glass fibre filter mat and [3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are representative of n=3 assays.  Results expressed as mean ± SEM of 
triplicate samples.  * p<0.05, ** p<0.01 versus vehicle using an unpaired, two 
tailed t-test. 
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Figure 3.23  Effects of monoamine oxidase inhibition with iproniazid on 
5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with iproniazid (0.1mM) (monoamine oxidase inhibitor).  Cells were then 
stimulated for 5 minutes with increasing concentrations of 5HT (0-10µM) or 
PMA (2µM).  Cell lysates were prepared and equalised for protein concentration 
by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  Statistical 
analysis using unpaired, two tailed t-tests revealed no significant differences 
between vehicle and iproniazid pre-treated cells. 
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Figure 3.24  Effects of monoamine oxidase inhibition by iproniazid on 
5HT-induced proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of iproniazid (0.1mM) for a further 24 hours, 
with 0.5µCi/well [3H]-thymidine added for the final 6 hours of this incubation.  
Cell were then harvested onto a glass fibre filter mat and [3H]-thymidine 
incorporation assessed by liquid scintillation counting.  Data shown are 
representative of n=3 assays.  Results expressed as mean ± SEM of triplicate 
samples. 
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Figure 3.25  Effects of Rho-kinase inhibition by Y27632 on 5HT-induced 
proliferation.   
 
CCL-39 cells were serum starved for 24 hours then incubated with 0-100µM 
5HT in the presence or absence of Y27632 (5µM) (Rho-kinase inhibitor) for a 
further 24 hours, with 0.5µCi/well [3H]-thymidine added for the final 6 hours of 
this incubation.  Cell were then harvested onto a glass fibre filter mat and [3H]-
thymidine incorporation assessed by liquid scintillation counting.  Data shown 
are representative of n=3 assays.  Results expressed as mean ± SEM of 
triplicate samples.  *** p<0.001 versus vehicle using an unpaired, two tailed t-
test. 
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Figure 3.26  Effects of ROCK inhibition with Y27632 on 5HT-induced ERK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with Y27632 (5µM).  Cells were then stimulated for 5 minutes with 
increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific and 
total ERK antibodies.  Blots shown are representative.  Results are expressed 
as mean ± SEM (n=4).  * p<0.05 versus vehicle pre-treated cells using an 
unpaired, two tailed t-test. 
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Figure 3.27  Effects of Rho-GTPase inhibition with C3 transferase on 5HT-
induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pretreated for 6 hours 
with cell permeable C3 transferase (specific Rho-GTPase inhibitor).  Cells were 
then stimulated for 5 minutes with 5HT (1µM) or vehicle.  Treatment with PMA 
(2µM) for 5 minutes was used as a positive control for pERK.  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific and 
total ERK antibodies.  Blots shown are representative.  Results are expressed 
as mean ± SEM (n=4).  * p<0.05 versus 5HT, ** p<0.01 versus vehicle using 
Newman-Keuls multiple comparison test. 
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Figure 3.28  Timecourse of 5HT-induced cyclin D1 accumulation.   
 
CCL-39 cells were serum starved for 16 hours and then stimulated with 5HT 
(1µM) for 0-24 hours.  Cells grown in media containing 10% serum were used 
as a positive control for cyclin D1 accumulation.  Cell lysates were prepared and 
equalised for protein concentration by BCA assay.  Samples were then 
analysed by SDS-PAGE and immunoblotting using cyclin D1 and GAPDH 
antibodies.  Blots shown are representative.  Results are expressed as mean ± 
SEM (n=5).   * p<0.05, ** p<0.01 versus vehicle using Newman-Keuls multiple 
comparison test. 
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Figure 3.29  Effects of ROCK inhibition with Y27632 on 5HT-induced 
Cyclin D1.   
 
After serum starvation for 16 hours CCL-39 cells were treated with Y27632 
(5µM) and 5HT (1µM) for 6 hours. Cells grown in media containing 10% serum 
were used as a positive control for cyclin D1 accumulation.  Cell lysates were 
prepared and equalised for protein concentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using cyclin D1 and GAPDH 
antibodies.  Blots shown are representative.  Results are expressed as mean ± 
SEM (n=3).   * p<0.05 versus vehicle and † p<0.05 versus 5HT using Newman-
Keuls multiple comparison test. 
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In order to determine if the ROCK pathway functions selectively downstream of 
either 5HT receptors or 5HTT, various pharmacological agents were employed.  
As described previously, inhibition of ROCK significantly reduced 5HT-induced 
ERK1/2 activation (41±3% reduction, p<0.05, n=3).  Stimulation with α-methyl-
5HT (α-meth) (1µM), a 5HT2-selective agonist, resulted in ERK1/2 activation in 
CCL-39 cells (Figure 3.30).  This activation was around 55±8% of that observed 
with 5HT.  Co-administration of α-meth with Y27632 had no effect on the ability 
of agonist to induce ERK1/2 activation (α-meth induced 54.6±8% of the maximal 
response, while α-meth + Y27632 induced 56.3±13% of maximal 5HT 
response), suggesting that the ROCK pathway is not involved downstream of 
5HT2 receptors.  CP93129, a selective 5HT1B receptor agonist was also used. 
CP93129 (1µM) was also found to induce ERK1/2 activation, with the maximal 
response produced reaching 51±10% of that elicited by 5HT (Figure 3.30).  In 
contrast to α-meth, pre-treatment with Y27632 significantly attenuated the ability 
of the 5HT1B agonist to activate ERK1/2, reducing the level of ERK1/2 activation 
by 76±3% (p<0.05, n=3).  These findings suggest that ROCK is an important 
mediator specifically, downstream of the 5HT1B receptor. 
In light of the fact that there are no selective agonists for 5HTT, selective 5HT 
receptor antagonists were instead used in order to block 5HT receptors thus 
allowing 5HT to act preferentially on 5HTT (Figure 3.31). Inhibition of 5HT2A and 
5HT1B/1D receptor significantly reduced 5HT-mediated ERK1/2 activation by 
60±7% (p<0.001, n=3).  However, pre-treatment with Y27632 had not effect on 
the attenuation induced by these antagonists.  In addition to this, as shown 
previously, citalopram attenuated 5HT-mediated ERK1/2 activation (31±2% 
reduction, p<0.01, n=3) and this response also remained unaffected by ROCK 
inhibiton (32±9%, p<0.01, n=3).   
To further elucidate the mechanism of action as to how ROCK modulates ERK 
phosphorylation, the effect of Y27632 on MEK, the upstream kinase responsible 
for phosphorylating ERK1/2, was studied.  Immunoblotting using a phospho-
specific MEK antibody revealed that Y27632-mediated inhibition of ROCK had 
no effect on 5HT-induced MEK activation (Figure 3.32).   
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Figure 3.30  Effects of ROCK inhibition with Y27632 on 5HT2A and 5HT1B 
receptor-mediated ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pretreated for 30 minutes 
with Y27632 (5µM) or vehicle.  Cells were then stimulated for 5 minutes with 
either 5HT (1µM), α-methyl5HT (1µM) (5HT2A agonist) or CP93129 (1µM) 
(5HT1B agonist).   Treatment with PMA (2µM) for 5 minutes was used as a 
positive control for pERK.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total ERK antibodies.  Blots shown 
are representative.  Results are expressed as mean ± SEM (n=3).  * p<0.05 
versus CP93129 treated cells using an unpaired, two tailed t-test. 
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Figure 3.31  Effects of ROCK inhibition with Y27632 and selective 
antagonists on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 1 hour 
with Y27632 (5µM) and either citalopram (1µM), or a combination of ketanserin 
(1µM) and GR55562 (1µM) before stimulation with 5HT (1µM)  for 5 minutes.  
Treatment with PMA (2µM) for 5 minutes was used as a positive control for 
pERK.   Cell lysates were prepared and equalised for protein concentration by 
BCA assay.  Samples were then analysed by SDS-PAGE and immunoblotting 
using phospho-specific and total ERK antibodies.  Blots shown are 
representative.  Results are expressed as mean ± SEM (n=3).  ** p<0.01, *** 
p<0.001 versus 5HT using Newman-Keuls multiple comparison post test. 
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Figure 3.32  Effects of ROCK inhibition with Y27632 on 5HT-induced MEK 
activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with Y27632 (5µM).  Cells were then stimulated for 5 minutes with 
increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates were 
prepared and equalised for protein conentration by BCA assay.  Samples were 
then analysed by SDS-PAGE and immunoblotting using phospho-specific MEK 
and total ERK antibodies.  Blots shown are representative.  Results are 
expressed as mean ± SEM (n=3).  Statistical analysis using an unpaired, two 
tailed t-test revealed no significant differences between vehicle and Y27632 
treated cells. 
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ROCK has also been previously reported to be involved in facilitating the 
translocation of active ERK to the nucleus (Liu et al., 2004).  Given the ability of 
Y27632 to attenuate the induction of cyclin D1 in CCL-39 cells (Figure 3.29), 
studies into the role of ROCK in the nuclear translocation of pERK in this cell 
type were also carried out.  Stimulation with 5HT resulted in an increase in the 
level of pERK1/2 in both cytoplasmic and nuclear cell fractions (Figure 3.33).  
Inhibition of ROCK with 5µM Y27632 specifically attenuated ERK1/2 
phosphorylation in the cytoplasm (33±8% reduction, p<0.01, n=4) but had no 
effect on the levels of pERK1/2 present in the nucleus in response to 5HT, 
suggesting inhibition of ROCK is unable to affect the ability of pERK1/2 to 
translocate into the nucleus.  
Since inhibition of ROCK resulted in the attenuation of 5HT-induced ERK1/2 
activation, yet had no effect on MEK activation, it may therefore regulate dual 
specificity phosphatases (DUSPs), responsible for de-phosphorylating ERK1/2.  
In order to investigate this hypothesis, the effects of the tyrosine phosphatase 
inhibitor, sodium-ortho-vanadate, on the ability of Y27632 to attenuate ERK1/2 
activation was tested (Figure 3.34).  Treatment with sodium-ortho-vanadate on 
its own significantly increased basal levels of ERK1/2 activation (51±5% versus 
vehicle, p<0.001, n=3).  Stimulation with 5HT in the presence of sodium-ortho-
vanadate resulted in an increase in ERK1/2 activation similar to that of 5HT 
alone.  Moreover, the phosphatase inhibitor was unable to reverse the ability of 
the ROCK inhibitor to reduce 5HT-induced ERK1/2 activation, suggesting 
ROCK does not mediate its effects by regulating DUSPs responsible for de-
phosphorylating ERK1/2. 
In order to further elucidate the mechanisms by which 5HT utilises ROCK to 
mediate its mitogenic effects, the ability of 5HT to directly activate the ROCK 
pathway was studied.  To do this, myosin phosphatase, a downstream 
substrate of ROCK was monitored.  Activation of ROCK results in the 
phosphorylation of the myosin binding subunit of myosin phosphatase (MYPT1) 
(Amano et al., 2000).  Immunoblotting using a phospho-specific antibody to 
MYPT1 (pMYPT1), revealed that over a period of 2 hours, stimulation with 5HT 
(1µM) had no effect on MYPT1 phosporylation, suggesting that 5HT does not 
directly activate this pathway (Figure 3.35).   
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Figure 3.33  Effects of ROCK inhibition with Y27632 on the nuclear 
translocation of pERK.   
 
CCL-39 cells were serum starved for 16 hours.  The cell monolayer was then 
pre-treated for 30 minutes with Y27632 (5µM) or vehicle prior to stimulation with 
5HT (1µM) or PMA (2µM) for 5 minutes.  Cytosolic and nuclear fractions were 
prepared and equalised for protein concentration by Bradford’s assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using a phospho-
specific ERK antibody.  Immunoblotting using SP1 and GAPDH antibodies was 
also carried out to determine the integrity of nuclear and cytosolic fractions 
respectively.   Blots shown are representative. Results are expressed as mean 
± SEM (n=4).  ** p<0.01 using an unpaired two-tailed t-test. 
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Figure 3.34  Effects of tyrosine phosphatase inhibition with vanadate and 
ROCK inhibition with Y27632 on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were treated for 30 minutes 
with either sodium ortho-vanadate (100µM) or Y27632 (5µM) alone or in 
combination.  Treatment with PMA (2µM) for 5 minutes was used as a positive 
control for pERK.  Cells were then stimulated with 5HT (1µM) for 5 minutes 
before cells were harvested.  Cell lysates were prepared and equalised for 
protein concentration by BCA assay.  Samples were then analysed by SDS-
PAGE and immunoblotting using phospho-specific and total ERK antibodies.  
Blots shown are representative.  Results are expressed as mean ± SEM (n=3).  
†
 p<0.001 versus vehicle, *** p<0.001 versus 5HT using Newman-Keuls multiple 
comparison post test. 
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Figure 3.35  Timecourse of effects of 5HT on phosphorylation of myosin 
phosphatase.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific and total antibodies to the myosin 
binding subunit of myosin phosphatase.  Blots shown are representative.   
Results are expressed as mean ± SEM (n=3).  Statistical analysis using 
Newman-Keuls multiple comparison test revealed no significant differences. 
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In addition to this, cofilin, another downstream substrate of ROCK, was also 
studied.  When active, ROCK phosphorylates LIMK, which in turn 
phosphorylates cofilin (Amano et al., 2000).  Upon stimulation with 5HT, an 
initial rapid increase in the levels of phosphorylated cofilin (p-cofilin) was 
observed (51±12% increase from basal).  However, due to large variability, this 
increase was not found to be statistically significant (p>0.05, n=5) (Figure 3.36).  
Furthermore, pre-treatment with the ROCK inhibitor Y27632 had no effect on 
the ability of 5HT to activate cofilin (Figure 3.37), suggesting cofilin is being 
phosphorylated independently of ROCK.   
Finally, the effects of 5HT on actin stress fibres, the formation of which is a Rho 
mediated response, were studied.  Under vehicle conditions, actin stress fibres 
were detected in CCL-39 cells by light microscopy (Figure 3.38).  Stimulation 
with 5HT (1µM) over a period of 2 hours was unable to induce any change in 
the presence of actin stress fibres within the cells.  However, inhibition of ROCK  
was able to disrupt the actin cytoskeleton and abolish the presence of actin 
stress fibres (Figure 3.39).  In light of the findings that 5HT does not appear to 
directly activate the ROCK pathway, but ROCK inhibition is able to disrupt the 
formation of actin stress fibres, the role of the actin cytoskeleton in 5HT-induced 
ERK1/2 activation was investigated.  Given that inhibition of ROCK attenuates 
5HT-induced ERK1/2 activation and also disrupts the actin cytoskeleton, the 
effects of other inhibitors on the gross morphology of the actin cytoskeleton 
were determined.  Citalopram, ketanserin, GR55562, NAC and U0126, which 
have all been previously show to attenuate the ability of 5HT to activate ERK1/2 
had no effects on the actin cytoskeleton (Figure 3.40).  The effects of agents 
such as cytochalasin D and latrunculin B which are known to disrupt actin 
cytoskeleton morphology were also analysed.  Latrunculin B mediates its effects 
by associating with actin monomers, preventing them from repolymerising and 
forming filaments (Morton et al., 2000; Spector et al., 1983).  Cytochalasin D 
has a different mode of action disrupting the actin cytoskeleton by binding both 
barbed and pointed ends of actin filaments causing both depolymerisation and 
inhibition of polymerisation (Cooper, 1987; Spector et al., 1983).  Figure 3.41 
demonstrates the ability of both cytochalasin D and latrunculin B to disrupt the 
actin cytoskeleton in CCL-39 cells.  The effect of these agents on 5HT-induced 
ERK activation was also investigated.  Cytochalasin D was found to significantly 
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attenuate 5HT-induced ERK1/2 activation, with a reduction of around 35±19% 
at the maximal 5HT response (p<0.05, n=3) (Figure 3.42).  Similarly, latrunculin 
B also significantly reduced 5HT-induced ERK1/2 activation.  The maximal 5HT 
response was reduced in this case by 62±8% (p<0.01, n=3) (Figure 3.43).   
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Figure 3.36  Timecourse of effects of 5HT on phosphorylation of cofilin 1.   
 
Following serum starvation for 16 hours, CCL-39 cells were stimulated with 5HT 
(1µM) for 0-120 minutes. Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific cofilin 1 and GAPDH antibodies.  Blots 
shown are representative.   Results are expressed as mean ± SEM (n=5).  
Statistical analysis using Newman-Keuls multiple comparison test revealed no 
significant differences. 
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Figure 3.37  Effects of ROCK inhibition with Y27632 on cofilin 1 
phosphorylation.   
 
Following serum starvation for 16 hours cells were pre-treated for 30 minutes 
with either vehicle or Y27632 (5µM).  Cells were then either treated with vehicle 
or 5HT (1µM) for 5 minutes.  Treatment with LPA (100µM) for 15 minutes was 
used as a positive control.  Cell lysates were prepared and equalised for protein 
concentration by BCA assay.  Samples were then analysed by SDS-PAGE and 
immunoblotting using phospho-specific cofilin 1 and GAPDH antibodies.  Blots 
shown are representative.   Results are expressed as mean ± SEM (n=4).  * p < 
0.05 versus vehicle using Newman-Keuls multiple comparison test. 
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Figure 3.38  Timecourse of effects of 5HT on actin stress fibre formation in CCL-39 cells. 
 
CCL-39 cells were serum starved for 16 hours then stimulated with 5HT (1µM) for 0-120 minutes.  Cells were then fixed with 4% 
paraformaldehyde and the actin cytoskeleton detected by immunofluorescence using Alexa Fluor 594 conjugated-phalloidin.  No 
changes in the actin cytoskeleton were detected following treatment with 5HT.  Images were captured using a Ziess fluorescent 
microscope using x 40 objective lens.  Pictures shown are representative of n=3 experiments. Scale bar represents 100µm. 
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Figure 3.39  Effects of ROCK inhibition with Y27632 on actin stress fibres 
in CCL-39 cells.   
 
CCL-39 cells serum starved for 16 hours then treated with either vehicle or 
Y27632 (5µM) for 30 minutes.  Subsequently, cells were fixed with 4% 
paraformaldehyde and the actin cytoskeleton detected by immunofluorescence 
using Alexa Fluor 594-conjugated phalloidin.  Treatment with Y27632 was 
observed to disrupt the actin cytoskeleton.  Images were captured using a Ziess 
fluorescent microscope using x 40 objective lens.  Pictures shown are 
representative of n=3 experiments.  Scale bar represents 100µm. 
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Figure 3.40  Effects of signal pathway inhibitors on actin stress fibres in 
CCL-39 cells. 
 
CCL-39 cells were serum starved for 16 hours then treated with either 
citalopram (1µM), ketanserin (1µM), GR55562 (1µM) for 1 hour or N-
acteylcysteine (0.1mM), U0126 (1µM) for 30 minutes.  Subsequently, cells were 
fixed with 4% paraformaldehyde and the actin cytoskeleton detected by 
immunofluorescence using Alexa Fluor 594-conjugated phalloidin.  No changes 
in the actin cytoskeleton were detected following treatment with inhibitors.  
Images were captured using a Ziess fluorescent microscope using x 40 
objective lens.  Pictures shown are representative of n=3 experiments.  Scale 
bar represents 100µm. 
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Figure 3.41  Effects of Cytochalasin D and Latrunculin B on the actin 
cytoskeleton of CCL-39 cells.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with either latrunculin B (10µM) or cytochalasin D (10µM).  
Subsequently, cells were fixed with 4% paraformaldehyde and the actin 
cytoskeleton detected by immunofluorescence using Alexa Fluor 594-
conjugated phalloidin.  Images were captured using a Ziess fluorescent 
microscope using x 40 objective lens.  Treatment with latrunculin B or 
cytochalasin D was observed to disrupt the actin cytoskeleton.  Pictures shown 
are representative of n=3 experiments.  Scale bar represents 100 µm. 
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Figure 3.42  Effects of Cytochalasin D on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with cytochalasin D (10µM).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and total ERK antibody.  Blots shown are representative.  Results are 
expressed as mean ± SEM (n=3).  * p < 0.05 versus vehicle pre-treated cells 
using an unpaired, two tailed t-test. 
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Figure 3.43  Effects of Latrunculin B on 5HT-induced ERK activation.   
 
After serum starvation for 16 hours CCL-39 cells were pre-treated for 30 
minutes with latrunculin B (10µM).  Cells were then stimulated for 5 minutes 
with increasing concentrations of 5HT (0-10µM) or PMA (2µM).  Cell lysates 
were prepared and equalised for protein concentration by BCA assay.  Samples 
were then analysed by SDS-PAGE and immunoblotting using phospho-specific 
and total ERK antibodies.  Blots shown are representative.  Results are 
expressed as mean ± SEM (n=3).  * p < 0.05 , ** p < 0.01 versus vehicle pre-
treated cells using an unpaired, two tailed t-test. 
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3.3  DISCUSSION 
 
As stated in the introduction, the ability of 5HT to activate ERK MAP kinase 
plays a critical role in its mitogenic effects and as such may contribute to the 
remodelling process that occurs during PAH.  Therefore, investigation into the 
signalling mechanisms utilised by 5HT may give rise to potential therapeutic 
targets for new drugs in the treatment of PAH.  To further elucidate these 
signalling pathways, this study investigated potential mediators of the 5HT 
induced response and how these components contributed to 5HT-mediated 
ERK activation and proliferation. 
Previous studies have characterised the rapid activation of ERK1/2 in PASMCs 
with maximal activation occurring around 5 minutes (Lee et al., 1999).  This is 
consistent with the results shown in Figure 3.1, where 5HT is able to induce a 
rapid and transient activation of ERK1/2.  Furthermore, in CCL-39 cells the 
mitogenic effects of 5HT appear to be dependent on its ability to activate 
ERK1/2 (Figure 3.2).  Other studies have also confirmed the requirement for 
ERK1/2 activation in 5HT-induced proliferation (Bianchi et al., 2005; Lawrie et 
al., 2005). Interestingly, 5HT only resulted in an initial rapid and transient 
activation of ERK, with no further activation witnessed over the 24 hour period.  
Previous studies have indicated that in this cell type sustained MAP kinase 
activation is required for cyclin D1 induction and DNA synthesis (Balmanno and 
Cook, 1999).  The study suggested agonists such as LPA and TRP-7, which 
caused only transient ERK activation, were poor inducers of proliferation.  
However, stimulation with thrombin, which induced a sustained activation of 
ERK, resulted in a proliferative response.  Work carried out by other groups has 
also shown 5HT was unable to induce late phase ERK activation (Meloche et 
al., 1992) but still induced proliferation in CCL-39 cells (Pouyssegur et al., 1988; 
Lee et al., 1999). 
The role of p38 in 5HT-mediated signalling remains unclear.  It has previously 
been shown that 5HT is able to activate p38 via the 5HT2A receptor under 
hypoxic conditions (Welsh et al., 2004).  Furthermore, in NIH3T3 cells 
overexpressing the 5HT2A receptor, 5HT was shown to activate both ERK1/2 
and p38 (Kurrasch-Orbaugh et al., 2003).  In human astrocytoma cells, 5HT has 
also been reported to activate p38 via the 5HT7 receptor (Lieb et al., 2005).  In 
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contrast to these findings, 5HT was unable to induce activation of p38 in CCL-
39 cells (Figure 3.4).  This is consistent with findings in both bovine PASMCs 
and in rat vascular SMCs where 5HT had no effect on the activation status of 
p38 (Banes et al., 2001; Lee et al., 2001).  Despite being unable to activate p38, 
inhibition of p38 resulted in a marked reduction in 5HT induced proliferation in 
CCL-39s (Figure 3.5).  This phenonenom has also been witnessed in PASMCs 
suggesting p38 may act as a negative regulator of 5HT-induced proliferation 
(Lee et al., 2001).  However, in the present study, the concentration of 
SB203580 that was effective in abolishing proliferation also significantly 
attenuated the activation of ERK by PMA (Figure 3.7).  This suggests the ERK 
cascade in general may be affected, thus explaining the effects of SB203580 on 
5HT-induced proliferation.  In addition to this, inhibition of p38 has been 
reported to decrease 5HTT activity and 5HT uptake (Samuvel et al., 2005).  The 
effects of p38 inhibition on 5HTT described in this study may contribute to 
reduction in proliferation observed in Figure 3.5.  
CCL-39 cells have been shown to uptake 5HT, a process which can be blocked 
by various inhibitors of 5HTT (Lee et al., 1999), confirming the presence of 
functional 5HTTs in this cell type.  By using pharmacological approaches, this 
study and that of others also suggested the presence of 5HT1B/1D and 5HT2A 
receptors (Lee et al., 1999).  In the present investigation the role of 5HT 
receptors and transporter in 5HT-induced ERK activation were assessed.  
Inhibition of 5HTT (Figure 3.8), 5HT2A (Figure 3.12) or 5HT1B/1D receptors 
(Figure 3.14) all significantly reduced 5HT-mediated ERK activation.  In addition 
to this, inhibition of anyone of these components resulted in almost complete 
abolition of the proliferative response.  Furthermore, simultaneous inhibition of 
5HT1/2 receptors and 5HTT did not have an additive effect, resulting in a 50% 
reduction in ERK1/2 activation, similar to that witnessed by inhibition of one 
component alone (Figure 3.16).  These findings suggest 5HT receptors and 
5HTT may co-operatively interact to mediate the effects of 5HT.  Several 
examples of cross- talk between GPCRs have been documented.  Gi-coupled 
receptors have been shown to amplify the effects of those coupled to Gq.  For 
example, stimulation of 5HT1B receptors augments SMC contraction induced by 
histamine (H1) receptors or thromboxane A2 in rat femoral arteries and iliac 
arteries (MacLennan et al., 1993; Yildiz and Tuncer, 1995).  Furthermore, Gq-
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coupled receptors have also been reported to augment Gs-coupled receptor-
stimulated adenylyl cyclase activity (Selbie and Hill, 1998).  In support of the 
hypothesis of cross-talk, functional interactions between 5HT1B receptors and 
5HTT have been reported to mediate vasoconstriction in small pulmonary 
arteries (Morecroft et al 2005).  Interactions between 5HTT and 5HT receptors 
have also been demonstrated by the finding that chronic inhibition of 5HTT 
affects 5HT2A receptor signalling (Damjanoska et al., 2003).  Inhibition of 5HTT 
has also been shown to dampen 5HT receptor signalling in HEK293 cells 
(Johnson et al., 2003).  Furthermore, stimulation of 5HT2A receptors results in 
activation of PKC and increases levels of intracellular calcium (Rahimian and 
Hrdina, 1995), both of which are involved in the regulation of 5HTT 
(Ramamoorthy et al., 1998).  In addition, inhibition of 5HTT has also been 
reported to upregulate 5HT2B receptors in mouse astrocytes (Kong et al., 2002).  
The contribution of 5HTT and 5HT receptors in mediating mitogenic effects has 
been most extensively characterised in bovine PASMCs, where interactions 
between signalling pathways induced by receptors and transporter are required 
to produce cell proliferation. In this cell type, while 5HTT appears to be 
responsible for initiating signalling that results in ERK activation.  5HT2 and 
5HT1B/1D receptors are also required to perpetuate the proliferative response 
(Liu and Fanburg, 2006).  However, in this case inhibition of 5HT receptors 
does not decrease ERK activation but modulates processes required for ERK to 
induce its mitogenic effects.  In human PASMCs stimulation with 5HT appears 
to result in ERK activation via 5HT2A receptor and not 5HTT (Lawrie et al., 
2005).  In these PASMCs, 5HTT also plays a role in mediating the effects of 
5HT but is not involved in the activation of ERK.  Taken together these findings 
suggest functional interactions between 5HT receptors and 5HTT and cross-talk 
between the signalling pathways induced in executing cellular mitogenesis.  
5HT2A receptors have previously been found to interact with caveolin-1 in 
different cell types, a process which modulates 5HT signalling (Bhatnagar et al., 
2004; Cogolludo et al., 2006).  Caveolin-1 forms an important component of 
caveolae, specialised plasma membrane microdomains that have been found to 
compartmentalize and integrate numerous signalling events including the MAP 
kinase cascade (Shaul and Anderson, 1998).  5HTT has also been reported to 
be partitioned into lipid microdomains in the plasma membrane.  The 
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compartmentalisation of 5HT receptors and 5HTT into specialised areas of the 
membrane may facilitate their ability to cross-talk. 
The role of internalisation in 5HT-induced ERK activation was also assessed.  
In certain circumstances clathrin-mediated endocytosis and caveolin have been 
implicated in the regulation of signalling from 5HT receptors and 5HTT 
(Bhatnagar et al., 2004; Della Rocca et al., 1999; Jayanthi et al., 2005).  In this 
instance inhibition of internalisation using the structurally unrelated compounds 
ConA and MDC had little effect on the 5HT-induced ERK activation (Figures 
3.17 and 3.18).  ConA significantly increased ERK activity under basal 
conditions and a similar increase was also witnessed in response to 5HT, 
suggesting conA may activate ERK MAP kinase pathway in this cell type.  The 
increased activity of ERK observed may be due to the binding of ConA to cell 
surface glycoproteins.  For instance ConA has previously been shown to 
crosslink PZR glycoproteins, an immunoglobulin superfamily of cell surface 
proteins, resulting in their tyrosine phosphorylation (Zhao et al., 2002).  In CCL-
39 cells ConA may crosslink receptor tyrosine kinases, resulting in their 
activation and thus contributing to the elevated basal levels of ERK activation.  
No effects of 5HT-induced ERK activation were witnessed in response to MDC 
treatment suggesting internalisation from the plasma membrane is not a 
requirement for 5HT-induced ERK activation.  In addition to this, MDC reversed 
the inhibitor effects of 5HT receptor antagonists (Figure 3.20) and the 5HTT 
blocker fluoxetine (Figure 3.19).  This may be due to the ability of MDC to inhibit 
receptor desensitisation and down regulation of 5HTT by preventing receptor 
and 5HTT internalisation from the plasma membrane, thus potentiating the 
effects of 5HT.  These findings suggest endocytosis is not a requirement for 
5HT-induced ERK activation and proliferation.  However, it would be beneficial 
to monitor receptor endocytosis directly in this model before drawing a final 
conclusion.  Attempts were made to generate CCL39 cell lines stably 
overexpressing a green fluorescent protein (GFP)-tagged rat 5HT2A receptor in 
order to monitor receptor internalisation.  Cells transfected with 5HT2A-GFP 
receptor also confer resistance to the neomycin derivative G418, allowing 
selection of 5HT2A-GFP positive cells.  Despite isolation of multiple G418-
resistant clones over several separate transfections that were resistant to  
treatment with 1 mg/ml G418, only 5-10% of the cells expressed the GFP-
 141 
tagged receptor construct, as determined by fluorescence microscopy.  
Moreover, the 5HT2A-GFP cells were also refractory to further enrichment by 
fluorescence-activated cell sorting (FACS) (data not shown). 
ROS have also been implicated in mediating the effects of 5HT.  As stated 
previously, ROS appear to be a downstream mediator of 5HTT, required to 
induce ERK1/2 activation in PASMCs.  In this study, N-acetyl-cysteine, an 
antioxidant, significantly reduced 5HT-induced ERK1/2 activation, suggesting 
ROS are also required in CCL-39 cells to form part of the mitogenic signalling 
response (Figure 3.21).  This is consistent with previous studies that have 
reported the generation of superoxide in this cell type in response to stimulation 
of 5HT (Lee et al., 1999).  The ability of ROS such as O2- and H2O2 to activate 
ERK has been well documented.  A number of growth factors have been shown 
to generate intracellular ROS production, a process that appears to be essential 
for their mitogenic signalling.  For instance, PDGF stimulated increases in  
intracellular ROS are required for ERK activation, DNA synthesis and regulation 
of gene expression (Sundaresan et al., 1995).  Furthermore, in mesangial cells, 
ROS generation via the 5HT2A receptor is though to be responsible for ERK 
activation (Grewal et al., 1999).  The mechanisms by which ROS regulate ERK 
activation remain unclear, although it has been proposed they are able to 
regulate the activity of phosphatases responsible for modulating ERK activity 
(Kim et al., 2003). 
ROS have also been shown to play a critical role in cardiac hypertrophy 
(Bianchi et al., 2005) and a variety of other vascular diseases (Yung et al., 
2006).  In cardiomyocytes, entry of 5HT into the cell via 5HTT is thought to 
result in the formation of H2O2 due to its breakdown by MAO.  The reactive 
oxygen species formed are then responsible for ERK activation and subsequent 
hypertrophy (Bianchi et al., 2005).  In the present study, inhibition of MAO had 
no effect on 5HT-mediated ERK activation, suggesting production of ROS by 
MAO has no role in the proliferative response in CCL-39 cells.  This is similar to 
findings in PASMCs (Lee et al., 1999).  Another study has suggested that ROS 
generation by MAO is not required for ERK activation, but does play a role in 
mediating the nuclear translocation of pERK (Lawrie et al., 2005).  However, 
given that inhibition of MAO had no effect on 5HT-induced proliferation this 
mechanism is unlikely to occur in CCL-39 cells. 
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The RhoA/ROCK pathway has also been implicated in the actions of 5HT.  5HT 
has been shown to activate RhoA in rat aortic rings (Sakurada et al., 2001).  
Furthermore, RhoA/ROCK appears to be involved in 5HT-mediated contractions 
in bovine cerebral arteries (Nishikawa et al., 2003).  In addition to its role in 
contraction, ROCK may also mediate mitogenic effects and has been 
suggested to play a role in PDGF BB-induced proliferation in systemic vascular 
SMCs (Chapados et al., 2006).  Based on data presented here, ROCK also 
appears to be involved in mediating 5HT-induced proliferation in CCL-39 cells 
(Figure 3.25).  This effect may be due to the ability of the Rho/ROCK pathway 
to modulate 5HT-induced ERK activation as inhibition of both Rho (Figure 3.27) 
and ROCK (Figure 3.26) significantly reduce 5HT-induced ERK activation.  This 
effect appears to be specific to 5HT as inhibition of ROCK has no effect on 
PMA-induced ERK activation.  Studies in human aortic SMCs have also shown 
the inhibition of ROCK attenuates 5HT-induced ERK activation (Matsusaka and 
Wakabayashi, 2005b).  Conversly, sustained activation of ROCK has been 
found to promote ERK activation in NIH-3T3 fibroblasts (Croft and Olson, 2006).  
ROCK also plays a role in ERK activation induced by angiotensin II in 
mesenteric resistance arteries (Matrougui et al., 2001).  However, in these 
studies the mechanisms by which inhibition of ROCK modulates ERK activation 
were not addressed.   
The requirement of ROCK for 5HT-induced proliferation has been shown 
previously in PASMCs (Liu et al., 2004). However in that study inhibition of 
ROCK had no effect on ERK phosphorylation, but was required to mediate the 
translocation of active ERK to the nucleus to stimulate the transcription factor 
phosphorylation required for cell cycle progression and cellular proliferation.  
Thus, the role of ROCK in nuclear translocation was also investigated in CCL-
39 cells.  These experiments suggested that ROCK attenuates the 
phosphorylation of ERK in the cytoplasm but has no effect on the ability of 
pERK to translocate to the nucleus (Figure 3.33).  In addition to this, inhibition of 
ROCK was also able to completely abolish 5HT-induced cyclin D1 expression 
(Figure 3.29), consistent with findings by Liu et al 2004.  Rho has previously 
been associated with normal cell cycle progression and expression of  cyclin D1 
(Welsh et al., 2001b; Jaffe and Hall, 2005).  Moreover, ROCK is also involved in 
the regulation of the cyclin D1-cdk4 complex via ERK-dependent cyclin D1 
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expression (Roovers and Assoian, 2003).  The current study would suggest that 
cytoplasmic effectors of ERK are responsible for mediating 5HT-induced 
proliferation.  It has previously been reported that in PC12 cells proliferative 
signals cause a transient activation of ERK which remains mainly in the 
cytoplasm (Marshall, 1995). 
The RhoA/ROCK pathway may interact with components of the ERK MAPK 
cascade upstream of ERK thus explaining the effects of RhoA/ROCK inhibition 
on 5HT-induced ERK activation.  However in CCL-39 cells inhibition of ROCK 
had no effect on 5HT-mediated MEK activation (Figure 3.32).  This suggests the 
Rho/ROCK pathway regulates the phosphorylation status of ERK independently 
of MEK its upstream kinase.  Various studies have highlighted interactions 
between the RhoA/ROCK pathway and members of the Ras/Raf/MEK/ERK 
signalling pathway.  Rho-GTPases have been shown play a role in Ras 
mediated Raf activation (Li et al., 2001).  Furthermore Raf-1 appears to operate 
as a regulator of Rho downstream signalling associating with ROCK II via its 
amino-terminus in primary mouse keratinocytes (Ehrenreiter et al., 2005).  This 
interaction controls the subcellular distribution of ROCK II and limits its 
activation.  In mouse embryonic fibroblasts where the BRAF gene has been 
knocked out, levels of ROCK II and pERK where decreased (Pritchard et al., 
2004).  In other cell types active Rho has been shown to bind to MEKK1 and 
stimulate its kinase activity (Gallagher et al., 2004).  MEKK1, an upstream 
kinase in the JNK and p38 pathways is known to bind and function as a scaffold 
for ERK (Morrison and Davis, 2003).  Mechanisms as to how interactions 
between the Rho/ROCK pathway and ERK MAP kinase pathway mediate 5HT-
induced proliferation remain unclear.  It is possible that scaffolding proteins 
which interact with the MEK/ERK pathway may mediate cross talk between the 
pathways.  It is well documented that scaffolding proteins target MEK/ERK 
complexes to specific cellular location and affect the activity of specific 
components of the signalling cascade (Kolch, 2005). 
Phosphatases play an important role in the regulation of ERK MAP kinases.  It 
is possible that in CCL-39 cells the Rho/ROCK pathway may modulate 
phosphatases involved in the regulation of the ERK phosphorylation and as 
such, affect its activation in response to 5HT.  Using vanadate as a non-specific 
tyrosine phosphatase inhibitor had no effect on ability of the ROCK inhibitor to 
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attenuate 5HT-induced ERK activation, suggesting phosphatases are not 
involved in mediating the effects of ROCK (Figure 3.34).  Treatment with 
vanadate alone elevates basal activity of ERK presumably by inhibiting DUSPs, 
which are responsible for maintaining ERK activation status under basal 
conditions.  This effect may mask any alterations in ERK phosphorylation 
induced by vanadate in the presence of the ROCK inhibitor.  Therefore the 
ability of ROCK to modulate phophatases involved in 5HT-induced ERK 
activation cannot be ruled out.  It may be beneficial to investigate the role of 
phosphatase by other means such as using inhibitors to specific phosphatases 
or monitoring ERK-specific phosphatase activity within the cells.   
It has previously been reported that 5HT modulates the Rho/ROCK pathway via 
the 5HT1B/1D receptor (Liu et al., 2004).  Using selective agonists, this was also 
shown to be the case in CCL-39 cells (Figure 3.30), with 5HT1B/1D receptors 
involved in mediating the effects of ROCK but not 5HT2 receptors.  Interestingly, 
using 5HTT blockers to ensure the effects of 5HT were mediated via 5HT 
receptors, ROCK inhibition had no further effect in reducing 5HT-receptor 
mediated ERK activation (Figure 3.31).  This implies ROCK is not involved 
downstream of 5HT receptors present in CCL-39 cells.  Furthermore, using 5HT 
receptor antagonists to ensure 5HT acts preferentially via 5HTT, inhibition of 
ROCK had no further effect on the reduction in ERK activation, suggesting 
ROCK does not function downstream of 5HTT. 
To try and address this issue further, the ability of 5HT to activate the 
Rho/ROCK pathway was assessed.  Prior studies have shown the ability of 5HT 
to activate this pathway in a variety of tissues and cell types including PASMCs 
(Liu et al., 2004), and aortic SMCs (Matsusaka and Wakabayashi, 2005b). 
In PASMCs 5HT has been shown to activate Rho and its downstream effector 
MYPT1.  However, in CCL-39 cells, following stimulation with 5HT no activation 
of MYPT1 (Figure 3.35) was observed.  This may be due to the high basal level 
of MYPT1 phosphorylation present.  5HT did however elevate levels of p-cofilin, 
another downstream mediator of ROCK (Figure 3.36). Although, this response 
was consistently observed, due to high basal levels and variability it was not 
found to be statistically significant.  Furthermore, this variable phosphorylation 
could not be attenuated by inhibition of ROCK (Figure 3.37).  LIMK is the direct 
upstream mediator of cofilin and can be activated via the Rac/PAK pathway.  
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This may explain why inhibition of ROCK is unable to prevent the 
phosphorylation of cofilin.  In addition to this, under quiescent conditions CCL-
39 cell displayed a high degree of actin stress fibres.  Stimulation with 5HT 
resulted in no notable change in the presence of these fibres (Figure 3.38).  
These findings are in contrast to a study in PASMCs, where application of 5HT 
was shown to cause disruption of the actin cytoskeleton (Day et al., 2006), 
highlighting the differences in 5HT signalling pathways between different cell 
types.  Furthermore the high levels of pMYPT1, p-cofilin and presence of actin 
stress fibres observed in unstimulated CCL-39 cells suggests a high degree of 
basal Rho activity, making any potential increase in the activity of the 
Rho/ROCK pathway induced by 5HT difficult to quantify.  In the future it may be 
valuable to use other methods, such as a GST-fusion proteins containing 
domains derived from Rho target proteins (e.g. GST-tagged rhotekin-RBD 
protein) in order to detect the effects of 5HT on the Rho/ROCK pathway.   
Figure 3.39 shows the ability of the ROCK inhibitor to disrupt the presence of 
actin stress fibres in CCL-39 cells.  Given the effects of ROCK inhibition on 
actin stress fibre formation it was hypothesised that the actin cytoskeleton may 
play a crucial role in the regulation of 5HT-induced ERK activation.  Others have 
reported the role of the cytoskeleton in mediating ERK activity.  For example, 
disruption of the actin cytoskeleton by cytochalasin D has been shown to 
prevent Raf activation by inhibiting its translocation to the plasma membrane in 
response to GTP loading of Ras (Krepinsky et al., 2005).  The cytoskeleton also 
plays a role in mediating the translocation of active ERK to the nucleus.  For 
instance, disruption of the actin cytoskeleton has been shown to prevent 
stretch-induced nuclear localisation of ERK in ventricular myocytes, a process 
that can be restored by agents such as jasplakinolide, which cause actin 
polymerisation (Kawamura et al., 2003).  ROCK and the actin cytoskeleton are 
also involved in mediating pressure-induced ERK activation and 
phosphorylation in mesenteric arteries (Matrougui et al., 2001).  In order to 
address whether inhibition of 5HT receptors or 5HTT resulted in any change in 
the cytoskeleton and thus resulted in a reduction in ERK activation, actin stress 
fibres were assessed.  None of the antagonists or inhibitors used previously had 
any notable effect on the presence or distribution of actin stress fibres within the 
cells, suggesting the ability of these inhibitors to attenuate 5HT-induced ERK 
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activation is not via modulation of the actin cytoskeleton (Figure 3.40).  
However, treatment with cytochalasin D and latrunculin B, agents that disrupt 
the actin cytoskeleton by distinct mechanisms, resulted in a significant reduction 
in 5HT-mediated ERK activation but had no effect on ERK activation induced by 
treatment with PMA (Figure 3.42 and 3.43) suggesting these findings are 
specific to 5HT.  Disruption of the actin cytoskeleton using agents such as 
cytochalasin D has previously been suggested to inhibit internalisation from the 
plasma membrane.  However, neither MDC nor con A, agents that also inhibit 
internalisation were able to attenuate ERK activation, suggesting that the effects 
of cytochalasin D are due to its ability to disrupt the actin cytoskeleton alone.  
These results imply that in this cell type the actin cytoskeleton, and ROCK in 
particular, play a crucial role in mediating 5HT-induced ERK activation.  The 
role of the actin cytoskeleton in meditating the distribution of signalling 
components within the cell may be key in the ability of 5HT to activate ERK.  As 
mentioned previously ROCK and the actin cytoskeleton have been reported to 
mediate the translocation of various components of the ERK cascade and thus 
regulate its activity (Krepinsky et al., 2005; Kawamura et al., 2003, Liu et al., 
2004).  Interestingly, stress fibre formation can also directly regulate gene 
expression of a subset of serum response factor-dependent genes (Copeland 
and Treisman, 2002; Geneste et al., 2002; Gineitis and Treisman, 2001).   
5HT has previously been shown to induce reorganisation of vimentin filaments 
in tracheal SMCs (Tang et al., 2005).  It may therefore be beneficial to 
determine the role of other components of the actin cytoskeleton, such as 
microtubules and intermediate fibres in mediating the effects of 5HT.  The 
PAK/LIMK pathway is also involved in regulation of the cytoskeleton.  Given the 
apparent importance of the actin cytoskeleton in mediating the effects of 5HT, it 
may prove useful to investigate the potential role of this pathway in the process.  
LIMK has already been implicated in the expression of cyclin D1 (Roovers et al., 
2003) and PAK is thought to be involved in the 5HT-mediated reorganisation of 
vimentin (Tang et al., 2005). 
In CCL-39 cells, entry of 5HT into the cell via 5HTT appears to be required to 
mediate its proliferative effects.  What is unclear however, is where 5HT acts 
once inside the cell.  As stated previously, studies suggest intracellular 5HT 
may be broken down by MAO to produce ROS, which are involved in ERK 
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activation and thus contribute to cellular proliferation.  This appears not to be 
the case in this cell type as inhibition of MAO is unable to modulate 5HT-
induced ERK activation.  One other possibility is that once inside the cell 5HT 
acts as a “second messenger” modulating proliferative signalling pathways.  
One group has suggested that once inside the cell 5HT is transamidated to Rho 
rendering it constitutively GTP-bound and active (Walther et al., 2003; Guilluy et 
al., 2007).  Other molecules such as spingosine-1- phosphate (S1P) have been 
shown to regulate ERK1/2 activity via both its extracellular and intracellular 
actions (Goodemote et al., 1995).  Thus, it is possible that inside the cell 5HT 
may activate intracellular receptors which form part of a 5HT signal transduction 
pathway.  Indeed, several GPCRs have been detected intracellularly and are 
thought to function in mediating intracellular signalling.  For instance the LPA1 
receptor has been reported to be constitutively expressed in the nucleus of 
several mammalian cell types where it participates in the intracellular signalling 
of LPA and regulates protein phosphorylation (Waters et al., 2006).  If this is the 
case for 5HT, our data would suggest that ROCK may be important in 
maintaining the intracellular localisation of these receptors. 
It may also prove fruitful to further investigate the role of ROS in this system.  
ROS have previously been shown to be involved in the activation of the 
Rho/ROCK pathway (Jin et al., 2004).  Rho is also thought to contribute to the 
formation of superoxide in certain cells (Kim et al., 2004).  Given the 
requirement of ROS in 5HT-mediated ERK activation, investigations into the 
effects of ROCK inhibition on ROS production may shed some light on the 
mechanisms by which ROCK regulates the 5HT response.  It has previously 
been shown that H2O2 inhibits phosphatases PP1 and PP2A resulting in 
increased ERK phosphorylation (Kim et al., 2003).  Therefore, if the Rho/ROCK 
pathway via stimulation with 5HT is responsible for ROS generation in CCL-39 
cells, its inhibition may affect the activity of phosphatases responsible for 
activating ERK thus attenuating 5HT-incuded ERK activation.  
To summarise, 5HT1B/1D, 5HT2A receptors and 5HTT all appear to play a role in 
mediating 5HT-induced ERK activation and proliferation, suggesting cross-talk 
between receptor and transporter signalling pathways.  ROCK also plays a role 
in mediating the mitogenic effects of 5HT via the 5HT1B/1D receptor.  However, 
5HT does not appear to directly activate the Rho/ROCK pathway, at least not 
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within the means of detection used in this study.  The ability of ROCK to 
modulate cytoskeletal dynamics appears to be pivotal in its ability to modulate 
5HT-induced ERK activation.  
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Chapter 4 
Characterisation of the Effects of ROCK  
Inhibition on an In Vivo Model of Pulmonary Hypertension. 
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4.1  INTRODUCTION 
 
As described previously, ROCK is a major downstream effector of the small 
GTP-ase Rho.  Its functions include: the dynamic regulation of cytoskeletal 
proteins, cell migration, proliferation and smooth muscle contraction.  
Dysregulation of the Rho/ROCK pathway has also been implicated in numerous 
pathophysiological processes in the cardiovascular system such as 
atherosclerosis (Mallat et al., 2003), angina (Masumoto et al., 2002; Mohri et al., 
2003), myocardial infarction (Satoh et al., 2003), restenosis (Sawada et al., 
2000) and hypertension (Kobayashi et al., 2002).   
RhoA has been found to play a particularly important role in the hypertensive 
process in several in vivo models.  For instance, increased expression and 
activity of RhoA has been observed in  vascular SMCs (Seko et al., 2003), in 
addition to the implication of Rho-dependent signaling pathways, in resistance 
artery remodeling occurring during hypertensive process (Mukai et al., 2001; 
Wesselman et al., 2004).  Moreover, ROCK is thought to mediate calcium 
sensitization in VSMCs, a process involved in the pathobiology of hypertension 
(Uehata et al., 1997).  Furthermore, in spontaneously hypertensive rats, 
upregulation of ROCK was found to precede the development of hypertension 
(Mukai et al., 2001).  ROCK has also been shown to be involved in 
hypertension in humans (Masumoto et al., 2001). 
A growing body of evidence also exists highlighting the role of the Rho/ROCK 
pathway in the pulmonary circulation. Pulmonary artery endothelial cells from 
pulmonary hypertensive piglets have been shown to display increased RhoA 
activity (Wojciak-Stothard et al., 2006).  In addition to this, RhoA activity and 
ROCK 1 protein expression are each elevated in mildly hypoxic fawn hooded 
rats compared to those maintained at sea level (Nagaoka et al., 2005), with 
similar findings also reported in chronically hypoxic rats (Hyvelin et al., 2005).  
The activities of RhoA and ROCK have also been reported to be elevated by 
high flow-induced PAH (Li et al., 2007).  Moreover, exposure of rat PASMCs to 
hypoxia has also been shown to significantly increase ROCK activity (Wang et 
al., 2001). 
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ROCK appears to play a dual role in the pathophysiology of pulmonary 
hypertension contributing to both vasoconstriction and vascular remodeling.  
Several laboratories have reported the vasodilatory properties of ROCK 
inhibition on hypoxia-induced vasoconstriction in pulmonary vessels.  In 
intrapulmonary vascular rings maintained in hypoxic conditions, slow sustained 
contraction was markedly reduced by treatment with Y27632, a ROCK inhibitor 
(Wang et al., 2001; Robertson et al., 2000a).  Furthermore, studies carried out 
in rats suggest that ROCK-mediated calcium sensitization plays a pivitol role in 
the increased basal pulmonary artery tone and sustained vasoconstriction 
observed in pulmonary vessels during chronic hypoxia (Nagaoka et al., 2004).   
ROCK-mediated vasoconstriction is also thought to be an important component 
of severe occlusive PAH (Oka et al., 2007). 
In addition to this, chronic treatment with ROCK inhibitors has also been shown 
to reduce elevated pulmonary artery pressure in models of pulmonary 
hypertension.  Administration of fusadil reduced pulmonary artery pressures in 
chronic hypoxic (Nagaoka et al., 2005), high flow-induced (Li et al., 2007) and 
monocrotaline-induced animal models of pulmonary hypertension (Abe et al., 
2004).  Moreover, Y27632 had similar effects, significantly reducing pulmonary 
artery pressures in the chronic hypoxic rat (Hyvelin et al., 2005). ROCK may 
also couple vasoconstriction with vascular remodeling in pulmonary arteries by 
contributing to matrix synthesis in vascular smooth muscle cells (Chapados et 
al., 2006).  Indeed, the beneficial effects of ROCK inhibition on RVH and 
pulmonary vascular remodeling have been described.  For example, 
administration of fusadil was found to decrease RVH and medial pulmonary 
artery wall thickness in in vivo models (Nagaoka et al., 2005; Abe et al., 2004; Li 
et al., 2007).  In addition to this, the potentially beneficial effects of sildenifil 
(Sauzeau et al., 2003; Guilluy et al., 2005) and statins (Girgis et al., 2007; Xing 
et al., 2006) in the treatment of PAH may be partially owing to the ability of 
these drugs to inhibit the RhoA/ROCK pathway.  
The results discussed previously in chapter 3 suggest ROCK as a possible 
downstream mediator of 5HT in its proliferative response.  Given the pivotal role 
of 5HT and 5HTT in the development of pulmonary hypertension (Eddahibi et 
al., 2001) and the apparent importance of ROCK, any cross-talk between these 
systems in vivo were investigated.  Specifically, in this chapter, the effects of 
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ROCK inhibition on chronic hypoxia-induced pulmonary hypertension in WT and 
5HTT+ mice were assessed. 
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4.2  RESULTS 
 
Initially, relative expression levels of ROCK 1 and ROCK 2 transcripts in whole 
lung tissue from WT and 5HTT+ under both normoxic and hypoxic conditions 
were assessed.  In the case of ROCK 1, under normoxic conditions WT and 
5HTT+ mice display similar levels of expression (Figure 4.1).  Hypoxia resulted 
in the elevation of ROCK 1 transcript levels in WT and 5HTT+ mice (WT: 
359±21% increase, p<0.05, n=5.  5HTT+: 1041±27%, p<0.01, n=5), with the 
increase more pronounced in 5HTT+ mice.  Furthermore, under normoxic 
conditions relative levels of ROCK 2 are similar in both WT and 5HTT+ mice 
(Figure 4.2).  Exposure to chronic hypoxia on the other hand caused a 
significant increase in ROCK 2 levels in both WT (600±28% increase from 
normoxic, p<0.01, n=6) and 5HTT+ mice (863±37% increase from normoxic, 
p<0.05, n=6) resulting in similar levels of transcript expression.  This suggests 
that overexpression of 5HTT enhances the hypoxia-induced transcription of 
ROCK 1. 
The effects of ROCK inhibition on RVP in WT and 5HTT+ mice maintained in 
both normoxic and hypoxic conditions were assessed.  Hypoxia was found to 
cause a significant elevation in mRVP in WT and 5HTT+ mice (WT: p<0.01, n=5 
5HTT+: p<0.05, n=5) (Figure 4.3).  Under normoxic conditions 5HTT+ mice 
exhibited higher mRVP than WT mice (WT: 12.5±1.5mmHg, 5HTT+: 
16.08±3mmHg).  Furthermore, inhibition of ROCK had no effect on mRVP in 
normoxic WT mice (n=6); it did however reduce the elevated mRVP in normoxic 
5HTT+ mice (p<0.05, n=7).  In addition to this, under hypoxic conditions, 
administration of Y27632 attenuated the elevated mRVP seen in WT mice 
(p<0.05, n=8).  Moreover, when administered to 5HTT+ mice in hypoxic 
conditions, Y27632 reduced mRVP (p<0.001, n=8) resulting in pressures similar 
to than seen in normoxic vehicle-dosed WT mice (5HTT+ hypoxic Y27632: 
12.9±3mmHg, n=8, WT normoxic vehicle: 12.5±1.5mmHg, n=8). 
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Figure 4.1  Relative expression levels of ROCK 1 transcript in whole lung 
tissue from WT and 5HTT+ under both normoxic and hypoxic conditions.   
 
Whole lungs were removed from euthanised animals for RNA isolation.  After 
reverse transcription, relative transcript levels of ROCK1 were determined by 
TaqMan RT-PCR.  Results expressed as mean ± SEM relative to levels of 18s 
ribosomal RNA, WT n=5, WT hypoxic n=5, 5HTT+ n=5, 5HTT+ hypoxic n=5.  * p 
< 0.05, ** p < 0.01 using Newman-Keuls multiple comparison test. 
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Figure 4.2  Relative expression levels of ROCK 2 transcript in whole lung 
tissue from WT and 5HTT+ under both normoxic and hypoxic conditions.   
 
Whole lungs were removed from euthanised animals for isolation of RNA.  After 
reverse transcription, relative transcript levels of ROCK 2 were determined by 
TaqMan RT-PCR.  Results expressed as mean ± SEM relative to levels of 18s 
ribosomal RNA, WT n=5, WT hypoxic n=6, 5HTT+ n=5, 5HTT+ hypoxic n=6.  * p 
< 0.05, ** p < 0.01 using Newman-Keuls multiple comparison test. 
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Figure 4.3  Effects of Y27632 administration on mean right ventricular 
pressure (mRVP).   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg-1) daily by oral gavage.  Subsequently mRVP was measured 
by a transdiaphramatic approach.  Results expressed as mean ± SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8, 5HTT+ vehicle n=7, 5HTT+ Y27632 n=7, 5HTT+ vehicle hypoxic n=5, 
5HTT+ Y27632 hypoxic n=8. * p < 0.05, ** p < 0.01, *** p < 0.001 using 
Newman-Keuls multiple comparison test. 
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Similar effects were also observed on sRVP.  Under normoxic conditions 5HTT+ 
mice displayed a pulmonary hypertensive phenotype, exhibiting elevated sRVP 
compared to WT mice (WT: 18.7±1.2mmHg, n=8, 5HTT+: 27.6±3.4mmHg, n=7, 
p<0.05) (Figure 4.4).  Again, hypoxia significantly elevated sRVP in both WT 
and 5HTT+ mice (WT: p<0.05, 5HTT+: p<0.01).  Y27632 significantly attenuated 
this response (WT: p<0.05, 5HTT+: p<0.01) having a more pronounced effect in 
the 5HTT+ group. 
Comparable trends in dRVP were also noted, with hypoxia elevating pressures 
in both WT (p<0.05) and 5HTT+ (p<0.01) mice (Figure 4.5).  Under normoxic 
conditions dRVP in 5HTT+ animals appears elevated compared to WT (WT: 
5.7±1.5mmHg, n=8, 5HTT+: 8.9±3.4mmHg, n=7, p>0.05).  Administration of 
Y27632 had no effect on dRVP observed under normoxic conditions in WT 
mice; it did however marginally reduce the elevated pressure seen in 5HTT+ 
mice.  Notably, the most marked effects of ROCK inhibition occurred in 5HTT+ 
mice under hypoxic conditions, where Y27632 significantly reduced the 
elevation in dRVP (p<0.01) and returned pressures near to levels witnessed in 
normoxic WT animals (WT normoxic vehicle: 5.7±1.5mmHg, n=8, 5HTT+ 
hypoxic Y27632: 5.5±2.4mmHg, n=8).  These findings show that ROCK 
inhibition, attenuates hypoxia-induced increases in RVP and that this effect is 
most notable on sRVP.  Given that sRVP is significantly higher in 5HTT+ mice, 
the benefical effects of ROCK inhibition are more pronounced in these mice.  
The effects of Y27632 observed were specific to the pulmonary circulation as 
mean systemic arterial pressures and heart rates were found to be unaltered by 
administration of Y27632 (Table 4.1).  Furthermore, neither overexpression of 
the 5HTT gene nor chronic hypoxia has any effect on systemic haemodynamics 
(Table 4.1). 
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Figure 4.4  Effects of Y27632 administration on systolic right ventricular 
pressure (sRVP).   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg-1) daily by oral gavage.  Subsequently sRVP was measured 
by a transdiaphramatic approach.  Results expressed as mean ± SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8, 5HTT+ vehicle n=7, 5HTT+ Y27632 n=7, 5HTT+ vehicle hypoxic n=5, 
5HTT+ Y27632 hypoxic n=8.  * p < 0.05, ** p < 0.01 using Newman-Keuls 
multiple comparison test. 
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Figure 4.5  Effects of Y27632 administration on diastolic right ventricular 
pressure (dRVP).   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg-1) daily by oral gavage.  Subsequently dRVP was measured 
by a transdiaphramatic approach.  Results expressed as mean ± SEM, WT 
vehicle n=8, WT Y27632 n=6, WT vehicle hypoxic n=5, WT Y27632 hypoxic 
n=8, 5HTT+ vehicle n=7, 5HTT+ Y27632 n=7, 5HTT+ vehicle hypoxic n=5, 
5HTT+ Y27632 hypoxic n=8.  * p < 0.05, ** p < 0.01 using Newam-Keuls 
multiple comparison test.  
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Table 4.1  Effects of Y27632 administration on systemic arterial pressure 
(SAP) and heart rate (HR).   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30mgkg-1) daily by oral gavage.  Subsequently SAP and HR were 
measured by cannulation of the right carotid artery.  Results expressed as 
mean ± SEM. No significant differences between groups were found using 
Newman-Keuls multiple comparison test. 
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The effects of ROCK inhibition on RVH were also assessed (Figure 4.6). In WT 
animals under normoxic conditions, administration of Y27632 had no effect on 
the RV/LV+S ratio (n=7).  Exposure to chronic hypoxia induced a marked 
elevation in this ratio (p<0.001, n=14) and treatment with Y27632 had no effect 
on this hypertrophic response (n=9).  Similarly, in 5HTT+ mice, Y27632 had no 
effect on the RV/LV+S ratio under normoxic conditions (n=10) and exposure to 
chronic hypoxia markedly increased RVH (p<0.001, n=14).  However, in 
contrast to WT mice, when administered with Y27632, 5HTT+ mice exhibited 
significantly reduced RVH under hypoxic conditions (p<0.001, n=9). 
Pulmonary vascular remodeling was also assessed (Figure 4.7).  Hypoxia 
significantly elevates the percentage of remodeled arteries in WT and 5HTT+, 
with the remodelling observed in 5HTT+ mice more marked (16.8±1%  versus 
23.3±2%, p < 0.001, n=6).  In addition, administration of Y27632 under hypoxic 
conditions significantly attenuates the percentage of remodeled pulmonary 
arteries in WT (12.6±0.8%, p<0.01, n=4) and 5HTT+ mice (11.7±0.8%, p<0.001, 
n=7). 
Taken together, these observations suggest that inhibition of ROCK not only 
reduces elevated pulmonary artery pressure but also markedly attenuates 
pulmonary vascular remodeling.  These inhibitory effects are more prominent in 
5HTT+ mice, highlighted by the fact that ROCK inhibition selectively reduces 
RVH in these mice. 
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Figure 4.6  Effects of Y27632 administration on right ventricular 
hypertrophy.   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30 mgkg-1) daily by oral gavage.  Following haemodynamic 
measurement hearts were removed and right ventricular hypertrophy assessed 
by calculating the ratio of the right ventricle to left ventricle plus septum 
(RV/LV+S).  Results expressed as mean ± SEM, WT vehicle n=12, WT Y27632 
n=7, WT vehicle hypoxic n=14, WT Y27632 hypoxic n=9, 5HTT+ vehicle n=14, 
5HTT+ Y27632 n=10, 5HTT+ vehicle hypoxic n=14, 5HTT+ Y27632 hypoxic n=9.  
*** p < 0.001 using Newman-Keuls multiple comparison test. 
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Figure 4.7  Effects of Y27632 administration on the pulmonary vascular 
remodelling.   
WT and 5HTT+ mice were maintained in either normoxic or hypoxic conditions 
for 14 days during which period they were administered with either vehicle or 
Y27632 (30 mgkg-1) daily by oral gavage.  Following haemodynamic 
measurement lung tissue was removed for analysis. Results expressed as 
mean ± SEM, WT vehicle n=6, WT Y27632 n=4, WT vehicle hypoxic n=6, WT 
Y27632 hypoxic n=4, 5HTT+ vehicle n=7, 5HTT+ Y27632 n=5, 5HTT+ vehicle 
hypoxic n=6, 5HTT+ Y27632 hypoxic n=7.  **p<0.05, ** p< 0.01, *** p < 0.001 
using Newman-Keuls multiple comparison test. 
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4.3  DISCUSSION 
 
ROCK is thought to play a role in the pathophysiology of several vascular 
diseases including PAH.  5HT and 5HTT are also implicated in the development 
of the condition.  Given the results discussed in Chapter 3 of this thesis and 
studies carried out by others (Liu et al., 2004), potential cross-talk between 5HT 
signaling pathways and ROCK were investigated in vivo. 
Chronic hypoxia is a commonly used model of pulmonary hypertension (Marcos 
et al., 2003; Long et al., 2006; Eddahibi et al., 1998), and in this study, exposure 
of WT mice to hypoxia resulted in elevated RVP and RVH, hallmarks of 
experimental PAH.  As mentioned previously 5HTT is thought to be involved in 
the development of PAH and consistent with previously published results 
(MacLean et al., 2004; Guignabert et al., 2006), 5HTT+ mice appeared to 
display a spontaneously pulmonary hypertensive phenotype, with significantly 
elevated sRVP under normoxic conditions.  Polymorphisms in the 5HTT gene 
promoter associated with overexpression of 5HTT, have also been observed in 
a large percentage of patients with PAH (Eddahibi et al., 2001). 
ROCK is an important mediator of vascular tone and has previously been 
implicated in hypoxic pulmonary vasoconstriction, with its inhibition attenuating 
vasoconstriction in isolated rat lung and pulmonary arteries (Robertson et al., 
2000a; Fagan et al., 2004).  This may explain the ability of ROCK inhibition to 
significantly attenuate sRVP in both WT and 5HTT+ mice (Figure 4.4).  The 
effects of ROCK inhibition appears specific to the pulmonary circulation, as 
Y27632 had no effect on mSAP or HR (Table 4.1).  The beneficial effects of 
ROCK inhibition on RVP observed in this study are consistent with findings by 
others in chronically hypoxic, fawnhooded and monocrotaline treated rats 
(Hyvelin et al., 2005; Nagaoka et al., 2006; Abe et al., 2004; Guilluy et al., 
2005). 
The beneficial effects of ROCK inhibition on RVP appear more pronounced in 
5HTT+ mice, with all parameters of RVP significantly attenuated (Figures 4.3 to 
4.5).  The more marked effect of ROCK inhibition in these mice is also 
highlighted by the fact that Y27632 appears to specifically attenuate hypoxia 
induced RVH in 5HTT+ mice but not WT mice (Figure 4.6).  Others have also 
suggested the beneficial effects of ROCK inhibition on RVH in chronically 
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hypoxic rats (Abe et al., 2004; Guilluy et al., 2005; Nagaoka et al., 2006).  
Furthermore, inhibition of ROCK has previously been shown to attenuate 
pulmonary vascular remodelling and vessel wall thickness in a variety of models 
of pulmonary hypertension (Abe et al., 2004; Guilluy et al., 2005; Nagaoka et 
al., 2006).  These finding agree with the present study in which administration of 
the ROCK inhibitor Y27632 significantly attenuated hypoxia-induced pulmonary 
vascular remodelling (Figure 4.7). 
Moreover, the effects of chronic hypoxia on relative levels of ROCK 1 and 
ROCK 2 transcript were assessed.  Hypoxia resulted in elevation of ROCK 2 in 
both WT and 5HTT+ to a similar extent.  In the case of ROCK 1 however, a 
more marked increase was observed in 5HTT+ mice (Figure 4.1).  This 
observation may also be related to the augmented effects of ROCK inhibition on 
RVP, vascular remodelling and RVH in 5HTT mice.  These findings suggest a 
potential link between 5HTT and ROCK 1 expression.   
A number of studies have previously shown the ability of hypoxia to upregulate 
RhoA in a variety of cell types and tissues, including PASMCs (Bailly et al., 
2004), PAECs (Wojciak-Stothard et al., 2006) and rat pulmonary arteries 
(Guilluy et al., 2005).  Increased protein levels of ROCK 1 have also been 
reported in the pulmonary arteries of fawnhooded rats kept at high altitude 
(Nagaoka et al., 2006).  Furthermore, consistent with findings in the present 
study, elevated ROCK 1 and 2 mRNA levels have been observed in lungs from 
chronically hypoxic rats (Hyvelin et al., 2005).  However, the mechanisms 
resulting in increased ROCK expression during hypoxia have not been 
addressed. 
Hypoxia is known to modulate the expression of a wide variety of genes.  One 
major class of transcription regulators activated in response to hypoxia are 
hypoxia inducible factors (HIF) (Wang et al., 1995).  HIF-1α, HIF-2α (Ema et al., 
1997; Tian et al., 1997; Flamme et al., 1997), HIF-3α (Gu et al., 1998) subtypes 
have been identified, with HIF-1α most ubiquitously expressed and extensively 
characterised (Semenza, 2004).  HIF comprises of heterodimeric transcription 
factors HIFα and HIFβ, which bind to consensus DNA binding motifs within the 
regulatory promoter region of hypoxia responsive genes, known as the hypoxia 
response elements (HRE), resulting in transcriptional regulation of the target 
gene (Wang et al., 1995).  
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A large number of genes with a wide range of functions are regulated by HIF-1 
including VEGF (Levy et al., 1995),  inducible NOS (iNOS) (Melillo et al., 1995), 
cyclo-oxygenase 2 (COX-2) (Kaidi et al., 2006) erythropoietin (EPO) (Semenza 
and Wang; 1992, Semenza et al., 1991) and GLUT1 (Chen et al., 2001).  It is 
possible that ROCK genes may also be upregulated by HIF-1 under hypoxic 
conditions, thus explaining the increased mRNA levels observed in this study in 
chronically hypoxic mice.  Indeed, data analysis of the promoter region of 
murine ROCK 1 and ROCK 2 genes identified potential HIF-1 consensus 
sequences, suggesting HIF-1 may be involved in hypoxia-mediated ROCK 
upregulation (Figure 4.8).  
Other transcription factors, such as nuclear factor kappa B (NFкB),  cAMP 
response element binding protein (CREB), p53, Egr-1 Sp-1 and AP-1 have all 
been found to be activated either directly or indirectly by hypoxia (Cummins and 
Taylor, 2005), contributing to altered gene transcription.  Hypoxic activation of 
the afore mentioned transcription regulators may also contribute to the 
increased transcript levels of ROCK observed under chronically hypoxic 
conditions in the present study.  Indeed, data analysis of the promoter region of 
the human ROCK gene suggested several possible cis DNA elements including 
AP-1 and Sp-1 (Shimokawa and Takeshita, 2005).  However, the function of 
these elements has not been evaluated.  Similarly, data anlaysis of murine 
ROCK 1 and ROCK 2 identified a potential Sp-1 and AP-1 binding sites in each 
promoter region.  This analysis also detected potential NFкB and CREB 
transcription factor binding sites. 
In addition to this, inflammatory stimuli may be involved in the regulation of 
ROCK expression during hypoxic conditions.   Hypoxic activation of NFкB has 
been found to increase the level of inflammatory mediators such as COX-2, 
tumour necrosis factor α (TNFα) and interleukin-6 (IL-6).  The upregulation of 
inflammatory mediators by this mechanism may influence ROCK expression, as 
angiotensin II and interleukin 1β (IL-1β) have previously been shown to 
increase the expression and function of ROCK in vascular SMCs.  This process 
was dependent of NFкB (Hiroki et al., 2004).  
Hypoxia also activates various kinases, which may result in altered gene 
transcription.  The MAP kinases ERK (Stenmark et al., 2002; Minet et al., 2000), 
p38 (Stenmark et al., 2002; Welsh et al., 2001a) and JNK (Stenmark et al., 
 167 
2002) have been found to be activated under hypoxic condition, as have other 
protein kinases such as PKC (Yuan et al., 2005), PKA (Beitner-Johnson et al., 
1998), CaMK (Beitner-Johnson et al., 1998; Yuan et al., 2005) and Src (Thobe 
et al., 2006).  Activation of such kinases during hypoxia may result in the 
modulation of signalling pathways and alterations in gene transcription, 
accounting for the increased levels of ROCK transcript.  For instance, there is 
evidence to suggest that in various circumstances activation of p38 results in 
the expression of various inflammatory mediators including TNFα and iNOS 
(Wang et al., 2004).  Given the effect of inflammatory stimuli on ROCK, this may 
in turn result in its upregulation.  Furthermore the increased entry of 5HT into 
cells in 5HTT+
 
mice may potentiate signal transduction resulting in the increased 
transcription of ROCK 1. 
Paracrine factors released during hypoxia may also contribute to the regulation 
of ROCK activity.  Mediators such as adenosine are released during hypoxic 
conditions. The accumulation of extracellular adenosine has previously been 
found to affect the transcription of genes such as VEGF and eNOS 
(Ramanathan et al., 2007; Min et al., 2006).  Therefore, accumulation of 
adenosine could potentially effect ROCK expression by activating signal 
transduction pathways that mediate its transcription.  Furthermore, given both 
adenosine and p38 both play important roles in the regulation of 5HTT activity 
(Zhu et al., 2004; Zhu et al., 2005), the increased presence of these mediators 
during hypoxic conditions may contribute to the augmented hypoxic-
upregulation of ROCK 1 in 5HTT+ mice.    
To conclude, the more pronounced beneficial effects of ROCK inhibition on 
RVP and vascular remodelling in 5HTT+ mice and the ability of Y27632 to 
reduce right ventricular hypertrophy in 5HTT+ mice but not WT mice, suggests 
cross-talk between 5HT and ROCK signaling systems.  This hypothesis is 
consistent with the marked elevation in the expression of ROCK1 observed in 
the lungs of 5HTT+ mice in response to hypoxia.  Whilst, both ROCK 1 and 
ROCK 2 promoter regions contain potential HIF-1 binding sites explaining their 
upregulation during hypoxia, the mechanisms as to how overexpression of 
5HTT results in increased transcript levels of ROCK 1 in the lung requires 
further investigation.  
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Figure 4.8  Schematic diagram showing the potential position of HIF-1 
consensus sequences in the promoter region of murine ROCK 1 and 
ROCK 2 genes.  
 
Data analysis of ROCK 1 and ROCK 2 genes revealed several potential HIF-1 
binding sites in their promoter regions. For each gene, a 2kb region upstream of 
the transcription initiation site was analysed for HIF-1 consensus sequences 5’-
GCTGT-3’ and 5’-ACTGT-3’.  
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SUMMARY 
 
5HT is a monoamine, synthesised by the body from dietary tryptophan and 
plays a major role in wide variety of physiological and pathological processes, 
including pulmonary hypertension (Levy, 2006, MacLean et al., 2000, Hoyer et 
al., 2002).  Evidence exists implicating 5HT in the vasoconstriction and vascular 
remodelling that occurs during PAH (MacLean et al., 2000).  5HT has been 
shown to act as a mitogen in a variety of cell types (Lee et al., 1999, Liu and 
Fanburg, 2006, Lawrie et al., 2005, Bianchi et al., 2005) and it is this effect that 
may contribute to the vascular remodelling that occurs in patients with PAH.  
This project has characterised signalling pathways utilised by 5HT to induce 
fibroblast proliferation, in particular highlighting the role of the Rho/ROCK in this 
process.  Furthermore, using an in vivo model where the 5HTT protein is 
overexpressed, inhibition of the Rho/ROCK pathway was found to have marked 
beneficial effects on the symptoms of PAH. 
In Chapter 3, examination of 5HT mitogenic signalling using CCL-39 hamster 
lung fibroblasts revealed that proliferation was ERK-dependent and that 
5HT1B/1D receptors, 5HT2A receptors and 5HTT were all required for optimal 
ERK activation and proliferation, suggesting cross-talk between 5HT receptors 
and the transporter.  Furthermore, pharmacological inhibition of Rho/ROCK  
pathway significantly inhibited 5HT induced ERK activation, cyclin D1 
accumulation and proliferation.  However, no effect on 5HT-induced MEK 
activation or on the ability of active ERK to translocate to the nucleus was 
observed.  Instead, inhibition of the ROCK was found to specifically inhibit the 
activation of a cytoplasmic pool of ERK.   These findings suggest that ROCK 
inhibition may reduce the ability of MEK to promote ERK phosphorylation.  
Furthermore, ROCK functions downstream of the 5HT1B receptor in mediating 
5HT-induced ERK activation.  In the cell type used in this study, the direct 
activation of Rho/ROCK pathway by 5HT was not detected by means of 
immunoblotting for the activation of downstream substrates of ERK.  However, 
actin stress fibres were detected in the cells prior to stimulation with 5HT, 
suggesting a high basal activity of Rho which may mask the effects of 5HT on 
the Rho/ROCK pathway.  The function of ROCK in maintaining cytoskeletal 
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intergrity is central to its role in 5HT-induced ERK activation in this cell type as 
disruption of the actin cytoskeleton by other agents such as latrunculin B and 
cytochalasin D also markedly attenuate the ability of 5HT to activate ERK.  The 
role of the ROCK and the actin cytoskeleton in mediating 5HT-induced ERK 
activation are specific to 5HT pathways as neither inhibition of ROCK nor 
disruption of the actin cytoskeleton had any effect on the ability of PMA to 
activate ERK. 
In Chapter 3, this study characterised the effects of ROCK inhibition on 5HT-
induced ERK activation and proliferation, however it may also be useful to 
determine the effects of ROCK activation on these processes, as this would be 
expected to promote proliferation.  One possible way in which to address the 
effects of ROCK activation would be to use a conditionally active ROCK 
construct.  Indeed, a study carried out by Croft et al 2006, using a conditionally 
activated ROCK-estrogen receptor (ROCK-ER) fusion construct, reported that 
activation of ROCK-ER by an estrogen analogue was sufficient to stimulate cell 
cycle progression in NIH 3T3 mouse fibroblasts.  Based on the findings in 
Chapter 3, estrogen-mediated ROCK-ER activation in CCL-39 cells would be 
expected to potentiate 5HT-stimulated proliferation and ERK activation.    
Chapter 3 also suggesst that the ROCK pathway, via 5HT1B stimulation controls 
MEK activation of a cytoplasmic pool of ERK.  One possible mechanism by 
which many GPCRs are able to activate specific pools of ERK is via the action 
of scaffolding proteins such as β-arrestin, which can mediate the recruitment of 
Src or Raf/MEK/ERK signalling complexes following agonist stimulated receptor 
phosphorylation (DeFea et al., 2000, Wang et al., 2006b, Shenoy et al., 2006).  
Much work has been carried out on the regulation of 5HT2A receptor 
phosphorylation and interactions with β-arrestin (Bhatnagar et al., 2001, Gray et 
al., 2003, Gray and Roth, 2001, Gray et al., 2001).  However little evidence on 
5HT1B receptor regulation exists.  Interestingly, data analysis of the protein 
sequence of the human 5HT1B receptor revealed a cluster of serine and 
threonine residues within its third intracellular loop.  This is characteristic of G-
protein-coupled receptor kinase (GRK) phosphorylation sites, which have a high 
affinity of β-arrestins.  Similar sites have previously been described for other 
GPCRs, including the V2 vasopressin receptor and the α2A adrenoreceptor (Pao 
and Benovic, 2005, Innamorati et al., 1997).  Therefore, future experiments to 
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characterise 5HT1B receptor regulation may be useful in determining the 
mechanisms by which 5HT, via the 5HT1B receptor and the Rho/ROCK pathway 
specifically controls a cytoplasmic pool of ERK.  
The results presented in Chapter 3 also identify a role for the actin cytoskeleton 
in 5HT-mediated mitogenesis.  It appears that ROCK maintains the integrity of 
the cytoskeleton in order to facilitate 5HT-mediated ERK activation and 
proliferation.  These findings may be of physiological relevance as other 
components involved in the control of actin cytoskeletal dynamics have been 
implicated in the development of PAH.  LIMK, a key regulator of actin dynamics, 
has been found to interact with the tail region of the BMPR2 receptor, a process 
which inhibits LIMK activity (Foletta et al., 2003).  A BMPR2 mutant with a 
truncation in the COOH-terminus that has also been described in patients with 
PAH was reported to be unable to bind or inactivate LIMK (Foletta et al., 2003).  
Given the role of BMPR2 in the development of PAH these findings suggest that 
deregulation of actin dynamics may contribute to the pathobiology of PAH.  
Furthermore, the upregulation cofilin-2 and LIMK 2 have been reported in 
cultured PASMCs and in pulmonary arteries from monocrotaline-treated rats 
(Dai et al., 2006).  Increased levels of these proteins were suggested to 
promote cell motility, a process that may contribute to vascular remodelling and 
occlusion of pulmonary arteries.  The cytoskeleton also plays a vital role in the 
regulation of pulmonary vascular permeability.  For example, actin filaments are 
of importance to endothelial cell permeability, with disruption of these filaments 
resulting in decreased endothelial barrier integrity and infiltration of 
inflammatory mediators, a process that occurs in disease states such as acute 
lung injury and acute respiratory distress syndrome (Dudek and Garcia, 2001).  
Therefore, cytoskeletal integrity may have a widespread role in PAH affecting 
both BMPR2 and 5HT signalling.     
Give the apparent role of ROCK in mitogenic 5HT-activated signalling 
pathways, Chapter 4 investigated the role of ROCK in a chronic hypoxic mouse 
model of PAH, using transgenic mice that ubiquitously overexpress 5HTT in 
order to determine any potential interactions between 5HT and ROCK pathways 
in vivo. 
Using quantitative RT-PCR, chronic hypoxia was found to upregulate both 
ROCK 1 and ROCK 2 transcripts, with the upregulation of ROCK 1 potentiated 
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in 5HTT+ mice.  Furthermore, ROCK inhibition resulted in a marked reduction in 
hypoxia-induced sRVP and vascular remodelling, effects that were significantly 
greater in 5HTT+ mice compared to WT.  In addition, the hypoxia-induced RVH 
that occurred in both WT and 5HTT+ groups was only sensitive to ROCK in 
5HTT+ mice.  Taken together, Chapters 3 and 4 highlight a role for Rho/ROCK 
pathway in the development of PAH and suggest interactions between 5HT and 
Rho/ROCK systems in mediating the mitogenic effects of 5HT.   
In Chapter 4, inhibition of ROCK was found to have more significant effects in 
5HTT+ mice, an effect which may be due to the potentiated hypoxia-induced 
upregulation of ROCK 1.  The increased expression of ROCK transcript 
detected in the chronic hypoxic mouse model, suggested increased ROCK 
activity, which may contribute to the remodelling process and cell proliferation.  
Analysis of mouse lung tissue by immunoblotting is required to determine the 
levels of ROCK protein, as well as the activation status of downstream ROCK 
substrates, in order to confirm that ROCK activity is increased during hypoxia. 
Recently it has been demonstrated that entry of 5HT into the cell via 5HTT 
mediates the prolonged activation of Rho by the transglutaminase-mediated 
serotinylation of RhoA (Guilluy et al., 2007, Walther et al., 2003).  This may 
contribute to the potentiated effects of hypoxia in 5HTT+ mice, given the more 
marked beneficial effects of ROCK inhibition in these animals.  If this 
mechanism is functional in fibroblasts, using the data presented in Chapters 3 
and 4, a potential model to explain how the enhanced expression of ROCK 1 
observed in 5HTT+ mice promotes remodelling by enhancing the mitogenic 
effects of 5HT in fibroblasts may be proposed (Figure 5.1).  In this model, entry 
of 5HT into the cell via 5HTT facilitates the transglutaminase (TG)-catalysed 
serotonylation of Rho, rendering it constitutively active.  Serotonylated Rho 
proteins can then bind and activate ROCK1 and ROCK2.  As ROCK1 transcript 
levels are markedly elevated in response to hypoxia and 5HTT overexpression, 
this may be the predominant isoform affected.  In pulmonary fibroblasts, 
enhanced ROCK expression may facilitate 5HT1B receptor activation of the ERK 
pathway by assisting MEK-mediated ERK phosphorylation.  To confirm this 
hypothesis the phenomenon of serotonylation must be confirmed in the 
fibroblasts studied.  For instance, detection of 5HT binding to RhoA may be 
determined by immunoprecipitating RhoA from 5HT stimulated fibroblasts and 
 174 
subsequently immunoblotting using an anti-5HT antibody.  However, in 
disagreement with the hypothesis of serotonylation, pretreatment of CCL-39 
cells with MDC had no effect on 5HT stimulated ERK activation (Figure 3.18).  
MDC inhibits the transglutaminase enzyme required for serotonylation to occur 
and thus if serotonylation occurs it CCL-39 cells it may have been expected that 
MDC would inhibit 5HT-induced ERK activation.  MDC has previously been 
found to inhibit binding of 5HT to RhoA in mouse aortic SMCs (Guilluy et al., 
2007). However, the concentration of MDC (200µM) used in this study was 
significantly higher than that used in Chapter 3 (100µM) and this may explain 
why MDC pre-treatment was unable to inhibit 5HT-stimulated ERK activation.  
Therefore, the process of serotonylation cannot be ruled out in CCL-39 cells.  
Furthermore, given the hypoxia-induced upregulation of ROCK in mice, future 
experiments may include the use of a hypoxic cellular model to determine if this 
phenomenon also occurs in vitro and to ascertain any changes that may arise in 
the ROCK-dependent 5HT mitogenic signalling during hypoxia.  Studying 
signalling pathways under hypoxic conditions and also the use of a primary cell 
line derived from mouse pulmonary arteries would allow a more direct 
comparision and intregration between  the cellular signal transduction pathways 
investigated and  the chronic hypoxic mouse model of PAH.   
This study highlights the role of ROCK in the development of pulmonary 
hypertension and indicates cross-talk between 5HT and Rho/ROCK signalling 
pathways.  The results are of clinical relevance, given ROCK inhibitors such as 
fusadil are currently being investigated as potential therapies for PAH (Ishikura 
et al., 2006).  Furthermore, inhibition of ROCK appears to have selective effects 
on the pulmonary circulation, as shown in this study (Table 4.1) and by others 
where fusadil selectively induces vasodilation in pulmonary arteries but not 
aorta in an animal model of PAH (Jiang et al., 2007).  In addition to this, other 
agents such as sildenafil and statins appear to mediate their beneficial effects 
on the symptoms of PAH via inhibition of the ROCK pathway (Xing et al., 2006, 
Guilluy et al., 2005).  To conclude, ROCK appears to be a promising therapeutic 
target in the treatment of PAH, with drugs targeting ROCK having beneficial 
effects on pulmonary vasoconstriction and pulmonary vascular remodelling.  
The findings in this study confirm ROCK’s importance in the development PAH 
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and suggest potential mechanisms of action for the therapeutic effects of ROCK 
inhibitors. 
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Figure 5.1  Proposed model of how chronic hypoxia and increased 5HTT 
activity control 5HT-mediated proliferation via ROCK. 
 
Overexpression of 5HTT results in elevated levels of 5HT entering the cell.  Entry 
of 5HT facilitates the transglutaminase (TG)-catalysed serotinylation of Rho, 
resulting in the constitutive activation of Rho.  Active Rho then binds and 
activates ROCK, predominantly ROCK 1.  Active ROCK is required for 5HT1B 
receptor-mediated phosphorylation and activation of ERK by MEK.  Once active 
ERK mediates cellular proliferation and contributes to vascular remodelling. 
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